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Abstract 
Background: Hypertriglyceridaemia increases the risk of developing an atherogenic 
lipoprotein phenotype (ALP) in patients with type 2 diabetes (T2D) and non-alcoholic fatty 
liver disease (NAFLD). An ALP is associated with an increased the risk of coronary heart 
disease (CHD) and cardiovascular disease (CVD). 
Objectives: To determine the effects of exercise and a glucagon like peptide-1 (GLP-1) 
receptor agonists on hypertriglyceridaemia and high-density lipoprotein (HDL) metabolism in 
patients with altered lipid metabolism, by conducting two clinical trials using stable isotope 
trace labelling technique: 
1. To determine the effect of exercise on HDL apolipoprotein A-I (apoA-I) and very low-
density lipoprotein (VLDL) apoB-100 subgroups (VLDL1-apoB-100 and VLDL2-apoB-100) 
kinetics in NAFLD.  
2. To determine the effect of the GLP-1 receptor agonist lixisenatide on postprandial 
triacylglycerol-rich lipoprotein (TRL) apo-B-100 and B-48 and HDL-apoA-I kinetics in T2D. 
Study design: In the NAFLD study, participants were randomised into two groups for a 
period of 16 weeks. The first group received a supervised moderate-intensity exercise 
programme and the second group was the control group. Total HDL-apoA-I was measured 
using a primed constant intravenous infusion of 1-13C leucine for 9 hours in a total of 27 
recruited participants; 15 participants in the exercise group and 12 in the control group. 
In the lixisenatide study participants were randomised in a double-blinded two-period cross-
over design (lixisenatide versus placebo). Participants received treatment with lixisenatide or 
placebo for four weeks followed by a four-week washout period then another four weeks 
with the other treatment. TRL-apoB-100, TRL-apoB-48 and total HDL-apoA-I were measured 
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using a primed constant intravenous infusion of 1-13C leucine for 8 hours during repeated 
meal feeding in a total of six participants. 
Laboratory protocol: For both studies, hourly blood samples were taken during the study 
period. TRL-apoB-100, TRL-apoB-48 and total HDL-apoA-I fractions were isolated using 
ultracentrifugation. Fractions were delipidated and separated by sodium dodecyl sulphate – 
polyacrylamide gel electrophoresis (SDS-PAGE). Protein bands from SDS-PAGE were 
hydrolysed, purified, and then derivatised. The isotopic enrichment of 13C leucine in TRL-
apoB-100, TRL-apoB-48 and total HDL-apoA-I were measured using gas chromatography – 
mass spectrometry (GC-MS). Fractional catabolic rate (FCR) and production rate (PR) were 
calculated for TRL-apoB-100, TRL-apoB-48 and total HDL-apoA-I. TRL-apoB-100 and TRL-
apoB-48 concentrations were measured using competitive ELISA. Total HDL-apoA-I, lipid 
profile including triacylglycerol (TG), cholesterol, and free fatty acids (FFA), also called non-
esterified fatty acids (NEFA), and glucose concentrations were measured using automatic 
analysers. 
Results: In the NAFLD study, sixteen weeks of exercise had no significant effect on HDL-
apoA-I kinetics. However, the HDL-apoA-I pool size (PS) was significantly increased from 
[17.4±0.8 g/l to 18.9±0.75 g/l (P =0.05)] after exercise in the exercise group. VLDL1-apoB-100 
FCR and PR were significantly increased between the exercise and control group; Exercise 
group FCR [(7.2±0.6) vs (10.9±1.5) pools/day P=0.02]; PR [(3.7±0.7) vs (5.5±0.5) mg/kg/day 
P= 0.003]. Fasting hypertriglyceridaemia was not significantly changed after exercise. 
In the lixisenatide study, TRL-apoB-100 FCR significantly increased after lixisenatide 
treatment versus placebo; (6.3±0.4 vs 4.1±0.6 pools/day P=0.01). TRL-apoB-100 PR was 
increased with borderline significance after lixisenatide treatment (P=0.06) versus placebo. 
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TRL-apoB-48 and HDL-apoA-I kinetics were not significantly changed after lixisenatide 
treatment versus placebo. Fasting and postprandial plasma glucose concentrations were 
significantly lower after lixisenatide treatment (P=0.05 and P=0.001 respectively) versus 
placebo. Postprandial serum insulin concentration was significantly higher after lixisenatide 
treatment (P=0.001) versus placebo. Postprandial plasma TG, cholesterol and FFA 
concentrations were significantly lower after lixisenatide treatment (P=0.002, P=0.02 and 
P=0.05 respectively) versus placebo. 
Conclusion: Exercise and lixisenatide were both effective in increasing VLDL-apoB-100 FCR 
which has the potential to reduce plasma TG concentrations in patients with altered lipid 
metabolism. However, exercise did not correct fasting hypertriglyceridaemia in patients with 
NAFLD due to increased VLDL1-apoB-100 PR. Liver fat was reduced by over 50% in the 
exercise group although was not normalised suggesting hepatic IR was maintained. To 
correct fasting hypertriglyceridaemia, accumulated liver fat must be further cleared to 
restore hepatic insulin sensitivity which would decrease VLDL1-apoB-100 PR. A longer 
exercise period is therefore needed to remove more liver fat and to correct fasting 
hypertriglyceridaemia. Postprandial hypertriglyceridaemia was lowered after lixisenatide 
treatment despite the fact that VLDL-apoB-100 PR was increased with borderline 
significance. A decrease in plasma TG concentration would be expected to reduce the rate of 
transfer of TG and CE between TRL and HDL via cholesteryl ester transfer protein (CETP) and 
increase HDL-cholesterol (HDL-C) concentration. The lack of effect of exercise on HDL 
kinetics in the NAFLD study reflects the failure to lower hypertriglyceridaemia. The lack of 
effect of lixisenatide to increase HDL despite lower plasma TG may be due to the study being 
underpowered. 
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1. Chapter 1: General Introduction 
1.1 Triacylglycerols (TAG) 
Triacylglycerol (TAG), also called triglycerides (TG), are one of the most important sources of 
energy in the body which can be utilised instantly or stored in adipose tissues to be used 
when energy supply is reduced. They play several significant roles such as the maintenance 
of the cell membrane structural integrity, cell signalling and hormonal functions (Frayn, 
2010, Hussain, 2014). TGs are non-polar and hydrophobic, and are composed of three 
individual fatty acids (FAs), each linked by an ester bond to a glycerol molecule (Figure 1.0). 
TG derived from the diet is called exogenous TG. Endogenous TGs are mainly synthesised in 
the liver and derived from FAs derived from peripheral TG storage pools (such as adipose 
tissue) and de novo synthesised FAs. During digestion, TG is broken down (hydrolysed) into 
monoglycerides and FAs in the intestines by pancreatic lipase, and by lipoprotein lipase (LPL) 
in the circulation. TGs are transported in the blood in specialised particles called lipoproteins 
which contains TG, cholesterol, phospholipids and apolipoproteins (Frayn, 2010, Hussain, 
2014). 
 
Figure 1.0: The chemical composit ion of TG.  
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1.2 Lipoproteins  
Lipoproteins are macromolecular complexes which carry several lipids and proteins in the 
human blood (Figure 1.2). The fats circulating in the blood, mainly free fatty acids (FFAs) 
(McQuaid et al., 2011, Hussain, 2014), TG and cholesterol are not water soluble and require 
specialised transport mechanisms. Plasma long-chain FFA binds to albumin (McQuaid et al., 
2011, Hussain, 2014).  The core of the lipoproteins, contains the hydrophobic cholesteryl 
esters (CE) and TG while the surface contains mainly the amphipathic phospholipids, 
proteins, and small amounts of free cholesterol (FC) (Figure 1.2). This particular structure 
enables the lipoprotein to interact with the aqueous environment of the human blood and 
transport the water insoluble lipids to and from the peripheral tissues (Frayn, 2010, Hussain, 
2014).  
 
Figure 1.2: General structure of a lipoprotein particle with its components.  
1.3 Lipoprotein classification 
Lipoproteins can be divided into five main types based on their size, ultracentrifugation 
flotation density as shown in Table 1.0 which illustrates lipoprotein density, weight, size and 
lipid content for each lipoprotein (Evans et al., 2002, Hussain, 2014, Ginsberg, 1998). 
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Table 1.0 Physical and chemical characteristics of the major lipoprotein classes (Ginsberg, 
1998, Evans et al., 2002, Hussain, 2014).  
MW: Molecular weight; TG; triacylglycerols; CHOL: Cholesterol; PL: phospholipids. CM: 
chylomicron; VLDL: very low-density l ipoprotein; IDL: intermediate -density lipoprotein; LDL: 
low-density lipoprotein; HDL: high-density  lipoprotein.  
1.3.1 Chylomicrons (CM) 
CM are the largest and the least dense lipoprotein particles with Svedberg flotation (Sf) rate 
of > 400, and they form a creamy layer at the top of postprandial plasma when left to settle 
or spun (Hussain, 2014). CM size and density is related to the amount of TG and cholesterol 
absorbed from the diet, and the type of fat consumed in the food (Hussain, 2014). The 
principle role of CM is the delivery of dietary lipids to hepatic and peripheral cells. CM are 
synthesised in the enterocytes of the jejunum, and they represent exogenous TG in the 
blood (Bisgaier and Glickman, 1983, Hussain, 2014).  
1.3.2 Very low-density lipoproteins (VLDL) 
VLDL are approximately 30-80 nm in size with an Sf of 20-400, and divided into the larger TG-
enriched VLDL1 (Sf 60-400) and relatively smaller and denser VLDL2 (Sf 20-60) (Adiels et al., 
2005b). VLDL are enriched with TG and responsible for delivering hepatic-TG from the liver 
to the peripheral tissues, such as the adipose and muscle tissues. Therefore they represent 
Lipoprotein 
Density 
g/ml 
MW 
Daltons 
Diameter 
(nm) 
Lipid (%) 
TG CHOL PL 
CMs 0.95 400 × 10⁶ 75–1200 80–95 2–7 3–9 
VLDL 
0.95–
1.006 
10–80 × 10⁶ 30–80 55–80 5–15 10–20 
IDL 
1.006–
1.019 
5–10 × 10⁶ 25–35 20–50 20–40 15–25 
LDL 
1.019–
1.063 
2.3 × 10⁶ 18–25 5–15 40–50 20–25 
HDL 
1.063–
1.21 
1–1.5 × 10⁶ 5–1 1–5 50–70 25–30 
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the endogenous TG in the blood. In the fasting state, VLDL account for most of the turbidity 
in plasma (Ginsberg, 1998). Some dietary TG besides CM appears soon after eating in VLDL 
(Ginsberg, 1998, Adiels et al., 2005b, Adiels et al., 2005a). 
1.3.3 Intermediate density lipoproteins (IDL) 
IDL are smaller than VLDL and denser with an Sf of 12-20, and they are considered to be the 
remnants of VLDL hydrolysis in the circulation, and the immediate precursor of LDL. An 
increase in the IDL concentrations has been shown to be proportional to an increase in the 
risk of cardiovascular disease (CVD) (Superko, 1996, Ginsberg, 1998, Carmena et al., 2004). 
1.3.4 Low-density lipoproteins (LDL) 
LDL are smaller and denser than IDL with an Sf of 0-12. LDL are the major cholesterol-
carrying lipoprotein in the blood and are readily taken up by cells via the LDL-receptor in the 
liver and peripheral cells. The size and density of these particles are thought to be associated 
with plasma TG concentrations (Hevonoja et al., 2000). These particles especially the small 
dense LDLs (SDLDL) are hypothesised to be atherogenic and play a significant role in 
increasing the risk of CVD as they can migrate to the arteries endothelial wall and initiate 
and/or increase the pathogenicity of atherosclerosis (McNamara et al., 1992, Carmena et al., 
2004). 
1.3.5 High-density lipoproteins (HDL) 
HDL are the smallest and densest among all lipoproteins with an Sf of less than 0, and 
contain the highest protein composition of all lipoproteins. Newly synthesised HDL is 
discoidal in shape and has a high efficiency in removing cholesterol from the tissue cells. 
Once HDL acquires extra lipids, i.e. CE and TG from tissues, it transforms into a spherical 
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shaped HDL. Spherical HDL is divided into two major subclasses; HDL2 (1.063-1.125 g/ml) and 
HDL3 (1.125-1.21 g/ml), and these two subclasses can be divided further into five 
subfractions (Barter, 2002, Hussain, 2014). Spherical HDL is responsible for transporting 
cholesterol to the liver for bile acid synthesis (Morgan et al., 2004, Lewis and Rader, 2005, 
Hussain, 2014). 
1.4 Apolipoproteins 
Apolipoproteins (apo) are specific proteins associated with lipoprotein particles, and they 
are either an integral part of the lipoprotein or are located peripherally (Figure 1.3). They 
help in the solubilisation of core lipids and play essential roles in the process of regulating 
plasma lipids and lipoprotein transport. They facilitate the recognition of lipoproteins at cell 
surface receptors for lipid metabolism (Gursky, 2005). The major apos are classified into four 
main groups based on their weight and metabolic function as shown in Table 1.1; apo A, B, 
C, D and E, and each could be divided into further groups (Mahley et al., 1984, Gursky, 2005).  
Table 1.1 Characteristics of the major apolipoproteins (Ginsberg, 1998). 
Apo: apolipoprotein; LCAT: Lecithin cholesterol acyltransferase ; HDL: high-density l ipoprotein; 
CM: chylomicron; TG: triacylglycerol; VLDL: very low -density lipoprotein; LPL: l ipoprotein  
lipase; LRP: Lipoprotein receptor-related protein.  
Apolipoprotein MW Metabolic functions 
ApoA-I 28,016 LCAT activator ,  HDL Structural component 
ApoA-II 17,414 Unknown 
ApoA-IV 46,465 Enables transfer of apolipoproteins between  HDL and CMs 
ApoA-V 39,000 Linked with lower TG concentrations; unknown mechanism 
ApoB-48 264,000 Essential for the assembly and secretion of CMs 
ApoB-100 514,000 Essential for the assembly and secretion of VLDL from the liver 
ApoC-I 6,630 May prevent hepatic uptake of CMs and VLDL remnants 
ApoC-II 8,900 Activator of LPL 
ApoC-III 8,800 Inhibitor of lipoprotein lipase and uptake of CM and VLDL 
ApoE 34,145 
Ligand for binding of several lipoproteins to the LDL receptor, LRP and 
proteoglycans 
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1.4.1 Apolipoprotein A-I (apoA-I) 
ApoA-I is the main HDL structural component and is also found on CM and CMR (Segrest et 
al., 2000b). ApoA-I is synthesised in the intestine and the liver, and has a plasma 
concentration of 1-1.5 mg/ml. CM contains apoA-I, and during TG hydrolysis by lipoprotein 
lipase (LPL), apoA-I is transferred to HDL particles. ApoA-I plays a protective role against CVD 
in humans as an anti-atherogenic function of the HDL particles (Segrest et al., 2000b, Hattori 
et al., 2004). Furthermore, one of the primary roles of apoA-I is activating the lecithin-
cholesterol acyltransferase (LCAT) enzyme which is essential for extracellular cholesterol 
esterification (Miida et al., 2004, Lewis and Rader, 2005). 
1.4.2 Apolipoprotein B-100 (apoB-100) 
ApoB-100 is essential for the generation of VLDL, and also found in IDL and LDL (Burnett and 
Barrett, 2002). ApoB-100 is a large apolipoprotein containing 4536 amino acids (AA) residues 
with a molecular mass of about 513 kDa. It comprises many hydrophobic areas that possibly 
serve as strong lipid-binding domains (Marshall and Bangert, 2008). It also has many binding 
domains that might act as binding sites for heparin-like particles and form the base for some 
of the cell surface interactions of the apoB-containing lipoprotein (Marshall and Bangert, 
2008). It is synthesised in the rough endoplasmic reticulum (RER) of the human hepatocytes, 
and binds to the ligand-binding domain of the LDL receptor (Burnett and Barrett, 2002, 
Boren et al., 1992). 
1.4.3 Apolipoprotein B-48 (apoB-48) 
ApoB-48 is a short form of apoB-100 representing 48% of the protein sequence of the aboB-
100 C-terminal. It is required for the formation of CM at the small intestine, and cannot bind 
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to the LDL-receptor due to its short form (binding site close to C-terminal 3359-3369) 
(Powell et al., 1987, M.J. van Greevenbroek and W.A. de Bruin, 1998, Hussain et al., 2005). It 
consists of 2152 AA residues with a molecular mass of 241 kDa. It is synthesised in the RER in 
the enterocyte in the small intestine by post-transcriptional modification of the mRNA 
(Powell et al., 1987, Hussain et al., 2005, Hussain, 2014). In the process of premature CM 
particle formation, partly translocated membrane-bound apoB-48 polypeptide will be 
degraded if not bound to the lipid content of the RER membrane immediately (Milne et al., 
2004, Morel et al., 2004). Therefore, the formation of CM is directly dependent on the 
availability TG, cholesterol and phospholipids (Morel et al., 2004, Milne et al., 2004). 
1.4.4  Concentrations of apoB-100 and apoB-48 in human blood plasma 
Plasma apoB-100 and apoB-48 concentrations vary with the feeding state.(Karpe et al., 
1993)and(Karpe et al., 1996)measured apoB-100 and apoB-48 concentration as shown in 
Table 1.2 which shows the method of isolation, S floatation and fasting and postprandial 
concentration. The proportions of plasma concentrations of apoB-100 in fasting and 
postprandial states are higher when compared with minimum apoB-48 concentrations. The 
determination of  apoB-48 concentrations in fasting and postprandial state is difficult (Karpe 
et al., 1996). The reason for this is that there is only one non-exchangeable apoB-48 per CM 
and CMR particles which remains an integral part of the CMR particle following lipolysis 
(Phillips et al., 1997). ApoB-48 concentration is only synthesised in the intestines during the 
fed state for CM formation. Conversely, apoB-100 can be found in VLDL, IDL and LDL 
particles after VLDL-TG hydrolysis in both feeding and fasting states. Therefore, a proper 
assessment of apoB-48 requires an increase in its concentration by administering a 
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standardised feeding protocol as shown in many studies (Duez et al., 2006, Duez et al., 
2008b, Hogue et al., 2007a, Nogueira et al., 2012). 
Table 1.2 Plasma concentrations of apoB-100 and apoB-48 in fasting and postprandial states 
(Karpe et al., 1996). 
Test meal 
ApoB of 
interest 
Method of 
lipoprotein 
isolation 
Sf 
Fasting Conc. 
(mg/l) 
Peak 
postprandial 
Conc. (mg/l) 
Fat emulsion, 
50 g fat/m2 
BSA 
ApoB-48 
U.C 
Sf 60–400 2 15 
Sf 20–60 3 6 
ApoB-100 
Sf 20–60 36 73 
Sf 60–400 42 41 
U.C: ultracentrifugation; Apo: apolipoprotien; Sf: Svedberg flotation; BSA; bovine serum 
albumin; Conc: concentration. 
1.5 Essential enzymes and proteins involved in the lipid metabolic pathways 
1.5.1  Microsomal triacylglycerol transfer protein (MTP) 
MTP is a heterodimeric protein complex which is a member of a group of proteins that has 
lipid transfer activity between membranes (Hussain, 2014, Hussain et al., 2003). MTP is a 
dimer which comprises two subunits; a large M-subunit (97-kDa) and a small P-subunit (55-
kDa), and both subunits are bound together by non-covalent interactions. This protein is 
primarily located in the endoplasmic reticulum lumen and plays an essential role in the 
maturation of endoplasmic reticulum, and its secreted proteins (Hussain, 2014, Hussain et 
al., 2003). It binds and shuttles individual lipids between membranes (Hussain, 2014, Hussain 
et al., 2003). Insulin downregulates the MTP promoter region and it is up-regulated by 
cholesterol. MTP has four binding sites; one neutral lipid binding site which binds TG and CE, 
and two or three phospholipid binding sites (Hussain, 2014, Hussain et al., 2003). MTP has 
been proposed to perform in a sequence cycle in which it transiently interacts with a 
membrane, extracts lipid molecules from it, dissociates from the membrane, delivers the 
lipids to another membrane and then returns for another cycle (Hussain, 2014, Hussain et 
al., 2003) as shown in Figure 1.3. MTP primarily transports ER membrane-bound lipid and 
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newly synthesised TG to recently translated apoB-48 in the small intestine and apoB-100 in 
the liver and facilitates their lipidation (Figure 1.3) (Hussain, 2014, Hussain et al., 2003). Both 
transportation steps to the RER lumen is considered as the first step in triacylglycerol-rich 
lipoproteins (TRL) (CM and VLDL) biogenesis before they are transported to Golgi apparatus 
to be secreted (Hussain, 2014, Hussain et al., 2003).  
 
Figure 1.3: MTP performance in a sequenced cycle for lipidating nascent apoB. Figure 
obtained from(Hussain et al.,  2003). ApoB: apolipoprotein B; ER: endoplasmic reticulum; MTP: 
microsomal triacylglycerol  transfer protein.  
1.5.2  Lipoprotein lipase (LPL) 
LPL is synthesised in two major sites; in parenchymal cells of the heart and skeletal muscles, 
mammary glands and in adipose tissues. The primary function of LPL is to hydrolyse the TG 
and phospholipids within CM and VLDL which transform them into remnants (Mead et al., 
2002, Zilversmit, 1995). Therefore, it is synthesised in the sites in which FA are oxidised for 
energy or stored (Eckel, 1989, Frayn, 2010, Mead et al., 2002). LPL requires the presence of 
certain apolipoproteins to maintain its regular function (Mead et al., 2002). For instance, LPL 
is activated in the presence of apoCII and modulated by apoCIII (Mead et al., 2002, Wang et 
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al., 1985). LPL is located on the luminal surface of the endothelial cells (ECs) in which 
enzymes are attached with membrane-bound chains of heparin sulphate proteoglycans 
(HSPG) (Enerback and Gimble, 1993). Furthermore, LPL facilitates the binding of lipoproteins 
and their receptors such as VLDL and, LDL and Lipoprotein receptor-related protein (LRP) 
receptors (Mead et al., 2002, Chappell et al., 1993, Medh et al., 1996, Takahashi et al., 1995). 
Also, it is reported that LPL may play a pro-atherogenic role in atherosclerosis within muscles 
and adipose tissues (Mead et al., 1999, Mead and Ramji, 2002). 
1.5.3  Hepatic lipase (HL) 
HL synthesis takes place in the hepatocytes, and it is located on the surface of the hepatic 
ECs which is located predominantly on the extracellular surface in the space of Disse 
(Zambon et al., 2003a). HL plays a similar role to LPL in the remodelling of TRL and HDL 
remnants, and also plays a role in the reverse cholesterol pathway. HL binds with HSPG to 
facilitate the hydrolysis of TG and phospholipids in all lipoproteins, and can hydrolyze CE, 
monoglycerides and diglycerides (Zambon et al., 2003a). Furthermore, HL activity is 
associated with produced LDL size, and can be modulated by insulin resistance (IR), dietary 
fat intake, abdominal obesity, physical activity and certain drugs (Zambon et al., 2003b). 
1.5.4  The LDL receptor and LDL receptor-related protein 
The LDL receptor (LDLR) is a glycoprotein receptor which is present on the surface of all cells, 
and it binds with lipoprotein containing apoB-100 and apoE to facilitate their breakdown 
within the cell. LDL receptor-related protein (LRP) is expressed by the hepatocytes and has 
multiple ligands including apo-E, HL and LPL (Strickland et al., 1995). IDL and HDL-containing 
apoE binds to the LDLR and the lipid content (CE and TG) which are then taken up by the cell 
through endocytosis for oxidation or storage, and then the receptor is recycled back to the 
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surface (Koo et al., 1988, Go and Mani, 2012). The LDLR number is related to the 
concentration of circulating LDL in the plasma. Therefore, LDLR expression is controlled by 
feedback control by allowing sufficient cellular cholesterol uptake to maintain cellular 
cholesterol homoeostasis (Go and Mani, 2012). The LDL synthesis is regulated by CE cellular 
concentration as it affects the recycling process of LDLR to the cell surface (Koo et al., 1988, 
Brown and Goldstein, 1986, Go and Mani, 2012). 
1.5.5 ATP-binding cassette transporter A1 (ABCA1) 
The ABCA1 transportation system is predominantly found in hepatic cells, brain cells, 
macrophages and in other tissues (Segrest et al., 2000a, Singaraja et al., 2006, Zannis et al., 
2006). The transportation system is one of the vital systems in the body in which molecules 
are transported via the breaking down of ATP for the movement of particles across the 
cellular membrane. ABCA1 plays a significant role in lipidating lipid-poor apoA-I through 
facilitating the efflux of cholesterol and phospholipids via the cell membrane. This efflux will 
result in the formation of discoidal apoA-I-containing HDL. This step is essential in 
synthesising HDL in the HDL metabolic pathway (Zannis et al., 2006, Barter, 2002). 
1.5.6 Acyl-CoA: cholesteryl acyltransferase (ACAT) 
The ACAT is responsible for facilitating the esterification of cholesterol (Chang et al., 2009). 
There are two recognised types; ACAT1, which is located in the ER of smooth muscle cells, 
and ACAT2 which is located predominantly in the ER of the enterocytes of the intestines and 
hepatocytes (Chang et al., 2009). The main function of ACAT1 is to saturate cellular 
membranes with cholesterol to an optimum concentration. ACAT2 acts mainly on the 
secretion of CE into VLDL-apoB100 in the liver and CM-apoB48 in the intestines (Chang et al., 
2009). 
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1.5.7  Lecithin cholesterol acyltransferase (LCAT) 
LCAT is synthesised in hepatocytes and is found bound to the HDL surface (Barter, 2002, 
Zannis et al., 2006). LCAT is activated by apoA-I (Frayn, 2010), and has many important 
functions such as the maturation of HDL particles and facilitating cholesterol transport from 
the peripheral tissues to the HDL particles. Also, it mediates CE esterification on the surface 
of HDL particles (Lewis and Rader, 2005).  
1.5.8  Phospholipid transfer protein (PTP) 
PTP is a plasma glycoprotein and plays a significant role in HDL metabolism (Colhoun et al., 
2002). PTP is essential for HDL remodelling, the generation of Pre-βHDL, the transfer of lipids 
from triacylglycerol-rich lipoproteins (TRL) to HDL during intravascular lipolysis, and 
facilitates the efflux of cholesterol and phospholipids from cells to HDL (Colhoun et al., 2002, 
Lewis and Rader, 2005). Moreover, PTP activity increases in hypertriglyceridaemia and it can 
be modulated by IR (Colhoun et al., 2002). 
1.5.9  Cholesterol ester transfer protein (CETP) 
CETP is a glycoprotein that is predominantly found in the liver and adipose tissue (Barter, 
2000, Bagdade et al., 1993). The primary function of CETP is to facilitate the relocation 
(redistribution) of TG and CE between HDL and TRL (VLDL and CM). As a result, TG from TRL 
are relocated within the HDL, and CE is relocated to the TRLs (TG is taken up by HDL from 
TRL and cholesterol is taken up by TRL from HDL) (Rye et al., 1999, Frayn, 2010) as shown in 
Figure 1.4. The concentrations and activity of CETP in the plasma are related to the state of 
either hypercholesterolaemia or hypocholesterolaemia in metabolic disorders (Barter, 2000, 
Bagdade et al., 1993, Frayn, 2010), and it is associated with plasma HDL-C concentrations 
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(Freeman et al., 1990) which is related to the CETP gene polymorphism (Freeman et al., 
2003). 
 
Figure 1.4: CETP facil itating the transfer of TG and CE between TRL and HDL. Figure obtained 
from (Lewis and Rader, 2005). SR-B1: Scavenger receptor class B type 1; HL: hepatic lipase; 
HDL: high-density lipoprotein; apoA -I: apolipoprotein A-I; TG: triacylglycerol; CETP: 
cholesterol ester transfer protein; CE: cholesterol ester; PL: phospholipid; PLTP: Phospholipid 
transfer protein; VLDL: very low-density lipoprotein.  
1.5.10 Scavenger receptor class B type 1 (SR-B1) protein  
SR-B1 is a polypeptide protein that binds to some lipoproteins such as VLDL, HDL, LDL and 
oxidised LDL (OXLDL) (Connelly et al., 1999, Greene et al., 2001, Shen et al., 2014, Reboul et 
al., 2006, Ueda, 2001). SR-B1 is expressed in the hepatocytes and enterocytes in the 
intestines. SR-B1 binds to HDL and mediates the selective uptake of CE from the core of HDL 
particles to their plasma membranes without entailing the uptake and degradation of the 
whole HDL particle. This process is dependent on the presence and correct orientation of 
apoA-I (Connelly et al., 1999, Greene et al., 2001, Shen et al., 2014, Reboul et al., 2006, 
Ueda, 2001). SR-B1 also facilitates the efflux of unesterified cholesterol from cells to 
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lipoproteins. This means that SR-B1 is essential for both ends of the reverse cholesterol 
pathway; Initially with the efflux of FC from peripheral cells to HDL, and for delivery of CE 
and unesterified cholesterol to the liver for secretion into bile and synthesis of bile acids 
(Connelly et al., 1999, Greene et al., 2001, Shen et al., 2014, Reboul et al., 2006, Ueda, 2001) 
. 
1.6 Significant metabolic pathways involved in lipid metabolism 
1.6.1  De-novo lipogenesis (DNL) pathway 
DNL transforms carbohydrates to FA in the liver and adipose tissues (Hellerstein, 1999, 
Ameer et al., 2014). This pathway is activated in the feeding state in which it is controlled by 
many transcription factors and hormonal factors such as insulin (Ameer et al., 2014). These 
factors include sterol response elements (SRE) binding protein isoform one (SREBP1-c) 
(Horton et al., 2002) and the liver X receptor-α (LXRα) (Liu et al., 2007). It has been 
demonstrated that SREB1-c upregulates all enzymes in the FA synthesis pathway and 
enzymes that regulate the availability of acetyl-CoA units in the pathway (Horton et al., 
2002). Also, LXRα regulates lipogenesis via inducing the expression of SREBP-1c (Liu et al., 
2007). Lastly, Insulin increases the activity of LXRα, which hence induces SREBP-1c 
expression (Hellerstein, 1999, Ameer et al., 2014, Liu et al., 2007). Approximately 4% of FAs 
syntheses in the endogenous lipid pathway are derived from DNL in fasting state, and it 
increases to 8% in the feeding state in healthy population (Hellerstein, 1999, Ameer et al., 
2014, Barrows and Parks, 2006). In individuals with obesity and IR, DNL significantly 
increases endogenous lipid synthesis (Ameer et al., 2014). 
1.6.2 Exogenous and Endogenous lipoprotein pathways 
The exogenous and endogenous lipoprotein pathways are shown in Figure 1.5. 
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Figure 1.5: The exogenous and endogenous lipid pathway s. Apo: apolipoprotein; CM: 
chylomicron; LPL: l ipoprotein l ipase; FFA: free fatty acid; CMR: chylomicron remnant; VLDL: 
very low-density lipoprotein; IDL: intermediate -density lipoprotein; LDL: low -density 
lipoprotein.  
1.6.2.1 The exogenous lipoprotein pathway 
Figure 1.5 illustrates the exogenous lipid pathway. Large digested Lipids particles are 
emulsified into smaller units called micelles by bile acids through creating a liquid-crystalline 
interface at the surface of the emulsified particles, and hydrolysed as TG primarily by 
pancreatic lipase in the jejunum (Benzonana and Desnuelle, 1965, Rustow and Kunze, 1987). 
Then pancreatic lipase act on the TG molecule resulting in the release of monoacylglycerol 
(MAG) and FFAs (Mattson and Beck, 1956, Mattson and Volpenhein, 1968), and MAG is 
absorbed from the small intestine. Pancreatic lipase also hydrolyses MAG resulting in the 
formation of glycerol and FFA (Hofmann and Borgstrom, 1963); FFAs are taken up from the 
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intestinal lumen into the enterocytes and used for neutral fat biosynthesis. Glycerol is taken 
up via two ways; taken up bound to FA as MAG, and via specialised channels called 
aquaglyceroporins (Mukhopadhyay et al., 2014, Hara-Chikuma and Verkman, 2006). CD36 
plays an important part in the uptake of FFAs (Abumrad, 2005, Bonen et al., 2007), and it is 
substantially expressed in the intestine (Chen et al., 2001). Specific binding proteins 
transport FFAs and MAG to the intracellular site where they will be used for the biosynthesis 
of TG. Once inside the enterocyte, the products of TG hydrolysis must cross the cytoplasm to 
reach the ER. Most TG biosynthesis in the enterocyte occurs via the MAG pathway in which 
fatty acyl-CoA and MAG are covalently joined to form diacylglycerol (DAG) in a reaction 
which is catalysed by monoacylglycerol acyltransferases (MGATs) (Coleman and Haynes, 
1986, Yen et al., 2008). Further DAG acylation by diacylglycerol acyltransferase (DGAT) leads 
to TG synthesis which is used for CM synthesis (Black, 2007, Mansbach and Gorelick, 2007). 
CM assembly is thought to be processed through two steps. The first step includes apoB-48 
translation with the expulsion of the amino-terminal portion of the protein into the ER 
lumen. MTP lipidates apoB-48 and rescues it from degradation, which results in the 
formation a primitive CM. Also, MTP transfers lipid from the smooth ER membrane and 
other sites directly and bind to apoB-48 to endorse proper folding and lipid acquisition 
(Mahmood Hussain, 2000, White et al., 1998). Secondly, MTP mediates additional bulk 
lipidation of the primitive particle (Mahmood Hussain, 2000, White et al., 1998), in which 
apoA-IV is fused to the particle surface which appears to play a role in the process of CM 
assembly. The primitive CM is formed in a specialised vesicle in the smooth ER, which is 
called a pre-CM transport vesicle (PCTV), to be carried to the Golgi apparatus. In Golgi, lipid 
composition is altered, apoB-48 glycosylation is modified, and the particle acquires apoA-I. 
Finally, CM particles go through exocytosis at the basolateral membrane, and are secreted 
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into the intestinal lymph (lacteals) (Tso and Balint, 1986), and released into the circulation 
(Mahmood Hussain, 2000, Hussain et al., 2005, Iqbal and Hussain, 2009, Tso and Balint, 
1986). CMs are macromolecules and cannot diffuse into the blood vessels. Instead, the 
lacteals transport them as chyle, and from which they diffuse readily through the lymphatic 
pores to the systemic circulation (Tso and Balint, 1986). After that, CM is secreted into the 
bloodstream through the lymphatic system (Hussain, 2014, Hussain et al., 2005). CM 
particles in the circulation interact with other lipoprotein fractions and exchange 
apolipoproteins other than apoB-48, comprising apoC-II, which mediates CM particles 
hydrolysis by LPL, and apoC-III, which inhibits LPL action. The hydrolysis of TG in CMs 
releases FAs, the majority of which will be taken up by the peripheral tissues (e.g. muscle, 
adipose tissue and liver) for oxidation or storage. The process of TG hydrolysis will result in 
significantly reduced CM particle size, with phospholipid transfer to HDL and movement of 
unesterified cholesterol from the core to the surface of the particle. Finally,  chylomicron 
remnant (CMR) catabolism in the liver is carried out by binding of surface apoE to cell 
surface receptors in the liver (Cooper, 1997). 
1.6.2.2 The endogenous lipoprotein pathway 
In the liver as shown in Figure 1.5, VLDL synthesis, assembly and maturation can be 
described in two main steps. Firstly, nascent apoB-100 particles translocate through the 
smooth ER membrane, which results in rapid proteasomal degradation in the absence of 
sufficient neutral lipids. These lipid contents can be TG, cholesterol and phospholipids, which 
may be derived from fat stores or de novo synthesis. MTP facilitates the transportation to 
form primitive lipoprotein particles (Fisher and Ginsberg, 2002, Gordon and Jamil, 2000, 
Gordon et al., 1996). Secondly, apoB-100 is transported from the smooth ER to the Golgi as 
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primitive lipoproteins, and fuses with lipid droplets (cholesterol (from exogenous CMRs) and 
phospholipids) facilitated by the MTP enzyme. Also, apoC-II and apoE in the hepatocytes are 
packaged with the same primitive particle by MTP to produce mature VLDL-sized particles 
(Olofsson et al., 1999).VLDL is then released into the circulation. The TGs content of VLDL are 
hydrolyzed by LPL on endothelial tissue surfaces facilitating the release of glycerol and FFAs 
in adipose tissue and skeletal muscle. VLDL particles shrink in size as TGs, carried in VLDL, are 
hydrolysed by LPL forming IDL, and LDL (Iqbal and Hussain, 2009). Finally, the LDL particles 
formed are catabolised by the liver and other tissues. 
1.6.3  HDL metabolism (also known as reverse cholesterol pathway) 
HDL synthesis starts after the secretion and release of apoA-I from both the liver and 
intestine into the plasma as shown in Figure 1.6 (Lewis and Rader, 2005, Frayn, 2010, Wang 
and Smith, 2014). Lipid-poor apoA-I in the intestines immediately obtains phospholipids and 
FC from the peripheral tissues by the help of LPL. In the liver, lipid-poor apoA-I receives 
similar lipid content from CM and VLDL remnants with the assistance of ATP-binding cassette 
transport A1 (ABCA1)(Wang and Smith, 2014, Hassan et al., 2007). The binding of these 
particles will form pre-mature HDL particles called nascent preβHDLs which are additionally 
enriched with cholesterol and phospholipids mediated via ABCA1 (Lewis and Rader, 2005, 
Frayn, 2010, Wang and Smith, 2014, Hassan et al., 2007). Enriched Pre-βHDL particles 
produced in the circulation interact with other HDL particles which carry LCAT which 
facilitates the esterification of enriched cholesterol to form CE. This process will facilitate the 
movement of CE to the core of these particles which will alter and modify the discoidal 
shape of these particles to form small spherical α-migrating particles called HDL3. Free 
circulating HDL3 are moreover exposed to LCAT which it causes further cholesterol 
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esterification and CE movement. Continued esterification enlarges HDL3 and alters their 
shape to form large spherical α-migrating particles called HDL2 (Lewis and Rader, 2005, 
Frayn, 2010). The final step is the remodelling of mature HDL particles which is done via two 
mechanisms. The first one takes place when circulating HDL interact with the TRL plasma 
pool in which CE molecules are transported and exchanged with TG molecules in TRL with 
the help of CETP, which controls forward and reverse cholesterol pathway. This 
transportation will result in the formation of enriched HDL-TG particles due to the process of 
TG enrichment and CE depletion. Furthermore, TG-enriched HDL particles will obtain 
phospholipids from TRL at the same time mediated by PLTP (Lewis and Rader, 2005, Frayn, 
2010). Upon the arrival of these particles to the liver, HL in hepatocytes causes the 
modification of these particles to become HDL remnant (HDLR) and to release the lipid-poor 
apoA-I for degradation via the renal system. The other way of HDL remodelling takes place 
via hepatic uptake of mature HDL particles from the circulation to interact with SR-B1. 
During particle interaction with SR-B1, CE is taken up by the hepatocytes to be used in the 
formation of bile acids. Remaining HDL particles after interaction will become HDLR, which 
are degraded by the renal system along with lipid-poor apoA-I (Lewis and Rader, 2005, 
Frayn, 2010) (Figure 1.6). 
 
20 
 
 
Figure 1.6: HDL formation, maturation and remodelling pathway. The Figure obtained 
from(Heinecke, 2012). apo: apolipoprtoein; HDL: high-density lipoprotein;  ABCA1: ATP-Binding 
cassette transporter A1; ABCG1: ATP-Binding cassette transporter G1;  LCAT: lecithin-
cholesterol acyltransferase; SR-B1: scavenger receptor class B type 1.  
 
1.7 Obesity and IR as CVD risk factors 
1.7.1 Cardiovascular disease  
The cardiovascular system comprises the heart, a muscular pump, and the systemic and 
pulmonary blood vessels. CVD occurs via disordered or altered function to any of these 
components (WHO, 2015a). CVD is the predominant cause of death globally. An 
approximately 17.5 million people died from CVD in 2012, representing 31% of all global 
deaths. About 7.4 million of them died due to coronary heart disease, and 6.7 million were 
due to stroke (WHO, 2015a). Most of the CVD deaths occur in developing countries more 
than the developed countries with low or intermediate income (WHO, 2015a). People with 
CVD or who are at high cardiovascular risk (due to the presence of one or more risk factors 
such as diabetes, hypertension, hyperlipidaemia) need early detection and management 
using counselling and medicines, as appropriate (WHO, 2015a). CVD represents many 
conditions such as coronary heart disease (CHD) also known as coronary artery disease, 
ischemic heart disease, cerebrovascular disease, peripheral arterial disease and many others 
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(WHO, 2015a). CHD most common representations are angina and myocardial infarction 
which are caused by an arterial blockage that stops blood flow to the myocardium. 
Cerebrovascular disease as haemorrhagic or thrombolytic stroke is caused by blood vessel 
leakage or bleeding in the brain (WHO, 2015a). 
In the UK, rates of cardiovascular mortality remain among the uppermost in the world 
(WHO, 2015a, British Heart Foundation, 2012). The approximate mortality rate is one in four 
deaths in men and one in five deaths in women. CVD is responsible for over 80,000 
premature deaths, and there are 120,000 confirmed cases of CHD discharges from the 
hospital per annum. The total estimated cost associated with CHD was £7 billion in 2004 
(British Heart Foundation, 2012). The WHO predicts an increase in the number of people 
who die from CVD mainly from CHD and stroke to reach to 23 million people by the year 
2030 (British Heart Foundation, 2012, WHO, 2015a). 
1.7.2 Atherosclerosis 
Atherosclerosis (also known as atherosclerotic vascular disease or ASVD) is the condition in 
which an artery wall thickens as the consequence of a build-up of fatty material such as, 
cholesterol which results to an endothelial dysfunction as altered vasoconstriction and 
vasodilation (Rasmussen et al., 2009) (Figure 1.7). It is a chronic inflammatory response in 
the walls of arteries, in large part due to the accumulation of white blood cells (macrophages 
and lymphocytes) and promoted by LDL without sufficient removal of fats and cholesterol 
from the tissues by functional HDL (Weber et al., 2008, Griffin, 1999). Atherosclerosis 
commonly develops from LDL and SDLDL molecules adhesion and accumulation at an arterial 
wall (Griffin, 1999). LDL particles become oxidised by free radicals; particularly reactive 
oxygen species (ROS). During the oxidation process, a series of reactions occur and the area 
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becomes inflamed due to injury. Inflammatory cytokines such as tumour necrosis alpha 
(TNF-α) and interlukin-6 (IL-6) are secreted as a sign of inflammation (Weber et al., 2008, 
Libby, 2002, Hansson and Nilsson, 2009). White blood cells (macrophages) start to adhere, 
migrate and infiltrate the arterial wall intima at the inflammatory site to start the process of 
phagocytosis (Weber et al., 2008, Libby, 2002, Hansson and Nilsson, 2009). During 
phagocytosis, dead macrophages with engulfed OXLDL form foam cells which, along with the 
inflamed endothelium, secretes macrophage chemoattractant protein-1 (MCP-1) which 
attracts further monocytes to the inflammation site (Weber et al., 2008, Libby, 2002, 
Hansson and Nilsson, 2009). The ongoing process results in the accumulation of foam cells 
which results in the formation of a cholesterol plaque that causes the muscle cells to enlarge 
and form a hard cover over the injured area, which narrows of the artery, reduces the blood 
flow and increases blood pressure. This manifestation can lead to the development of CHD 
as angina, and a sudden rupture of this plaque leads to the formation of a blood clot which 
blocks the blood supply to a certain area causing infarction (i.e. myocardial infarction) which 
may result in death or heart failure (Weber et al., 2008, Libby, 2002, Hansson and Nilsson, 
2009). The association between coronary risk factors and heart disease is well established. 
Risk factors such as hypercholesterolemia and hypertension promote the development of 
coronary atherosclerosis through two key mechanisms: endothelial dysfunction or injury, 
and accumulation and modification of cholesterol, primarily LDL and cholesterol. Coronary 
risk factors facilitate the atherosclerotic process by increasing LDL cholesterol 
concentrations, enhancing endothelial permeability to LDL cholesterol, and promoting 
cholesterol modification (oxidation, glycosylation, and acetylation). Modified cholesterol 
(e.g., oxLDL) produces endothelial dysfunction, which appears to precede even the earliest 
development of atherosclerosis (Hansson and Nilsson, 2009, Weber et al., 2008). 
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Figure 1.7: Pathophysiologic mechanisms by which coronary risk factors lead to 
atherosclerosis. S DLDL: small dense low-density lipoprotein; O XLDL: oxidised low-density 
lipoprotein.  
1.7.3  High LDL and low HDL concentrations in contribution to Atherosclerosis and 
CVD 
High concentrations of plasma LDLs are considered one of the most important risk factors 
which contribute to increasing the risk of CHD (Hoogeveen et al., 2014). SDLDL, a subfraction 
of LDL, is considered even more potent for CHD risk through many mechanisms via 
increasing the pathogenesis of atherosclerosis (Hoogeveen et al., 2014, Griffin, 1999). These 
mechanisms are as follows; SDLDL has a lower affinity for the LDL receptor which increases 
cholesterol delivery to cells (Hoogeveen et al., 2014). Therefore, this will facilitate their entry 
into the endothelial cells (EC) of the arteries and arterial wall. Once SDLDL penetrates the 
arterial wall, it strongly binds to the proteoglycans which increase their arterial retention 
(Hoogeveen et al., 2014). Finally, as a result of their arterial retention at the arterial wall, this 
will make them more susceptible to oxidation which results in increased availability of OXLDL. 
It directly increases the progression of atherosclerosis in the formation of foam cells at the 
lesion site of the arterial wall (Hoogeveen et al., 2014) as shown in Figure 1.7. 
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On the other hand, HDL plays a vital role as an atheroprotective particle with an inverse 
association with CVD. In many studies, it has been shown that reduced plasma HDL 
cholesterol (HDL-C) plasma concentrations can be used as a predictive marker for the 
development of premature CHD (Frick et al., 1987, Barter and Rye, 1996, Kontush and 
Chapman, 2006). The relationship between HDL-C and CHD has been widely addressed in 
many studies. It was shown that HDL-C is significantly associated with CHD development and 
incidence (Gordon et al., 1977, Gordon et al., 1989). HDL has several protective role against 
CVD which all help to correct and/or manage atherosclerosis (Kontush and Chapman, 2006). 
HDL can mediate the cholesterol efflux from cholesterol-loaded macrophages. This step will 
help in reducing and/or stopping the deposition of cholesterol-loaded macrophages at the 
arterial injury site in response to the inflammatory process. This will results in the inhibition 
of foam cell formation at the injury site (Barter et al., 2004, Brewer, 2004). The removal of 
cholesterol by HDL is promoted via interaction with the SR-B1 receptor and binding with the 
ABCA1 transporter. Excessive cholesterol obtained by HDL from arterial macrophages will be 
delivered to the liver and used for bile acids synthesis and excretion (Barter et al., 2004, 
Brewer, 2004). Also, HDL can significantly reduce the progression of atherosclerosis by 
protecting LDL from oxidation. This particular function of HDL is due to by the action of 
apoA-I and certain enzymes which are carried and/or located on the surface of the HDL 
particles (Kontush et al., 2003). ApoA-I as the primary HDL carrying apolipoprotein plays a 
vital role in inhibiting LDL oxidation. ApoA-I eliminates LDL-derived oxidised phospholipids 
and lipid hydroperoxides from LDL, and from the arterial wall injury site (Navab et al., 2004, 
Barter et al., 2004). HDL carries enzymes such as paraoxonase and platelet activating factor 
acetylhydrolase which play a role in degrading oxidised phospholipids from LDL and 
inhibiting LDL oxidation (Wang and Briggs, 2004). Furthermore, HDL plays an anti-
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inflammatory role in inhibiting the expression of adhesion proteins in EC needed for the 
development of the atherosclerosis lesion. Also, HDL reduces monocyte collection and 
grouping at the site of injury in the early stages of atherosclerosis (Barter et al., 2004, 
Kontush et al., 2003). Finally, HDL particles play a protective role by producing certain 
atheroprotective factors such as Nitric Oxide (NO) and endothelium-derived hyperpolarizing 
factor (EDHF). NO and EDHF are essential for controlling vasoconstriction and vasodilation 
within the artery (Rasmussen et al., 2009). Maintaining this artery function is necessary for 
preventing and/or reducing EC dysfunction. EC dysfunction takes place in the first stages of 
atherosclerosis which promotes the arterial lesion (Wang and Briggs, 2004). 
1.7.4 Obesity 
Obesity has become a widespread health problem in recent years. It is especially worrying 
that the increase was most noticed in children and that it occurred both in developed and 
increasingly in developing countries with low or intermediate income (Knight, 2011, WHO, 
2015c, Westphal, 2008). Worldwide obesity doubled since 1980 (WHO, 2015c). It is recorded 
by world health organization (WHO) that in 2014, more than 1.9 billion adults were 
overweight in which 600 million of them were obese (WHO, 2015c, Westphal, 2008). Also, it 
is recorded that 42 million children under five years old were overweight or obese in 2013 
(WHO, 2015c). Obesity is a globally independent risk factor for CHD (WHO, 2015c, WHO, 
2015a). Body mass is positively related to fasting TG concentration, plasma cholesterol and 
blood pressure, and inversely related to HDL-cholesterol (HDL-C) concentration (Westphal, 
2008). The distribution of body fat appears to be particularly important. Central or visceral 
obesity that is most strongly linked to IR and CHD risk (WHO, 2015a, Knight, 2011, WHO, 
2015c, Westphal, 2008). Obesity, especially central obesity, increases the risk for metabolic 
26 
 
syndrome which is a cluster of risk factor for type 2 diabetes (T2D) and CVD (WHO, 2015a, 
WHO, 2015c, Knight, 2011, Westphal, 2008). These factors include dysglycaemia, high blood 
pressure, elevated TG concentrations, low HDL-C concentrations, and obesity in particularly 
central obesity (Knight, 2011, WHO, 2015a, Alberti et al., 2009, Westphal, 2008). The 
metabolic syndrome is strongly related to an increased risk of developing many metabolic 
diseases such as T2D and non-alcoholic fatty liver disease (NAFLD) (Alberti et al., 2009, 
Westphal, 2008). Obesity, IR and hyperinsulinaemia are strongly associated with T2D (Alberti 
et al., 2009, Ogbera, 2010) and NAFLD (Kotronen et al., 2007, Hsiao et al., 2007). 
1.7.5 Insulin, IR, atherogenic dyslipidaemia and hyperinsulinaemia  
Insulin is a polypeptide hormone produced by the β cells of the islets of Langerhans 
(Greenfield and Campbell, 2004, Kriketos et al., 2004, Dimitriadis et al., 2011). These cells are 
are embedded in the exocrine portion of the pancreas. Insulin is the most important 
hormone coordinating the use of fuels by tissues. It is composed of 51 (amino acid) AA 
arranged in two polypeptide chains, designated A and B. These chains are linked together by 
two disulphide bridges. Insulin is carefully coordinated with the release of glucagon from 
pancreatic α cells. The relative amounts of both hormones released by the pancreas are 
regulated so that the rate of hepatic glucose production is kept equal to the use of glucose 
by peripheral tissues (Greenfield and Campbell, 2004, Kriketos et al., 2004, Dimitriadis et al., 
2011). The synthesis and release of insulin are decreased during the scarcity of dietary fuels 
and during stress. These latter effects are mediated by adrenaline which is a hormone 
secreted by the adrenal medulla in response to stress, trauma, or extreme exercise. On the 
other hand, insulin secretion and synthesis are increased by glucose, AA, FA and gut 
hormones (Greenfield and Campbell, 2004, Kriketos et al., 2004, Dimitriadis et al., 2011). 
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Insulin exerts important actions on metabolism as shown in Figure 1.8. For instance, in the 
liver and muscle tissues, insulin increases glycogen synthesis, and glucose breakdown by 
increasing glycogenesis and glycolysis respectively. In muscle and adipose tissue, insulin 
increases glucose uptake by increasing the number of glucose transporters (GLUT-4) in the 
cell membrane. Also, in the liver, insulin decreases the production of glucose through the 
inhibition of glycogenolysis and gluconeogenesis (Greenfield and Campbell, 2004, Kriketos et 
al., 2004, Dimitriadis et al., 2011). Insulin also decreases TG degradation by inhibiting 
lipolysis in adipose tissue. This is accomplished by inhibition of hormone-sensitive lipase 
(HSL) activity which reduces the concentration of circulating FFA. Insulin also increases TG 
synthesis in adipocytes by increasing the rate of transport and metabolism of glucose into 
adipocytes, providing the substrate glycerol 3-phosphate for TG synthesis. Insulin also 
increases LPL activity in adipose tissue by increasing its synthesis, which increases TG 
hydrolysis releasing FAs needed for TG synthesis. Also, insulin in the liver promotes de Novo 
Lipogenesis, AA cellular uptake and protein synthesis (Greenfield and Campbell, 2004, 
Kriketos et al., 2004, Dimitriadis et al., 2011). 
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Figure 1.8: Insulin action on various nutrients metabolism.  
An altered cellular biological response to insulin action is known as IR, and it is associated 
with T2D, obesity and metabolic syndrome (Greenfield and Campbell, 2004, Kriketos et al., 
2004). Therefore, IR is a strong sign of the risk of developing T2D especially in obese 
individuals who are presented with central or visceral obesity (Greenfield and Campbell, 
2004, Kriketos et al., 2004). In obese individuals, FFA flux from accumulated visceral fat is 
transported directly to the hepatocytes which triggers cellular gluconeogenesis and 
interferes with lipid metabolism resulting in the development of hepatic IR (Westphal, 2008). 
This pathogenesis is typically found among patients with NAFLD. This state is initiated by 
increased FFA flux to the liver due to altered suppression of lipolysis as a result of peripheral 
IR and hyperinsulinaemia. That will lead to the accumulation of TG in the hepatocytes which 
eventually causes hepatic IR and NAFLD development (Westphal, 2008). This will potentially 
lead to the development of a state of dyslipidaemia which manifests increased LDL and TG 
concentrations, and decreased HDL concentrations. 
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IR is also related to the development of an atherogenic plasma lipid profile which is found 
among patients with metabolic syndrome, T2D and NAFLD (Westphal, 2008, Adiels et al., 
2006, Guerin et al., 2001, Sobenin et al., 1996, Grundy, 1997, Bril et al., 2016, Carmena et al., 
2004). This is reflected in altered lipid metabolism and altered LPL and HL activities in the 
peripheral tissues and the liver respectively. That is due to increased lipolysis, circulating 
FFA, and accumulation of TG in the hepatocyte which results in hypertriglyceridaemia and 
the increased size and production of TRL (Westphal, 2008, Adiels et al., 2006, Guerin et al., 
2001, Sobenin et al., 1996, Grundy, 1997, Bril et al., 2016, Carmena et al., 2004). This results 
in an increase in IDL and LDL concentrations, both of which are atherogenic due to their role 
in enhancing the progression of atherosclerosis (Westphal, 2008, Adiels et al., 2006, Guerin 
et al., 2001, Sobenin et al., 1996, Grundy, 1997, Bril et al., 2016, Carmena et al., 2004). As a 
result, LDL particles interact with the expanded TG-rich plasma pool leading to an exchange 
of CE and TG facilitated by CETP (Westphal, 2008, Adiels et al., 2006, Guerin et al., 2001, 
Sobenin et al., 1996, Grundy, 1997, Bril et al., 2016, Carmena et al., 2004). This will lead to 
the production of SDLDL (Frayn, 2010, Barter, 2000). These particles are at more risk of 
oxidative damage as they lose their core lipids and fat-soluble antioxidant vitamins 
(Westphal, 2008, Adiels et al., 2006, Guerin et al., 2001, Sobenin et al., 1996, Grundy, 1997, 
Bril et al., 2016, Carmena et al., 2004). Also, SDLDL can infiltrate the arterial wall radially, 
oxidised, and taken up by macrophage scavenger receptors to initiate the process of foam-
cell formation. As described earlier, foam-cell formation is a significant step in 
atherosclerosis. Hence, SDLDL particles are directly associated with increasing the risk of CHD 
and CVD (Westphal, 2008, Adiels et al., 2006, Guerin et al., 2001, Sobenin et al., 1996, 
Grundy, 1997, Bril et al., 2016, Carmena et al., 2004). 
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IR also leads to hyperinsulinaemia. Eventually, this can contribute to the development and 
increased risk of CVD via atherosclerosis (Bugianesi et al., 2005, Giovannucci, 2007). There is 
evidence that hyperinsulinaemia causes changes in the arterial wall by enhancing smooth 
muscle cell proliferation (Bugianesi et al., 2005, Giovannucci, 2007), and this is, as 
mentioned earlier, essential in the development of atherosclerosis. As the condition 
progresses, it will cause blood vessel inflexibility (altered arterial elasticity) which controls 
resistance in the peripheral circulation and regulates blood pressure (Bugianesi et al., 2005, 
Giovannucci, 2007). Further progression of this condition will lead to hypertension which is 
indeed a crucial factor for CHD and CVD (Giovannucci, 2007). 
1.8 NAFLD and T2D Mellitus as CVD risk factors 
These two diseases are both manifestations of the metabolic syndrome and are associated 
with an increased risk of CVD. In both conditions, three key major metabolic risk factors can 
be found; IR, obesity, hypertriglyceridaemia, atherogenic lipoprotein phenotype (ALP) and 
hyperinsulinaemia (Westphal, 2008, Giovannucci, 2007). Therefore, both diseases are an 
area of interest as major factors for increasing the risk of CVD. 
1.8.1 Non-alcoholic fatty liver disease (NAFLD) 
NAFLD is a disorder with elevated lipid deposition in the liver (steatosis) that can lead to the 
development of an inflammatory condition called non-alcoholic steatohepatitis (NASH) 
which could lead to an end-stage disease or death (Vernon et al., 2011). NAFLD is considered 
the most common liver disease as it is estimated that around 20-30% of the adult population 
in the developed countries have NAFLD (Bellentani et al., 2010). There are several stages of 
NAFLD progression starting with steatosis (Preiss and Sattar, 2008). The process of steatosis 
is the abnormal retention of TG within the cell cytoplasm indicating impairment in the 
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synthesis and clearance of cellular TG. Progression of hepatic steatosis to NASH can increase 
the risk of developing liver fibrosis, cirrhosis, and hepatocellular carcinoma leading to death 
(Musso et al., 2011). 
The major risk factor that contributes to NAFLD is obesity (Preiss and Sattar, 2008). It is the 
primary driver for the development and prevalence of NAFLD. Hepatic cellular lipid retention 
is strongly correlated with central obesity (Sung et al., 2012, Seo et al., 2012). Also, ethnicity 
and genetic predispositions are potential risk factors based on preliminary data (Petersen et 
al., 2006). Importantly, there is a close link between T2D and NAFLD as both are considered 
as a risk factor for the other. NAFLD is associated with peripheral and hepatic IR, as 
explained previously, and contribute to increasing the risk of CVD in patients with metabolic 
syndrome (Kotronen et al., 2008a, Hsiao et al., 2007). 
1.8.1.1  Diagnosis 
NAFLD patients are often asymptomatic with abnormal liver function results. The essential 
element of NAFLD is the accumulation of TG as fat droplets within the cytoplasm of 
hepatocytes. The cut-off value is the accumulation of more than 5-10% of fat droplets in 
hepatocytes in the absence of alcohol consumption, and liver biopsy is an evident of a 
prerequisite for subsequent events of NASH (Hsiao et al., 2007, Miyake et al., 2015). Also, a 
typical biochemical pattern of increased concentrations of alanine aminotransferase (ALT) 
exceeding those of aspartate aminotransferase (AST) is necessary for NAFLD diagnosis (Sorbi 
et al., 1999). This standard pattern is particularly suitable for differentiating between hepatic 
steatosis from NAFLD and alcoholic liver injury, with the latter frequently associated with a 
high AST: ALT ratio (Sorbi et al., 1999). However, AST concentrations increase with a 
resultant rise in the AST: ALT ratio in the progression of hepatic steatosis to NASH and 
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hepatic fibrosis (Sorbi et al., 1999). Gamma-glutamyltransferase (γGT) might likewise 
increase (Sorbi et al., 1999). NAFLD can also be identified using hepatic echogenicity on 
abdominal ultrasonography (Westerbacka et al., 2004). History of past results for T2D or 
fasting glucose and/or HbA1c, lipid profiles, alcohol intake, weight are needed to confirm 
NAFLD diagnosis (Fraser et al., 2009, Wong et al., 2006, Chatterton et al., 2012). Also, 
computed tomography (CT) scan, and magnetic resonance spectroscopy (MRS) imaging can 
assess liver lipid stores of the abdominal region. Liver biopsy is needed to determine NAFLD 
progression to NASH (Miyake et al., 2015). 
1.8.1.2  NAFLD treatment and management; 
Lifestyle intervention is essential for managing NAFLD. Healthy diets with low fat intake and 
high intake of fibre and carbohydrates are advised which can lead to weight loss and 
decreased lipid storage (Thoma et al., 2012). Also, physical activity increases fat metabolism 
and reduces lipid storage (Thoma et al., 2012, American Diabetes Association, 2016). The 
combination of both approaches is considered key in the management of NAFLD and it is 
essential if the patient has T2D (American Diabetes Association, 2016). Finally, regarding 
drug treatment, numerous trials of vitamin E, metformin and statins have failed to 
demonstrate evidence in reducing liver disease progression. However, some studies have 
shown some improvement in early stages of NASH in patients with NAFLD under treatment 
with insulin sensitizers to treat hepatic IR such as pioglitazone (Shyangdan et al., 2011). 
There is an evidence showing that long-chain n-3 polyunsaturated fatty acids (PUFA) is a 
potential treatment for NAFLD in which they stimulate HL activity in the liver to which 
suppresses lipogenesis and increases FA oxidation (Clarke and Jump, 1997, Clarke et al., 
1998), and increased LPL activity in the adipose tissue which increasing TRL removal and TG 
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uptake (Jacobson, 2008, Khan et al., 2002, Harris et al., 1997). It is been shown that n-3 PUFA 
cause the redistribution of atherogenic SDLDL which reduces the intensity of ALP associated 
with NAFLD (Griffin, 2001) 
1.8.1.3  The effect of Exercise on altered lipid metabolism in patients with NAFLD 
It has been demonstrated in many studies that exercise can improve atherogenic 
dyslipidaemia in patients with NAFLD (Burton et al., 2008, Farah et al., 2010, Tsetsonis and 
Hardman, 1996, Zhang et al., 2002, Bril et al., 2016). Exercise has been shown to increase 
blood flow to the exercised muscle and the liver (Hurren et al., 2011). Increased skeletal 
muscle blood flow is necessary for postprandial TG clearance thereby increasing capillary 
blood volume and allowing an opportunity for more widespread hydrolysis of circulating TG 
(Hurren et al., 2011). Increased blood flow will increase hepatic and peripheral insulin 
sensitivity (Shojaee-Moradie et al., 2007, Borghouts and Keizer, 2000). Increased insulin 
sensitivity will increase the rate of hydrolysis in the hepatocytes and decrease adipocyte 
lipolysis (Patsch, 1998). An elevated hydrolysis rate in the liver will directly contribute to 
increasing insulin sensitivity by hydrolyzing cellular fat droplets which reduce fat cellular 
accumulation (Hurren et al., 2011, Cuthbertson et al., 2016, Shojaee-Moradie et al., 2007). 
Exercise increases whole body fat oxidation especially in skeletal muscles and the liver, and 
will lead to increase the activity of LPL and HL via decreasing insulin concentration and IR (Al-
Shayji et al., 2012, Shojaee-Moradie et al., 2007, Cuthbertson et al., 2016). Also, an exercise-
induced energy deficit may stimulate skeletal muscle LPL activity and hence increased TRL 
hydrolysis and FFA release for cellular uptake (Kantor et al., 1987, Wang and Eckel, 2009, 
Zhang et al., 2002). Ultimately this enhances the reduction in circulating FFA and hence 
improving overall insulin sensitivity (Shojaee-Moradie et al., 2007). There is evidence that 
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exercise decreases VLDL1-TG particle size, an effect that may raise the affinity of these 
particles for LPL hydrolysis and thus clearance from the circulation (Al-Shayji et al., 2012). As 
a result, more TRL are hydrolyzed, and TG concentration will decrease in the plasma (Wang 
and Eckel, 2009). Also, this will lead to an increase in glucose uptake in the peripheral tissues 
due to decreased IR, and that will result in reducing insulin secretion and correct 
hyperinsulinaemia (Newsom et al., 2010, Tuominen et al., 1997, Shojaee-Moradie et al., 
2007). 
Several studies have shown that exercise increases HDL-C in patients with altered lipid 
metabolism (Escola-Gil et al., 2015). However the possible mechanisms behind this are not 
yet clearly understood and further investigations are required. One possible hypothesis for 
this is that exercise decreases plasma TRL  (Bellou et al., 2013, Al-Shayji et al., 2012, 
MacEneaney et al., 2009) which will lead to decrease the rate of exchange of TG and CE 
between TRL and HDL facilitated via CETP (Barter, 2000, Frayn, 2010), which may reduce the 
formation of SDLDL and increases HDL-C concentrations which are manifestations of the ALP 
(Toft-Petersen et al., 2011). 
1.8.2 Type 2 Diabetes (T2D) 
T2D is a chronic disorder which is associated with impaired glucose and lipid metabolism 
with severe clinical consequences if not prevented and/or managed (WHO, 2015b). In 2014, 
it was estimated that the global prevalence of diabetes was 9% among adults above 18 years 
old (WHO, 2015b). In 2012, about 1.5 million deaths were directly caused by diabetes (WHO, 
2015b). Also, it is recorded that more than 80% of diabetes deaths occur in developing 
countries with low or intermediate income. The WHO have estimated that diabetes will be 
the seventh leading cause of death in 2030 (WHO, 2015b). Various complications of diabetes 
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can affect the body (WHO, 2015b) such as microvascular complications include neuropathy, 
nephropathy and retinopathy, and macrovascular complications which include stroke, 
ischaemic heart disease and peripheral CVD (WHO, 2015a, WHO, 2015b). The prevalence of 
T2D has been rising in the last few decades, accompanied by the worldwide increase in 
obesity (WHO, 2015c). T2D is a significant public health disorder associated with increased 
morbidity and reduced life expectancy. It imposes a financial burden on the patient and the 
health service provider (WHO, 2015b, American Diabetes Association, 2016). 
1.8.2.1 Diagnosis of T2D 
T2D classification and diagnosis has been a subject of much consultation, debate and 
revision. Expert teams such as the WHO and the American Diabetes Association (ADA) have 
established the diagnostic criteria for diabetes, which are based on the measurement of 
fasting or 2-h post-glucose load concentration (WHO, 2015b, American Diabetes Association, 
2016). The aetiological classification of diabetes has now been widely accepted, with type 1 
and T2D Mellitus being the two primary types of diabetes, and T2D accounting for the 
majority 90% of total diabetes prevalence (WHO, 2015b, WHO, 2015c, American Diabetes 
Association, 2016). 
The diagnosis of T2D can be determined by measuring fasting plasma glucose concentration 
in a blood sample, and it can be determined by using an oral glucose tolerance test (OGTT) 
as recommended by the WHO (WHO, 2015b). T2D is diagnosed if fasting plasma glucose 
concentration is  ≥ 7 mmol/l, and ≥ 11 mmol/l two hours after a 75g OGTT (WHO, 2015b, 
American Diabetes Association, 2016). In 2009, the ADA agreed to use haemoglobin A₁c 
(HbA₁ϲ) in the diagnosis of diabetes in the United States of America (USA) but not it is yet 
used in the United Kingdom (American Diabetes Association, 2016). The USA decided that 
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with the greater accessibility of a standardised HbA1c assay, it is now possible to use HbA1c 
as a diagnostic test (American Diabetes Association, 2016, WHO, 2015b). The main 
advantages of using HbA1c are practical as a random blood sample is adequate, and there is 
no necessity for special patient preparation. The ADA has adopted the recommendation of 
the expert committee on a cut-off value for the diagnosis of diabetes. The cut-off value is an 
HbA1c of 6.5% or more. It equals 47.5 mmol/mol in International Federation of Clinical 
Chemistry (IFCC) unit or 7.8 mmol/l (The Global Diabetes community, 2011, American 
Diabetes Association, 2016). 
1.8.2.2  Altered lipoprotein metabolism in T2D 
T2D is characterised by hyperglycaemia, IR, and impaired insulin secretion. IR has a 
significant role in the development of the characteristic ALP associated with T2D including 
reduced HDL and increased SDLDL concentrations (Adiels et al., 2006, Sobenin et al., 1996, 
King et al., 2011, Matikainen and Taskinen, 2013, Pettersson et al., 2011). It is noted that 
patients with T2D have increased fasting and postprandial TG and apoB-48 (Lewis et al., 
1991, Meng et al., 1983, Schaefer et al., 2002, Taniguchi et al., 2000, Curtin et al., 1996). 
Elevated concentrations of postprandial CM and CMRs in IR have been mainly attributed to 
impaired TRL clearance from the circulation (Shojaee-Moradie et al., 2013). Indeed, 
increased plasma apoB-48 is related to reduce catabolic rates of the CMRs in patients with 
T2D (Dane-Stewart et al., 2003, Hogue et al., 2007a). Therefore, clearance of CMRs could be 
impaired as a result of increased hepatic-VLDL secretion in IR (Lewis, 1995). That is because 
increased availability of TG and cholesterol in T2D increases VLDL-hepatic synthesis which 
might affect the LPL activity in clearing CMR (Lewis, 1995). Slow removal of CM and CMRs by 
reduced LPL activity is also addressed in IR (Kobayashi et al., 2007) due to the diminished 
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regulation of LPL by insulin (Patsch, 1998). Overproduction of intestinal lipoproteins has 
been recently recognised as a feature of IR. Studies have demonstrated that the intestine 
actively contributes to elevating TRL, as CM and VLDL particles, in the state of IR by 
increased CM production (Adelis and Lewis, 2008, Duez et al., 2008b). Several studies have 
shown high intestinal production of lipoproteins in IR and obesity in humans (Su et al., 2009, 
Mamo et al., 2001, Chan et al., 2002b, Cohn et al., 1999, Phillips et al., 1997, Shojaee-
Moradie et al., 2013). Recent studies suggested that obesity and IR may stimulate the action 
of MTP, which is responsible for assembling the apolipoprotein to the lipid fraction, which 
would increase TRL intestinal production by increasing TG per particle (Xiao et al., 2012). 
An important regulatory mechanism of apoB-100 production is the availability of TG and 
cholesterol in the liver (Sniderman and Cianflone, 1993, Thompson et al., 1996). Many 
studies have shown that obese and insulin resistant individuals have increased hepatic VLDL-
apoB-100 secretion compared with non-obese individuals (Riches et al., 1998, Chan et al., 
2002a). In IR, hepatic synthesis of cholesterol and TG substrates is elevated. IR also causes 
the impairment of LDL-receptor activity and expression needed for LDL-apoB-100 clearance 
(Taskinen, 2002, Ginsberg, 2003). Other studies have demonstrated that T2D patients have a 
significant increase in VLDL particle production as a result of improved hepatic secretion of 
VLDL1 apoB-100 (Adiels et al., 2006). IR effects can be partly mediated by visceral adipose fat 
mass accumulation, the elevated flux of FA from adipose tissue to the liver, and induced fat 
accumulation in the liver. Also, chronic hypertriglyceridaemia in T2D increases HDL 
interaction with expanded TG plasma pool resulting in the production of enriched TG-HDL 
particles and SDLDL. Collectively with hyperglycaemia, this leads to increased VLDL1 particles 
secretion and resulting in the formation of ALP (Adiels et al., 2006). 
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1.8.2.3 Prevention and management of T2D 
High-risk individuals with impaired glucose tolerance (Hupe-Sodmann et al., 1995), or those 
with T2D, can be managed by intensive lifestyle intervention or drug therapy with glucose-
lowering agents such as metformin (Wareham and Griffin, 2001). Also, insulin administration 
can be a treatment in T2D when medication fails to correct hyperglycaemia. Furthermore, 
lifestyle interventions comprise preservation of a healthy body weight through reducing 
sedentary behaviour, increasing physical activity and eating a healthy diet rich in fibre and 
low in fat (WHO, 2015b). Screening has been proposed in the anticipation that early 
detection and early treatment would reduce the long-term liability to individuals and the 
health services (WHO, 2015b). However, most authorities such as the National Health 
Service (NHS) have suggested additional research and limited screening targeting high-risk 
subgroups to find a better and/or improved treatment. There are many ways in which high 
blood glucose and associated dyslipidaemia can be reduced directly and/or indirectly 
through various drug actions and/or gastrointestinal bypass surgery (American Diabetes 
Association, 2016, WHO, 2015b, Pok and Lee, 2014, Bradley et al., 2012). Most of these 
drugs will control and/or manage diabetic associated hyperglycaemia without having a 
significant effect on controlling or correcting associated altered lipid metabolism. Glucagon-
like peptide-1 (GLP-1) receptor agonists have been recently approved as a treatment for 
uncontrolled hyperglycaemia, and it is been shown that it has a secondary effect on 
lipoprotein metabolism (Xiao et al., 2012). 
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1.9 GLP-1 and T2D 
1.9.1 GLP-1 and its actions 
GLP-1 is an incretin hormone composed of 30 AA derived from the proglucagon gene, which 
is secreted by neuroendocrine enteroglucagon-producing cells in the lower gut (L cells). L 
cells are located in the duodenum, jejunum, ileum, and the colon. GLP-1 secretion begins at 
the L cells which are directly stimulated by digested nutrients (AA, FA and glucose) and 
digestive juices such as bile acids. Nutrients interact with their apical surface which 
promotes GLP-1 secretion which reaches its highest concentration in blood plasma within 10 
min of consumption (Persson et al., 2000, Holst, 2007). GLP-1 secretion is also indirectly 
stimulated by other neural and endocrine factors such as a gastrin-releasing polypeptide 
(GRP), glucose-dependent insulinotropic polypeptide (GIP), and impulses transmitted by the 
vagus nerve through acetylcholine by interacting with neuronal and vascular tissues on the 
basolateral side of enterocytes (Fehmann et al., 1995, Holst, 2007, Baggio and Drucker, 
2007). GLP-1 diffuses through the basal lamina into the lamina propria and enters into 
circulation by intestinal capillaries, draining into the hepatic portal vein to act primarily at 
the pancreas on β cells, and finally into the systemic circulation (Steinert et al., 2009, 
Steinert et al., 2010). Once secreted into the circulatory system, the enzyme dipeptidyl 
peptidase-4 (DPP-4) mainly breaks down GLP-1 within minutes (Meier et al., 2004), and its 
elimination occurs by renal clearance through glomerular filtration and catabolism (Baggio 
and Drucker, 2007, Takei and Kasatani, 2004). Due to very efficient removal mechanisms 
especially by DPP‑4 activity, the concentration of the active GLP‑1 constitutes only 20% of its 
overall concentration (Deacon et al., 1995).  
GLP-1 binds to a particular receptor, GLP‑1 receptor (GLP‑1R), which shows a similar 
structure to the glucagon receptor (Wilmen et al., 1998). GLP-1R is widely expressed in 
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pancreatic islets, where GLP-1 stimulates insulin secretion, decreases glucagon 
concentration, and suppresses its release (Figure 1.9) (Takei and Kasatani, 2004, Taskinen, 
2005, Holst et al., 2011, Baggio and Drucker, 2007). GLP-1R has the classic structure of 
adenylate-cyclase-coupled and G-protein-coupled receptors. GLP-1 activates the GLP-1R 
signalling pathway in a glucose-dependent way, i.e., only during hyperglycaemia (Baggio and 
Drucker, 2007, Portha et al., 2011). The molecular mass of the GLP-1R is about 65 kDa. GLP-1 
stimulation results in an elevated intracellular cyclic adenosine monophosphate (CAMP) and 
calcium concentration, which in β cells is an indication of exocytosis of early synthesised 
insulin (Drucker et al., 1987). Also, protein kinase A activation promotes the biosynthesis of 
insulin and gene expression modification (Drucker, 2006) as shown in Figure 1.9. GLP-1R is 
also expressed in the gastrointestinal tract (GIT) such as gastric mucosal gland cells in the 
stomach and enterocytes of the intestines (Broide et al., 2013, Xiao et al., 2012). GLP-1 acts 
by decreasing the rate of gastric emptying and CM production respectively (Gutzwiller et al., 
1999, Broide et al., 2013, Xiao et al., 2012). Also, GLP-1R is expressed in the brain, where 
GLP-1 functions as a neurotransmitter in the hypothalamus, which controls satiety 
(Neumiller, 2011).  
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Figure 1.9: GLP-1 actions and target organs. GLP -1, through its receptor GLP -1R, has 
functional effects on a variety of tissues. The Figure is Modified and obtained from (Ceccarelli  
et al.,  2013). GLP-1: Glucagon-like peptide –  1.  
 
In patients with T2D, it is been suggested that the activity of GLP-1 is diminished, but the 
numbers of GLP receptors are unaltered. The reason behind this is debatable; it is been 
demonstrated that diminished effects of endogenous GLP-1 are due to chronic 
hyperglycaemia, hyperinsulinaemia and IR features found in T2D (Meier and Nauck, 2010). In 
patients with T2D, GLP-1 secretion cannot cope with chronic hyperglycemia resulted from IR 
(Meier and Nauck, 2010). Therefore, β cells become exhausted primarily due to continual 
insulin production in response to hyperglycaemia besides the secondary response to the 
minimal concentration of endogenous GLP-1 which diminishes its action (Arulmozhi and 
Portha, 2006, Marre and Penfornis, 2011, Meier and Nauck, 2010). 
Another explanation is that hyperleptinaemia and leptin resistance in obese individuals 
diminishes GLP-1 actions (Anini and Brubaker, 2003). Leptin resistance state could lead to 
the development of hyperleptinaemia (Anini and Brubaker, 2003). This results in the 
development of IR, hyperinsulinaemia, fat accumulation and obesity which are all 
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manifestations of T2D (Anini and Brubaker, 2003). There is growing evidence for the 
existence of an adipo-enteroendocrine axis which is responsible for the regulation of 
nutrient homoeostasis, genetic predisposition and stress responses (Anini and Brubaker, 
2003). It is associated with decreased nutrient-stimulated GLP-1 secretion via leptin 
resistance and altered lipolysis in obese individuals (Anini and Brubaker, 2003). 
1.9.2 GLP-1 receptor agonists 
GLP-1 receptor agonists are used for T2D therapy based on its actions on plasma blood 
glucose concentrations (Sadrzadeh et al., 2007, Vilsboll et al., 2001). However, endogenous 
GLP-1 is limited due to the metabolic instability caused once DPP-4 enzyme rapidly cleaves 
its N-terminal. The rapid cleavage of the secreted GLP-1 is almost immediate, resulting in a 
short half-life of less than 2 min. DPP-4 is mainly found on the luminal surface of the ECs, 
which means that a large portion of the GLP-1 that leaves the gut is already degraded as an 
inactive metabolite (Baggio and Drucker, 2007, Takei and Kasatani, 2004), and only 25% of 
the GLP-1 secreted reaches the portal circulation. Additionally, 40-50% of GLP-1 that 
bypasses gut is metabolised in the liver, and only the remaining 10-15% enters the systemic 
circulation (Holst, 2007). Long-acting GLP-1 receptor agonists have been developed to 
overcome premature GLP-1 metabolism by DPP-4. Alternatively, DPP-4 inhibitors can be 
used alone and are also being considered for concomitant administration with GLP-1 
receptor agonists (Unger, 2011). However, the action of GLP-1 receptor agonists is 
independent of the concentration of endogenous GLP-1 and provides much higher 
pharmacological concentrations than the DPP-4 inhibitors (Unger and Parkin, 2011, Garber, 
2011). 
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In 2005 and 2010, two GLP-1 receptor agonists, Exenatide (Bydureon®) and Liraglutide 
(Victoza®), were approved by the Food and Drug Administration for the treatment of T2D (Li 
et al., 2011). Exenatide (4186.6 Da) is the synthetic form of exendin (Arulmozhi and Portha, 
2006), a peptide isolated from the salivary gland of Gila monster (Heloderma suspectum), 
showing 53% homology to GLP-1. It has a half-life of 2.4 hours and acts by binding GLP-1R at 
least with the same affinity as native GLP-1 (Marre and Penfornis, 2011, Ahren, 2011, 
Garber, 2011, EMA, 2011). On the other hand, Liraglutide (3751.2 Da) shows 97% homology 
to GLP-1, being very similar to native peptide, and altered by only one AA substitution, being 
further linked by a FA side chain. This FA portion allows a non-covalent binding with serum 
albumin, which increases the half-life of the peptide for approximately 13 hours, resulting in 
slow degradation and clearance by DPP-4. Regardless of the modifications, the ability of 
binding with GLP-1R remains the same. Both Exenatide and Liraglutide are delivered 
subcutaneously and have been shown to improve glycemic control (Marre and Penfornis, 
2011, Li et al., 2011, Deacon, 2009). Many other GLP-1 receptor agonists are in late clinical 
development (Kalra et al., 2009); thus new agents are anticipated to reach the market in the 
future.  
Lixisenatide (Lyxumia ®), is a GLP-1 receptor agonist that has been safety tested and was 
licensed for use in the EU in February 2013 for the management of glycemic control in T2D 
patients. It is recommended to be given as a once-daily dose due to its half-life of 3 hours 
with long duration of action (EMA, 2013). It is recommended that lixisenatide should be 
given as combined treatment with oral glucose-lowering medicinal products and/or basal 
insulin when adequate glycemic control is not achieved even with controlled diet and 
increased physical activity (EMA, 2013). 
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1.9.3 GLP-1 effect on lipoprotein metabolism 
GLP-1 receptor agonist modulation of fasting glucose and HbA₁ϲ concentrations in T2D 
patients have been well established by many studies (Drucker and Nauck, 2006). In a study 
conducted by Cummings et al. (2010), the administration of Liraglutide into a young male 
T2D rat model caused a reduction in fasting plasma TG concentrations by about 50–60% in 
Liraglutide-treated animals compared with the control and food-restricted rats. Also, liver TG 
content was found lower in both Liraglutide-treated and food-restricted animals compared 
with control animals (Cummings et al., 2010). Chronic administration of CNTO736, a novel 
GLP- 1R agonist, was found to inhibit VLDL secretion in high-fat fed mice, whereas acute 
administration did not seem to affect this pathway (Parlevliet et al., 2009a). More recently, 
these findings were confirmed by a 2-week treatment of fructose-fed hamster and mouse 
models with exendin-4 which illustrated the significant decrease in intestinal CM secretion 
when compared to controls (Hsieh et al., 2010). In a recent study conducted in Japan, serum 
concentrations of TG were also decreased after three months of treatment in 188 T2D 
patients with 50 mg Sitagliptin, a DPP-4 inhibitor, for the first three months (Sakamoto et al., 
2013). In two separate studies, exenatide treatment in T2D patients resulted in a significant 
reduction in postprandial TG concentrations (Schwartz et al., 2008, DeFronzo et al., 2008) 
and Vildagliptin treatment, a DPP-4 inhibitor, decreased postprandial elevation of TG 
concentrations and apoB-48 in T2D patients (Matikainen et al., 2006). Interestingly, Meier et 
al. (2006) studied the effect of acute synthetic GLP-1 infusion on a test meal on TG 
concentrations in healthy participants. GLP-1 infusion during meal intake resulted in 
complete prevention of a postprandial increase in plasma TG by delaying in gastric emptying 
(Meier et al., 2006).  
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In a study published by Schwartz et al. (2010) which focused on the acute effects of GLP-1R 
modulation with exenatide on postprandial lipoprotein and TG concentrations in patients 
with recent onset T2D and impaired glucose tolerance (Schwartz et al., 2010a). Exenatide 
decreased the lipid content and the number of intestinally-derived lipoprotein particles 
(Schwartz et al., 2010a). Furthermore, the study showed that Exenatide treatment enhanced 
apoB-48 lipoprotein particle clearance, and decreased intestinal particle secretion into the 
circulation (Schwartz et al., 2010a). In a study by Xiao et al. which investigated the effect of 
exenatide treatment on postprandial production of CM-apoB-48, exenatide significantly 
suppressed TG concentration and the production rate (PR) of CM-apoB-48 (Xiao et al., 2012). 
These results suggest possible direct effects of Exenatide on the PR of intestinal lipoprotein 
particles (Xiao et al., 2012).  
It is important to note that postprandial lipaemia reduction via correcting 
hypertriglyceridaemia is possibly anti-atherogenic (Greene et al., 2001), and may be a novel 
approach to hyperlipidaemia treatment associated with other conditions. Therefore, it is 
important to elucidate the role of GLP- 1 receptor agonists on hepatic and intestinal 
lipoprotein PRs and to determine the mechanism of this effect. One well-established method 
to investigate lipid metabolism in humans in vivo is the use of isotope-labelled tracers for 
the quantitative evaluation of TG metabolism (Magkos and Mittendorfer, 2009). 
T2D patients with improved metabolic control have less postprandial apoB-48-containing 
particles (Phillips et al., 2000), and an intact insulin signalling pathway acutely suppresses 
hepatic VLDL secretion and intestinal CM production in vivo (Levy et al., 1996). It is 
important to note that increased insulin sensitivity in T2D patients treated with GLP-1 
receptor agonists may decrease the elevation of postprandial hepatic VLDL-apoB-100 
synthesis and intestinal CM-apoB-48 production through direct and indirect effects (Levy et 
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al., 1996, Phillips et al., 2000). As a consequence, this will correct postprandial 
hypertriglyceridaemia and lessen the exchange rate of CE and TG transfer between HDL 
particles and the TRL-TG pool in the plasma via CETP (Barter, 2000, Diffenderfer et al., 2012, 
Frayn, 2010). This may lead to a decrease in TG-enriched HDL formation and hence reduces 
the clearance of HDL-apoA-I from the circulation (Zannis et al., 2006). Consequently, this will 
increase the concentration of functional HDL-C and apoA-I and decrease SDLDL, which 
contributes to reducing the risk of CVD (Lamarche et al., 1999, Patsch, 1998, Greene et al., 
2001, Barter, 2000, Diffenderfer et al., 2012). 
1.9.4 GLP-1 potential direct effects on apolipoprotein-B and HDL-apoA-I 
Direct effects of GLP-1 on the enterocytes can be observed in rats where recombinant GLP-1 
inhibited lymph flow, lymph TG absorption, and lymph apoB-48 secretion in response to the 
intraduodenal fat infusion (Qin et al., 2005). Also, GLP-1 caused a direct effect on apoB-48 
secretion in the enterocytes observed in hamsters and mice (Hsieh et al., 2010). In humans, 
a study proposes that exenatide decreases the lipid content and the number of intestinally-
derived lipoprotein particles (Schwartz et al., 2010a). Also, the recent study conducted by 
Xiao et al. (2012) indicated possible direct involvement of GLP-1R signalling in intestinal 
lipoprotein particle secretion. The suggested effects of GLP-1 resulted in suppressing TRL 
intestinal production at least partly by directly suppressing CM assembly, and CM flow in the 
enterocytes (Xiao et al., 2012) but not hepatic VLDL-apoB100. The study also suggested that 
the decrease in CM-apoB-48 by exenatide not only by reducing apoB-48 protein synthesis 
but also CM packaging with neutral lipids, without suppressing and/or up-regulating MTP in 
the enterocytes (Xiao et al., 2012). Moreover, the study suggested that GLP-1 may suppress 
apoB-48 mRNA translation, apoB-48 intracellular trafficking, and stability in the enterocytes 
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(Xiao et al., 2012). Although human liver cells contain GLP-1R, there are no clinical studies 
showing direct active signalling of GLP-1 on human hepatocytes regarding VLDL-apoB100 
secretion. However, it is important to mention that MTP is expressed in human hepatocytes, 
and it is essential for VLDL-apoB100 synthesis. Therefore, GLP-1 might exert similar effects 
on VLDL-apoB100 in the liver which is seen in CM-apoB48 in the intestinal enterocytes. 
Furthermore, GLP-1 can exert a direct impact on VLDL-apoB-100 and HDL-apoA-I 
metabolism. Many studies have investigated the effect of GLP-1 receptor agonist on HDL-C 
concentration but not HDL-apoA-I in humans. For instance, a study conducted by Chehade et 
al. (2013) investigated the direct impact of GLP-1 on apoA-I gene expression in HepG2 liver 
cells and Caco-2 intestinal cells (Chehade et al., 2013). This study showed that GLP-1 induces 
apoA-I gene expression in HepG2 liver cells but not Caco-2 intestinal cells (Chehade et al., 
2013). Also, it was demonstrated in the same study that GLP-1 induces mRNA concentrations 
of ABCA1 which is strongly related to apoA-I and HDL metabolism (Wang and Smith, 2014). 
Chehade et al. (2013) found that GLP-1 induced apoA-I gene expression through an effect on 
the transcription factor SP1 and an insulin-responsive core element (IRCE) (Taylor et al., 
1996, Lam et al., 2003, Zheng et al., 2001, Chehade et al., 2013, Rye et al., 2016). It is 
essential to confirm these effects of GLP-1 on apoA-I and ABCA1 gene expression in human 
enterocytes and hepatocytes. Therefore, to confirm these potential direct effects, more 
clinical studies need to be performed. 
1.10 NAFLD, T2D and CVD; 
Genetic factors in combination with obesity and poor lifestyle can lead to the development 
of IR (Pietilainen et al., 2005, Kechagias et al., 2008, Valtuena et al., 2006). In this condition, 
insulin’s action on tissues will be impaired. Increased lipolysis in IR will lead to the increase in 
delivery and synthesis of FFA in the liver (Fabbrini et al., 2008, Kotronen et al., 2008a, 
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Kotronen et al., 2008b). As a result, this will cause an increase in the synthesis of TG and the 
evolvement of hepatic steatosis (Dowman et al., 2010). Increased VLDL-TG synthesis will 
result in the presence of hypertriglyceridaemia and reduced HDL-C concentrations (Dowman 
et al., 2010). In IR, gluconeogenesis and glycolysis increases, and uptake of glucose by 
muscles and adipose tissue is reduced which will lead to hyperglycaemia and 
hyperinsulinaemia (Lewis et al., 1993, Adiels et al., 2006). All the previous co-existing events 
will give rise to the development of T2D and/or NAFLD (Rashid et al., 2003, Eckel et al., 
2010). Also, an elevated postprandial TG plasma pool will increase TRL concentration which 
increases the risk of atherogenic dyslipidaemia in patients with T2D and NAFLD (Alcala-Diaz 
et al., 2014, Aathira and Jain, 2014, Tushuizen et al., 2010, Griffin et al., 1994). In both 
conditions, these co-existing factors take place although it is not necessary that a patient 
with NAFLD will develop T2D or vice versa. However, both diseases could be present in the 
same patient, and each disease if not treated and/or managed could lead to the 
development of the other (Eckel et al., 2010, Bulum et al., 2011). Also, both diseases are a 
manifestation of IR and obesity and lead to the increased incidence of CHD and CVD through 
atherogenic dyslipidaemia (Taskinen and Boren, 2015, Manoria et al., 2013, Hassing et al., 
2014, Tushuizen et al., 2010, Nicholls and Lundman, 2004). Patients with NAFLD but without 
T2D have a slight advantage is that their pancreas β-cells are still intact (not exhausted like in 
patients with T2D) and capable of producing adequate insulin when IR is corrected. While 
patients with T2D do not necessarily develop liver steatosis and/or NASH, however, they 
need to maintain their normal glucose concentrations using glucose-lowering agents to 
balance reduced insulin secretion and IR condition. 
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1.11 Stable isotope technique for measuring CMs and VLDL 
Investigation of lipid metabolism and its regulation requires information about the rates of 
lipid absorption into the body (from the intestine), production and transport in the body and 
utilisation by different tissues. In nature, there are three occurring isotopes of carbon: 12, 
13, and 14; in which ¹²C and ¹³C are stable in a proportion of approximately 99:1 as seen in 
Figure 1.10. Stable isotope tracer molecules are naturally occurring, non-radioactive isotopes 
of a given atom that are less abundant in a particle within a biological system than the 
lightest naturally occurring isotope (Boren et al., 2012). The use of stable isotopes revolves 
around the concept of ‘enrichment’. Enrichment is defined as the tracer/tracee ratio (TTR) 
within a sample, with the ‘tracer’ being the labelled substance introduced into the system 
and the ‘tracee’ is defined as the substance of interest within the body to be traced. 
Isotopically labelled materials, for example, an AA tracer can be administered orally or by an 
intravenous infusion to trace apolipoproteins in TG particles. Apolipoproteins are essential 
for the synthesis and assembly of TG molecules in vivo as explained earlier. Repeated 
feeding protocol is used to establish a constant TG concentration in the blood or a TG 
‘steady state’. This steady state enables the measurement of apolipoproteinB kinetics 
accurately within TRL particles. Enrichment is measured by gas chromatography-mass 
spectrometry (GC-MS) which can separate and quantify stable isotope tracers according to 
molecular mass (Boren et al., 2012). In this study, the rate of incorporation of infused ¹³C 
tracer (1-¹³C- leucine) in apoB-100 and apoB-48 moiety of VLDL and CM respectively, and the 
concentration of both apoB-100 and apoB-48 and α-ketoisocoporate (α-KIC), as a 
measurement of cellular precursor pool, will be used to determine the kinetics of VLDL-
apoB-100 and CM-apoB-48. This determination will reflect the rate of VLDL and CMs 
metabolism, as each molecule of VLDL, or CM is assembled with one particle of apoB-100 or 
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apoB-48 respectively. The measurement of CM and VLDL kinetics has been undertaken in 
many studies as shown in Table 1.3 which shows key information from previous studies such 
as the meal content, meal intervals, study duration and stable isotope used.  
 
Figure 1.10: An example of a tracer labelled stable isotope used in metabolic research is 1 -¹³C- 
Leucine.  
 
Table 1.3 Feeding protocols used in published studies. The table lists the meal content of fat; 
protein and carbohydrates expressed as energy% and/or amount of each content in grams. 
The meal intervals, study duration and isotope tracer were listed in each human study. 
Author, Year 
Fat/Protein/CHO 
(%) 
Meal intervals 
Study 
duration (h) 
Stable Isotope 
Infusion 
(Wong et al., 
2014) 
Meal 130g/17g/ 
21g with total of 
4800 kJ 
- 10 ²H₃-Leucine 
(Hermansen et 
al., 2013) 
Energy 61-65/19-
16/20-19 
- 42 days 
¹³C Octanoate 
orally added to the 
egg yolk 
(Xiao et al., 
2012) 
49/13/38 
Infusion of 40 mL/h for 
the 1st 2 hours and 80 
mL/h for the rest of the 
study 
16 ²H₃-Leucine 
(Hogue et al., 
2007a) 
Energy 40/15/45 1/30th every 30mins 15 
L-[5,5,5-D3]²H₃-
Leucine 
(Duez et al., 
2006) 
Energy 18/20/62 Identical hourly meals 12 
Deuterated L-
[5,5,5-²H₃]-leucine 
(Zheng et al., 
2006) 
Fat only (almond 
oil) 
9g every 30 minutes 12 
Tri deuterated 
leucine ²H₃-Leucine 
(Duvillard et 
al., 2005) 
Energy 39/7/55 
Identical meals every 2 
hours 
16 ¹³C-Leucine 
(Welty et al., 
2004) 
Energy 36/15/49 Identical hourly meals 15 
Deuterated [5,5,5,-
²H₃]leucine 
(Batista et al., 
2004) 
Energy 36/15/49 Identical hourly meals 15 
Deuterated 5,5,5,-
²H₃leucine 
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1.12 Stable isotope enrichment detection using Gas chromatography-mass 
spectrometry (GC-MS)  
GC-MS is a complicated two-part machine which it enables the measurement of the 
enrichment of an isotopically labelled molecule such as 13C leucine (Figure 1.10). In the case 
of using AA as a stable isotope, the GC side of the instrument isolates AA from a mixture of 
protein hydrolysate AAs. The GC then present them to be identified and quantified by the 
MS, which is the other part of the instrument (Bodamer and Halliday, 2001, Boren et al., 
2012, Rambal et al., 1992, Sunehag and Haymond, 2003). To measure AA isotopic 
enrichment, they need to be processed and prepared to be presented in a particular form of 
complexed molecules to be recognised by the GC-MS. Therefore, the sample containing a 
mixture of protein hydrolysate AAs go through a process called derivatization. Derivatized 
AAs are transformed into molecules that have the ability to evaporate at high temperatures 
(volatile products) (Bodamer and Halliday, 2001, Boren et al., 2012, Rambal et al., 1992, 
Sunehag and Haymond, 2003). These volatile products are then introduced to the injector of 
the GC at high temperature to evaporate them, and consequently, they are carried on the 
capillary column by the inert pressurised gas. This gas could be methane, hydrogen, nitrogen 
or helium based on the type of experiment chosen. AAs of interest are then separated from 
other molecules based on their volatility at certain temperatures. This complexed separation 
takes place in the column by the power of temperature-regulated interaction between the 
AA carried via the pressurised gas (also called mobile phase) and the coating of the inner 
column surface (also known as stationary phase). Separated AAs are then moved to the 
ionisation source of the MS to be ionised. Two different modes of source ionisation can be 
used to quantify and identify AAs; chemical ionisation (CI) and electron ionisation (EI) modes 
(Bodamer and Halliday, 2001, Boren et al., 2012, Rambal et al., 1992, Sunehag and 
Haymond, 2003). After the ionisation process, negatively charged electrons are transported 
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from the hot filament part and attach to the positive anode to the positively charged plate. 
Direct bombardment with electrons accomplishes the ionisation process in the EI mode in 
which they are broken into fragments by the power of applied energy. On the other hand, 
the ionisation by CI mode is different in which a gas such as methane is introduced as a 
reagent ion source for ionisation. This takes place by hitting released electrons by methane 
molecules to react with electrons and generate different methane ions. This can be achieved 
by either a positive chemical ionization (PCI) or by negative chemical ionization (NCI) to 
produce either positive or negative ions respectively based on the substance of interest 
(Bodamer and Halliday, 2001, Boren et al., 2012, Rambal et al., 1992, Sunehag and 
Haymond, 2003). The final step after ionisation is to analyse the generated ions based on 
their mass. This takes place via transporting the ions to a mass analyser by the help of 
focusing lenses to be filtered quickly depending on their mass. In the end, the mass of an 
interested ion with its quantity is detected and recorded with the help of a computer 
programme. Therefore, every AA has its mass to be identified and quantified to measure the 
isotopic enrichment and calculate the TTR (Bodamer and Halliday, 2001, Boren et al., 2012, 
Rambal et al., 1992, Sunehag and Haymond, 2003). 
In this project, ¹³C- leucine was used as a stable isotope to be infused intravenously for 
specified time periods in each clinical trial to measure apoA-I, apoB100 and apo-B48 kinetics 
in three different clinical studies. NCI mode was used by introducing methane as a reagent 
gas for generating negatively charged ions in ordered to measure TTR of ¹³C- leucine/12C-
Leucine with an ion mass of 210/209 respectively (Sunehag and Haymond, 2003). 
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1.13 Establishment of a postprandial TG steady state using repeated feeding 
protocol 
There have been several research studies involved in elucidation the role of GLP- 1 receptor 
agonists in lipid metabolism in healthy subjects in a fasted state  with an established fasting 
state there is a steady state of blood plasma TG due to the absence of exogenous TG which 
disrupts the steady state (Sakamoto et al., 2013). On the other hand, few studies have 
investigated the effect of GLP-1 receptor agonists on postprandial lipid metabolism required 
for the production of CM-apoB-48 (Xiao et al., 2012). One explanation for this is that it is 
hard to maintain a steady state of TG in blood in the fed state. Investigators have used a 
variety of feeding protocols and a wide range of meals with different nutrient compositions 
to maintain postprandial TG steady state in the blood as shown in Table 1.3. In some 
postprandial studies, administration of a meal bolus at the start of feeding protocol may or 
may not be required to achieve a postprandial steady state. Also, the administration of the 
meal bolus is directly dependent on the meal composition. Feeding protocols with the 
different nutrient composition to maintain postprandial TRL steady state in the blood from 
many published studies are shown in Table 1.3. 
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1.14 Hypotheses 
Central obesity, IR, hyperinsulinaemia and especially hypertriglyceridaemia are important 
manifestations of metabolic syndrome seen in T2D and NAFLD. These events can be treated, 
and/or managed to reduce the risk of CVD as follows; 
A. It is hypothesised that physical exercise will correct altered lipoprotein metabolism and 
reduce liver fat in patients with NAFLD by increasing hepatic and peripheral insulin 
sensitivity, reducing fasting hypertriglyceridaemia and increasing low HDL-C. This will be 
achieved by the exercise action on reducing the PR of VLDL-apoB-100 or increasing VLDL-
apoB-100 FCR, and directly increasing the PR of HDL-apoA-I or indirectly reducing FCR of 
HDL-apoA-I. This will contribute to reducing CVD risk. 
B. Lixisenatide treatment administration for patients with T2D will correct altered 
lipoprotein metabolism by increasing hepatic and peripheral insulin sensitivity and reducing 
postprandial hypertriglyceridaemia. This will be accomplished by reducing plasma 
postprandial TG concentration by decreasing CM-apoB-48 PR as a result of indirect and 
direct effects of lixisenatide on intestinal enterocytes, and will also reduce VLDL-apoB-100 
PR from the liver as a consequence of an improvement in insulin sensitivity. The latter will 
indirectly increase the PR of HDL-apoA-I. These effects will contribute to reducing CVD risk. 
1.15 Aims 
1. To conduct a clinical trial that will study the effects of a physical exercise programme on 
HDL-apoA-I kinetics and concentration, fasting hypertriglyceridaemia, liver fat, IR and lipid 
profile in patience with NAFLD using stable isotope trace-labelling technique. 
2. To conduct a clinical trial that will study the effects of a 4-week treatment with 
lixisenatide (a GLP-1 receptor agonist) versus placebo on postprandial lipoprotein 
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metabolism, hypertriglyceridaemia, IR and lipid profile in patients with T2D using a constant 
feeding protocol and a stable isotope trace-labelling technique. 
1.16 Objectives 
1. To develop a constant feeding protocol that will maintain an elevated plasma TG 
concentration to provide a postprandial TG steady state which is essential for the calculation 
of postprandial lipoprotein kinetics (TRL-apoB-100 and TRL apoB-48). 
2. To develop a laboratory protocol that will facilitate apoB-100, apoB-48 and apoA-I 
isolation, precipitation, measurement enrichment using GC-MS. 
3. To develop a clinical protocol to be used in a clinical trial that will facilitate the study time 
points for blood sample collection and administration of the trace-labelling stable isotope 
13C Leucine for the measurement of apoB-100, apoB-48 and apoA-I concentration and TTR 
enrichment 
4. To validate the developed constant feeding, laboratory and clinical protocols by 
conducting a pilot study for the measurement of fasting and postprandial lipoprotein 
kinetics (CM-apoB-48, VLDL-apoB-100 and HDL-apoA-I) using stable isotope trace-labelling 
technique. 
5. To develop two sensitive and specific techniques that will facilitate the measurement of 
apoB-100 and apoB-48 concentrations separately using competitive ELISA. 
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2. Chapter 2: Clinical protocols and methodology 
2.1 The methods used for participant recruitment in conducted clinical trials 
Many different ways of contact were applied in the recruitment procedure for the three 
clinical trials. The primary method was through the Primary Clinical Research Network South 
East (PCRN SE) with GP surgeries in Surrey, which searched for suitable patients using BMI, 
plasma lipids, blood glucose, blood pressure, current health, prescribed medication and 
distance of home from Guildford. Another important method was the use of newspaper 
advert which covered both the Surrey area and nearby counties to attract participants from 
a wider distance. Other methods that were applied included advertisement on the University 
of Surrey website (SurreyNet), and at local hospitals, public and private sector organisation 
by either poster leaflets or via email. 
2.2 Pilot feeding study (PFS) to develop a feeding protocol to measure apoB-100 
and apoB-48 in blood samples using a stable isotope technique (two parts): 
2.2.1 Participant recruitment for both parts of the PFS 
Both parts of the PFS were given a favourable opinion by the University of Surrey Ethics 
Committee in October 2013 EC/2013/98/FHMS. Caucasian men aged 40-65 with body mass 
index (BMI) 30-35 were recruited for the PFS. Participants had a screening visit in which they 
were asked to attend after an overnight fast, in the Clinical Investigation Unit (CIU) at the 
faculty of health and medical sciences (FHMS), University of Surrey. At the screening visit, 
the following was performed and recorded: medical history, current medication, physical 
examination, diastolic and systolic blood pressure, weight, height, age, tobacco smoking 
status, alcohol intake and haematocrit. Fasting blood samples were collected to measure TG, 
total cholesterol, blood glucose and insulin concentrations.  
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Subjects who were smokers and had cardiovascular and endocrine disease (such as unstable 
ischemic heart disease), diabetes and diabetic complications, uncontrolled hypertension, 
hepatic and renal disorders, gastrointestinal illness or surgery other than minor endoscopic 
procedures such as peptic ulcer injection, unstable weight in the past three month, mental 
incapacity, alcohol consumption of more than 2 units/day (more than 12 to 15 g of 
alcohol/day), had been taking any medication known to affect lipid and/or glucose 
metabolism, allergies to dairy products, and hormone therapy were excluded from the 
study. Potential participants who expressed interest and fulfilled the required criteria were 
recruited for the PFS as seen in Figure 2.0. A total of n=7 participants were screened and n=4 
were recruited for this pilot study; n=3 for the first part and n=1 for the second part (Figure 
2.0). 
2.2.2 Development of a feeding protocol to maintain postprandial plasma TRL 
concentrations at a constant concentration (part one); 
2.2.2.1 Liquid meal composition and preparation 
Based on the meal protocols described previously and shown in Table 1.3 in Chapter one 
section 1.11, a liquid meal was optimised to be used for the postprandial study to maintain a 
steadily elevated concentration of plasma TG. Three meal flavour options were developed, 
and each was a 100 ml liquid meal drink which could be chosen by the participant on the 
study day. Although they were different in the content added, they all had the same 
macronutrient content and caloric value as shown in Table 2.0 which shows the meal 
ingredient’s amounts in each meal option, total volume, and energy percentage with total 
calorie per drink. 
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Figure 2.0: The sequential  steps performed in both parts of the PFS.  N: number; PFS: pilot 
feeding study; TG: triglycerides.  
 
A total of N=3 
were recruited 
for this part 
A total of N=1 
were recruited 
for this part 
A total of N=7 were screened for this study 
A total of N=4 were  
recruited for this study 
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Table 2.0: The three meal options offered to the participants with an equal amount of energy 
and calories. 
Ingredients 
1st meal 
option 
2nd meal 
option 
3ed meal 
option 
Granulated sugar (Tate Lyle) 6.5 g 8.6 g 6 g 
Boiling water. 45 ml 45 ml 45 ml 
Unflavoured whey powder (Natures Best, 
UK) 
7 g X X 
Vanilla flavoured whey powder (instant 
whey-PRO.com) as 80% protein, 
X 8.75 g 8.75 g 
Extra virgin olive oil (Tesco own brand, 
UK). 
3.5 ml 3.5 ml 3.5 ml 
Sunflower oil (Tesco brand, UK) 3.5 ml 3.5 ml 3.5 ml 
Double cream (Tesco brand, UK) 10 ml 10 ml 10 ml 
Raspberry or chocolate flavouring 
(CRUSHA milkshake). 
10 ml X 10 ml 
Cold water X 10 ml X 
Final meal flavour 
Chocolate or 
Raspberry 
Vanilla 
Vanilla mixed 
with chocolate 
or raspberry 
Total volume per drink 100ml 100ml 100ml 
Energy % and total calorie per drink 
CHO 22%, Fat (saturated and non-saturated) 
66.1%, Protein 11.9% / 100ml /drink. 
2280 Kcal/drink 
2.2.2.2 Preparation of the liquid meal; 
Based on the selected meal option, granulated sugar (Tate Lyle) was weighed out in the 
required amount into a plastic beaker. Then 45ml boiled water was added and stirred with 
an electric mixer until the sugar was completely dissolved. Then, the necessary amount of 
whey powder was added, and mixed with an electric mixer to homogenise the components 
of the meal. Afterwards, the oil was added; olive oil (Tesco brand, UK) and sunflower oil 
(Tesco brand, UK), and mixed with an electric mixer to homogenise the components of the 
meal. Ten ml of cold double cream (Tesco brand, UK) was then added and mixed with the 
electric mixer. Finally, 10 ml of flavouring (CRUSHA raspberry milkshake) or cold water was 
added and mixed with an electric mixer. For better palatability and taste, the liquid meal was 
cooled down in the refrigerator until served. 
60 
 
2.2.3 Study design to achieve a steady state of TRL postprandial concentrations 
(part one). 
On the study day, weight and blood pressure was measured, and then a doctor inserted an 
intravenous cannula into an antecubital vein for blood sampling at -240 minutes (this was 
the first time point of the study instead of 0). After taking a fasting blood sample, 
participants were asked to drink hourly the prepared liquid meals. Blood samples (13 ml) 
were taken at hourly intervals for the measurement of exogenous and endogenous TRL for 
12 hours as; -240, -180, -120, -60, 0, 60, 120, 180, 240, 300, 360, 420 and 480 minutes as 
illustrated in Figure 2.1. Two feeding protocols (A and B) were tested to determine if a 
postprandial TG steady state could be achieved between 0 and 480 minutes as shown in 
Figure 2.1; 
1. In feeding protocol A hourly consumption of liquid meals were given in equal amounts to 
gradually elevate the plasma TG and keep it elevated in a steady state. 
2. Feeding protocol B was similar to protocol A except for the 1st liquid meal at -240 minutes 
which was consumed as twice the quantity and volume of the hourly drinks, i.e. the 1st liquid 
meal drink was considered as a bolus meal and used to trigger the TG plasma elevation. 
Then, equal hourly meals were given afterwards to maintain the elevated steady state of 
plasma TG. 
2.2.4 Study design for the pilot study with stable isotope infusion (part two) 
The results of PFS part one suggested that equal hourly feeding was better at achieving a 
plasma TG steady state. Therefore, this feeding protocol was chosen for conducting PFS part 
two of the study. Participants were asked to arrive at the CIU having fasted from 22:00 the 
previous evening. A doctor then inserted two cannulas into the antecubital vein. Four hours 
61 
 
later (t=0 minutes) after a plasma TG steady state was achieved, an intravenous primed 
(1mg/kg) constant infusion of 1-¹³C leucine at 1 mg/kg/min was administered. Hourly blood 
samples (13 ml) were taken for the measurement of TRL apoB (apoB-100 and apoB-48) 
kinetics for 8 hours as follows; 0, 60, 120, 180, 240, 300, 360, 420 and 480 minutes as 
illustrated in Figure 2.2.  
 
Figure 2.1: Illustration of PFS part one time points without (A) and with (B) the liquid bolus  
meal. Upward arrows indicate hourly blood sampling for 12 hours, and downward arrows 
indicate hourly liquid meals consumed.  
 
Figure 2.2: Sampling pr otocol for PFS part two with tracer infusion is shown here. Liquid 
meals were given hourly and blood samples collected before and after the injection of the 1-
¹³C leucine tracer bolus at (t=0) of 1mg/kg and constant infusion between 0 –  480 minutes of 
1mg/kg/min for 8 hours.  
 
A) 
B) 
Meal 
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2.3  The effect of GLP-1 receptor agonist (Lixisenatide) on postprandial TG 
metabolism against placebo in patients with T2D 
2.3.1 Participant recruitment 
This study was given a favourable opinion by three committees; the University of Surrey 
Ethics Committee with reference number EC/2013/104/FHMS, the RSCH research and 
development Ethics Committee with a reference number 13/SC/0378, and Medicines and 
Healthcare products Regulatory Agency (MHRA) at the national health services (NHS) clinical 
trial authorisation team with a reference number 2013-002826-22. Also, this clinical trial was 
registered at www.clinicaltrials.gov with a reference number NCT02049034. This study was 
un-blinded at 01/11/2016 which indicated the order of the lixisenatide and placebo 
treatments to define the participants into two groups to perform the statistical analysis 
tests.  
Caucasian men aged 40-65 with BMI 27-37 kg/m2 diagnosed with T2D with fasting blood 
glucose (FBG) of above 7 mmol/L and HbA1C between 7.5-9.5% were recruited. The 
recruitment procedure using an initial theoretically planned BMI range of 30-37 kg/m2 was 
not efficiently effective for recruiting participants in this study as the required number of 
patients with this BMI range could not be found at the designated searching area. Therefore, 
the BMI range was adjusted to 27-37 kg/m2 to help in recruiting more participants needed 
for this study. Inclusion criteria included a stable diabetes management with uncontrolled 
hyperglycaemia over the previous three months with a stable Metformin dose, able and 
willing to self-administer placebo/lixisenatide injection (once daily (10µg for 14 days 
followed by an increase to 20µg for 14 days), perform self-blood glucose monitoring, and 
wear a Continuous Glucose Monitoring System (CGMS) for three days. 
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Subjects who were smokers and had cardiovascular and cerebrovascular disease (such as 
unstable ischemic heart or brain disease), endocrine disease, uncontrolled hypertension or 
under β-Blockers treatment, hepatic and renal disorders, gastrointestinal illness or surgery 
other than minor endoscopic procedures such as peptic ulcer injection , unstable weight in 
the past three month, mental incapacity, alcohol consumption of more than 2 units/day 
(more than 12 to 15 g of alcohol/day), been taking any medication known to affect lipid 
and/or glucose metabolism except only Metformin and statins, allergic to dairy products and 
any GLP-1 receptor agonist or meta-cresol, under hormonal therapy were excluded from the 
study. Potential participants who expressed interest and fulfilled the required criteria were 
recruited for this study as seen in Figure 2.3. A total of six participants were recruited for this 
study and samples were used for all the laboratory measurements including TRL-apoB-100 
and TRL-apoB-48 kinetics (Figure 2.3). After the study was initiated and samples from the 
first two participants were analysed, an introduced objective of studying the effect of 
lixisenatide on HDL-apoA-I kinetics was added to this study’s objectives. Therefore, samples 
from only the last 4 out of 6 recruited participants were used to measure HDL-C and HDL-
apoA-I concentration and calculate HDL-apoA-I kinetics (Figure 2.3). 
2.3.2 Study power 
The power calculation used was obtained from Kane, (2011). There are no published data on 
the determination of lixisenatide effects on postprandial glucose and TG metabolism against 
placebo in patients with T2D by measuring postprandial glucose, TRL-apoB-100, TRL-apoB-48 
and HDL-apoA-I kinetics. The study power calculated for this study was originally based on 
postprandial plasma glucose rate of appearance (RaT) (measured on visit 3 and 7). 
Therefore, the sample size was based on the primary endpoint of total RaT following the 
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breakfast meal. This was calculated using data from a previous study by Cersosimo et. al 
2011, which measured the effect of two weeks treatment with exenatide (a GLP-1 receptor 
agonist) on glucose RaT following a meal in 17 type 2 diabetic patients (Cersosimo et al., 
2011). The glucose RaT (mean ± SD) in patients before treatment was 23.7±3.0 
mcmol/kg/minute which was significantly reduced to 14.3±3.5 mcmol/kg/minute after two 
weeks of treatment. The correlation between measurements in the same person was 
unknown so this was assumed to be zero. Based on this, completing the study with a data 
set of 12 subjects would have the power of 80% at the 5% concentration to detect a 
difference of 20% in which glucose RaT would be considered clinically significant.  
Another power calculation was conducted based on postprandial TRL-apoB-48 kinetics 
(Kane, 2011). The sample size was based on the primary endpoint of TRL-apoB-48 PR after 
elevation of plasma FFA. This was calculated using data from a previous study by (Duez et al., 
2008a which measured effect of short-term acute elevation of plasma FFA on TRL-apoB-48 
kinetics using a feeding protocol and a stable isotope technique for 12 healthy obese 
subjects. TRL-apoB-48 PR 5.95±1.13 mg/kg/day (mean ± SD) at baseline was significantly 
increased (P=0.03) after Intralipid/heparin (IH) treatment 3.53±0.58 mg/kg/day (Duez et al., 
2008a). The correlation between measurements in the same person was unknown so this 
was assumed to be zero. Based on this, completing the study with a data set of 18 subjects 
would have the power of 80% at the 5% concentration to detect a difference of 25% which 
would be considered clinically significant as shown in Figure 2.3. 
Another power calculation was conducted based postprandial HDL-apoA-I kinetics (Kane, 
2011). The sample size was based on the primary endpoint of HDL-apoA-I FCR after exercise. 
This was calculated using data from a previous study by Thompson et al., 1997 which 
measured the effect of 12 months of exercise intervention on HDL-ApoA-I kinetics using a 
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feeding protocol and radioactive tracer technique for 17 overweight males. HDL-apoA-I FCR 
0.23±0.03 pools/day (mean ± SD) before exercise at baseline was significantly decreased 
(P=0.01) after exercise treatment 0.21±0.03 pools/day (Thompson et al., 1997). The 
correlation between measurements in the same person was unknown so this was assumed 
to be zero. Based on this, completing the study with a data set of 14 subjects would have the 
power of 80% at the 5% concentration to detect a difference of 20% which would be 
considered clinically significant (Figure 2.3). 
 
Figure 2.3: A consort diagram to show participant recruitment number for the lixisenatide 
study. N: number; TRL: triglyceride -rich lipoprotein; HDL: high -density lipoprotein; PR: 
production rate; FCR: fractional catabolic rate; apoB: apolipoprotein B; apoA -I: apolipoprotein 
A-I .  
66 
 
2.3.3 Study design and clinical protocol 
This study was a randomised double-blind crossover study. This clinical trial was conducted 
to investigate the effect of lixisenatide vs. placebo (Sanofi, UK) treatment on postprandial 
glucose and TRL metabolism in patients with T2D. This was achieved by measuring the 
kinetics of TRL-apoB-100, TRL-apoB-48 and HDL-apoA-I. Patients were randomised into two 
groups. One group received a once daily subcutaneous injection of 10 µg for the first 14 days 
followed by 20µg for the remaining 14 days lixisenatide or placebo for four weeks followed 
by a four-week washout then once daily subcutaneous injection of 10 µg for the first 14 days 
followed by a 20µg for the remaining 14 days of the other treatment (Figure 2.4). 
Subjects were asked to fill in a seven-day diet diary and to monitor their blood glucose 
during the 3rd week of each treatment period. They were studied on two separate days at 
the end of each treatment period (Visits 3, 4, 7 and 8). At all visits, subjects were asked to 
attend the Centre for Diabetes, Endocrinology and Research (CEDAR), Royal Surrey County 
Hospital, Guildford (RSCH).  
Before screening took place, subjects were provided with verbal and written information 
about the trial and the procedures involved. The subjects were fully informed of their 
responsibilities and rights while participating in the trial, as well as of possible disadvantages 
in being treated with the trial product. They were given the opportunity to ask questions and 
an enough time for proper consideration of participating in the study. Subjects who wished 
to participate in the trial were required to sign and date an informed consent form before 
any trial-related activities took place. All subjects were provided with a copy of the Subject 
Information Sheet, and they signed and dated an informed consent Form. 
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At the screening visits, participants were asked to attend after an overnight fast, and the 
following were performed and recorded; medical history, current medication, physical 
examination, diastolic and systolic blood pressure. In addition to the measurments of 
weight, height, age, tobacco smoking status, alcohol intake, haematology (haemoglobin, 
total leukocyte count, and thrombocytes), clinical chemistry (sodium, potassium, creatinine, 
total protein, albumin, AST, ALT, and ALP), amylase, calcitonin, lipase, TG, total cholesterol, 
HbA1c, and blood glucose. The study involved multiple visits that took place in the CEDAR at 
RSCH as follows as seen in Figure 2.4; 
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Figure 2.4: The sequential  steps and visits took place in the Lixisenatide cl inical study.  
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Visit 1: Patients who were eligible for the study after screening were invited to the CEDAR 
where they had a one to one training session with a research nurse skilled in diabetes, on 
injection technique using the study drug device. They were randomised into two groups 
using computer randomisation. Depending on the randomization code the patient was 
prescribed either Lixisenatide or the placebo injection for 28 days. Patients were provided 
with a trial specific diary in which to record drug administration, any concomitant 
medication and any adverse events.  Patients were made aware of symptoms suggestive of 
hypoglycaemia and were issued with (and instructed on) the use of a capillary glucose 
monitor.   
Visit 2: This took place after 21 days. Patients were provided with a standardised meal to eat 
the evening before Visit 3. 
Visit 3: Patients were asked to attend after an overnight fast on the morning of day 25 of the 
first four-week treatment period. They were requested to bring their glucose monitor to this 
visit. The following were measured; weight and metabolic profile, and postprandial glucose 
kinetics. Patients were provided with a standardised meal to eat the evening before Visit 4. 
Visit 4: Visit 4 and 8 were identical, and they were the primary focus of this research. 
Patients were asked to attend after an overnight fast on the morning of day 28. The 
following were measured; blood biochemistry (as visit 1), physical examination and vital 
signs. Twenty µg of treatment (either Lixisenatide or placebo) were administered 
subcutaneously 30 minutes before the consumption of the first meal (the meal composition 
used in the PFS part two). Patients were given the option to choose which flavour of the 
meal they desired. Then equal liquid meals were given hourly for 11 hours to achieve an 
elevated steady state of plasma TG Figure 2.2. Four hours later, a primed continuous 
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infusion of 1-13C leucine (1mg/kg, 1mg/kg/h) was administered for 8 hours. Blood samples 
were taken hourly to measure the kinetics of TRL-apoB-100, TRLapoB-48 and HDL-apoA-I for 
8 hours at 0, 60, 120, 180, 240, 300, 360, 420 and 480 minutes (Figure 2.2). 
Visit 5: This visit was on day 56. The patient switched to either Lixisenatide or the placebo 
injection for 28 days. Patients were provided with a trial specific diary in which to record 
drug administration, any concomitant medication and any adverse events. 
Visit 6: This visit was on day 77 and was identical to visit 2. 
Visit 7: This visit was on day 81 and was identical to visit 3. 
Visit 8: This visit was on day 84 and was identical to visit 4. In this visit, patients had 
successfully finished this clinical trial. 
2.4 The effects of exercise training on visceral fat, insulin sensitivity, β-cell 
function and TG kinetics in patients with non-alcoholic fatty liver disease 
(NAFLD) 
2.4.1 Participant recruitment 
This study was given a favourable opinion by two committees; the University of Surrey Ethics 
Committee with reference number 08/H1/008/165/FHMS, the RSCH research and 
development Ethics Committee with a reference number 09/H1109/97. Also, this clinical 
trial was registered at www.clinicaltrials.gov with a reference number NCT01834300. 
Caucasian men aged 18 and over with BMI 27-37 kg/m2, diagnosed with NAFLD with more 
than 5% of liver fat droplets using imaging tests such as ultrasound, magnetic resonance 
imaging (MRI) and magnetic resonance spectroscopy (MRS).  The recruitment procedure 
using an initial theoretically planned BMI range of 30-37 kg/m2 was not efficiently effective 
for recruiting participants in this study as the required number of patients with this BMI 
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range could not be found at the designated searching area. Therefore, the BMI range was 
adjusted to 27-37 kg/m2 to help in recruiting more participants needed for this study. 
Inclusion criteria included positive NAFLD diagnosis with appearance suggestive of a fatty, 
echo-bright liver with no evidence of cirrhosis (in some cases, the diagnosis was confirmed 
histologically after liver biopsy) were recruited. In addition, motivation and willingness to 
engage in following an exercise programme were required for the study. 
Subjects who were smokers and unable to exercise, and had T2D and diabetic complications, 
cardiovascular and cerebrovascular disease (such as unstable ischemic heart or brain 
disease), endocrine disease, uncontrolled hypertension, hepatic disease (besides NAFLD) and 
renal disorders, gastrointestinal illness or surgery other than minor endoscopic procedures 
such as peptic ulcer injection, unstable weight in the past three month, mental incapacity 
and claustrophobia, alcohol consumption of more than two units/day (more than 12 to 15 g 
of alcohol/day), been taking any medication known to affect lipid and/or glucose 
metabolism (except statins), been prescribed with drugs known to cause secondary 
steatohepatitis such as corticosteroids, hormone therapy were excluded from the study. A 
total of n=30 participants were recruited; n=15 were randomly distributed each group (the 
supervised exercise and control groups), and n=3 were dropped out from the study (Figure 
2.5) 
2.4.2 Study power 
The primary endpoint for this study was VLDL apoB-100 secretion rate which was calculated 
from a previous study. There was one study with published data on the measurement of 
VLDL apoB-100 kinetics (but not HDL-apoA-I kinetics) in patients with NAFLD (Sullivan et al., 
2012). However, this study was not chosen to calculate our study power and sample size as 
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there was no significant difference of VLDL-apoB-100 secretion rate before and after the 
intervention period (Sullivan et al., 2012). However, another study conducted by Alam et al. 
2004, was used for the power calculation. In this study, eighteen patients with T2D were 
enrolled to determine the effect of a 6-month exercise program on VLDL-apoB-100 secretion 
rate (Alam et al., 2004). The study showed significant results including reduced VLDL-apoB-
100 secretion as mean±SEM (11.3±2.5 mg/kg/day at 0 months which reduced by 48% to 
5.5±2.0 mg/kg/day) which was detectable with nine patients in the supervised exercise 
group. Based on this, a data set of 15 patients in each exercise group (n=30 as n=15 in the 
supervised exercise group and n=15 for the lifestyle advice group) would have the power of 
80% at the 5% level to detect at least 20% reduction in VLDL-apoB-100 production difference 
between the two groups which would be considered clinically significant (Figure 2.5). 
The power calculation used to determine the sample size for measuring the effect of 
exercise on HDL-apoA-I kinetics was the same calculation used in the lixisenatide study 
mentioned earlier in section 2.3.3. Based on this, completing the study with a data set of 14 
subjects would have the power of 80% at the 5% concentration to detect a difference of 20% 
which would be considered clinically significant (Figure 2.5). 
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Figure 2.5: A consort diagram to show participant recruitment number for the NAFLD study. N: 
number; NAFLD: Non-alcoholic fatty liver disease; HDL: high -density lipoprotein; FCR: 
fractional catabolic  rate; apoA-I:  apolipoprotein A-I.  
2.4.3 Study design 
A randomised controlled, four-month exercise intervention study of 30 patients with NAFLD 
was conducted as 15 patients in the supervised exercise group and 15 patients in lifestyle 
advice group. All patients were examined at two-time points: at baseline (before 
commencing the exercise programme) and after the four-month intervention period (Figure 
2.6) which included; 
1- Measurement of the patient’s physical fitness (VO2MAX). 
2- The measurement of dietary habits via seven-day diet diaries. 
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3- Measurement of liver and muscle fat by magnetic resonance spectroscopy (MRS), and 
whole body fat by magnetic resonance imaging (MRI) at Hammersmith Hospital in 
London. 
4- The measurement of bioelectrical impedance analyses of body fat and anthropometry. 
5- The measurement of VLDL apoB-100, HDL apoA-I, and VLDL-TG kinetics. 
2.4.4 Study clinical protocol  
During the study, participants attended the CEDAR at RSCH for seven visits (Figure 2.6) as 
follows; 
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Figure 2.6: The sequential  steps and visits in the NAFLD study. (MRI); magnetic resonance 
imaging, (MRS); magnetic resonance spectroscopy, VO 2M AX ; physical fitness test.  
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Visit 1: this was the screening visit. Patients were asked to complete a Physical Activity 
Readiness Questionnaire (PAR-Q), which is designed to identify the patient’s physical ability, 
commitment and readiness to enrol in an exercise program prior commencing the study. The 
doctor reviewed and discussed the patient’s medical history and performed a physical 
examination, including height, weight, pulse and blood pressure. Then an electrocardiograph 
(ECG) was carried out to identify the participants’ current heart rates and ensure they had 
no heart disease. Blood samples were taken for plasma liver function and lipid profile tests. 
If the patient wished to continue in the study, written consent was given to him. Following 
this, a seven-day diet diary was distributed, and they were instructed on how to record their 
intake in the food diary. All patients had an assessment of dietary habits by filling a seven-
day food diary before the start of the intervention. A dietician examined the diet diary, and 
caloric intake was recorded. A seven-day activity recall was also administered. After that, all 
participants were randomly allocated to either the supervised exercise group (group 1) or 
the standard lifestyle advice group (group 2) by computer software. 
The participants were advised to be in the CEDAR at the RSCH for this visit. The following 
was recorded; weight, height, body mass index (BMI), waist circumference, blood pressure, 
resting heart rate and a short questionnaire to be used for eligibility determination for this 
study. Also, randomization was taken place for both groups. 
Visit 2: In this visit, measurement of fitness by VO2max was determined (maximum oxygen 
consumption during exercise) (Dlugosz et al., 2013). The measurement of the VO2max was 
performed using an electronically braked bicycle ergometer (Lode; Excaliber Sport, 
Groningen, the Netherlands) equipped with a computerised breath (oxygen [O2]/ carbon 
dioxide [CO2]) analyser system (Medical Graphics, St Paul, MN, USA). An ECG was also 
carried out during the exercise test to monitor the participants’ heart rates and ensure they 
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had no latent ischaemic heart disease. The VO2max measurements were performed within 
four days of the metabolic study. 
Visit 3: In this visit, the patient had an MRI and MRS scanning at the Hammersmith Hospital 
in London. 
Visit 4: This visit together with visit 7 were the primary focus of this research. The patients 
were given a standardised evening meal before the study day which was consumed at 20:00. 
On the morning of the study day, the patients were asked to come to the CEDAR at the RSCH 
having fasted from 20:00 the previous night. Patients were allowed to drink water only 
during the study period. The doctor then inserted two cannulas into the antecubital vein of 
each arm, one for obtaining 20 blood samples from the study. The other one was for the 
administration of a stable isotope of leucine ([1-13C]-Leucine) at 1mg/kg body weight 
followed by an immediate infusion of leucine at 1mg/kg/hr for 9 hours. T=0 was the baseline 
time point in which a blood sample was taken before the infusion of the leucine isotope. 
Blood samples were taken at hourly intervals for the measurement of the pre-exercise 
kinetics of hepatic VLDL apoB-100 and HDL apoA-I for 9 hours at 0, 60, 120, 180, 240, 300, 
360, 420, 480 and 540 minutes as shown in Figure 2.7. 
Visit 5: This visit which took place after the four-month intervention period. This visit was 
identical to visit 2. 
Visit 6: This visit was identical to visit 3. 
Visit 7: This visit was identical to visit 4. Post-exercise measurement of VLDL apoB-100 and 
HDL apoA-I kinetics were made. 
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Figure 2.7: The NAFLD study day protocol with tracer infusion is shown here. Blood samples  
were collected hourly before and after the injection of the 1-¹³C leucine tracer bolus at (t=0) 
of 1mg/kg and constant infusion between 0 –  540 minutes of 1mg/kg/min for 9 hours.  
2.4.5 Exercise programmes involved in this study 
Participants were randomised to either a four months supervised exercise programme group 
or conventional lifestyle advice group. 
2.4.5.1 Supervised exercise programme group (Group 1): 
Participants allocated to the supervised exercise programme group (group 1) were 
encouraged to exercise 4-5 times weekly moderate-high intensity exercise, including cycling 
and/or walking on automated treadmills, for 20 minutes progressing to 60 minutes per 
session under 40-60% VO2MAX equivalent to 65-80% HRMAX for 4 months. This dose of 
prescribed exercise is in correspondence with the American College of Sports and Medicine 
guidelines for sedentary or disease populations. This exercise regime was used and validated 
by a previous study investigating the effect of supervised exercise on insulin sensitivity in 
liver and muscle fat (Shojaee-Moradie et al., 2007). Exercise was either conducted singly or 
in groups at the gym or in their own environment. Their activity was carefully monitored, 
encouraged and they were motivated continually to continue in the exercise programme. An 
exercise physiologist was available to give support as necessary, and to be in contact with 
the participants throughout the study. The gym-based exercise used a variety endurance 
exercises which were guided by the heart rate responses on heart monitors. Borgs perceived 
exertion (RPE) scale (a method of RPE on a scale of 11 or 15 points) was used to measure a 
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participant's concentration of intensity in training by evaluating their body's physical signs 
such as heart and breathing rates, perspiration, and sweating) (Borg, 1982), and resistance 
exercises (involving x 2-3 sets of 10-12 repetition of a resistance circuit using the major 
muscle groups i.e. legs, back, abs, chest, and shoulders). 
2.4.5.2 Conventional lifestyle advice group (Group 2): 
Participants allocated to this group received no further communication or support from the 
exercise physiologist. However, they were asked to adhere to a healthy diet as much as 
possible and advised to undertake regular exercises. Throughout that period, any participant 
had the ability to contact the primary investigator to address issues concerning NAFLD or 
their position within the study. At the end of the four-month study, after the repeated 
measurements, those volunteers in group 2 were given the opportunity to enrol in the same 
exercise programme as group 1 i.e. weekly exercise consultations for another four months 
upon their request without any further measurements. 
2.4.6 Individual and group supervisions performed in this study 
Individual supervision: an induction session took place and allowed the participants to 
familiarise themselves with the exercise equipment. Also, they selected a programme that 
was tailored to an appropriate concentration of exertion and exercise preference. During the 
session, the exercise physiologist provided individually supervised sessions at regular 
intervals. Also, the exercise physiologist gave a minimum support every week along with 
telephone supervision in case of weekly sessions were not possible. At each supervised 
session, the participant had an opportunity to raise any issues, and the instructor provided 
proplastid feedback throughout the session. After that, both the instructor and the 
participant agreed on a plan to maintain their exercise activity for the following week. The 
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elements of consultation were repeated at regular intervals in which they enhanced the 
adherence, and re-addressed issued provided by the participant’s feedback. 
Group supervision: there was some allocated group exercise slots at convenient times, to 
enable participants to exercise together. Each week throughout the study, participants had 
the opportunity to exercise as part of a group to encourage them to meet and talk to each 
other. They were additionally invited to exercise in pairs with an exercise buddy. As a result, 
participants were enjoyed and motivated during their period of study. 
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3. Chapter 3: Laboratory protocols and methods 
3.1 Materials and equipment used 
The stable isotope levorotary Leucine (L-Leucine) [1-13C] (15mg/ml, 13C enrichment 99%) was 
obtained from Cambridge Isotopes (USA) and prepared by the Pharmacy Department, St 
Thomas’ Hospital (UK). The sterile tubes containing different anticoagulants for collecting 
blood samples were purchased from Becton Dickinson UK Limited (Oxford, UK). 
Chemical reagents used in the lab including hydrochloric acid (HCL), acetic acid, ethanol, 
diethyl ether, acetonitrile, toluene, ethyl acetate, ammonia solution S.G.0.88 (35%), and 
sodium dodecyl sulphate were obtained from Fisher Scientific UK Ltd (UK). Methanol (for 
HPLC) was purchased from Agros Organics (UK). Chemical reagents including 3-
Methylbutanol, N,N,N`,N`-Tetramethylethylenediamine (TEMED), glycine (for 
electrophoresis ≥99%), phosphate buffered saline (pH 7.4), Decane, bromophenol blue, 
trizma base (Primary standard and buffer ≥99.9%), sodium chloride, ammonium persulfate, 
β-mercaptoethanol, trifluoroacetic acid (TFA), trifluoroacetic anhydride (TFAA), N-tert-
butyldimethylsilyl-N-methyl trifluoroacetamide (>97%) and O-phenylenediamine were 
obtained from Sigma-Aldrich Ltd (UK). Coomassie brilliant (Blue R-250), calcium lactate and 
tween 20 were purchased from BDH, VWR International Ltd (UK). AG 50W-X8 resin, 
acrylamide (Bis Solution, 40%) fixative enhance concentration, development accelerator 
reagent, Silver Stain Plus kit (silver complex solution, reduction moderator solution, and 
image development reagent), AP conjugate substrate kit were obtained from Bio-Rad 
Laboratories (USA). 
Plasma and fraction TG, cholesterol, HDL-C, and apoA-I concentrations were measured using 
ABX Cobas MIRA auto analyser (Horiba ABX, France). The sample kits, reagents, sample 
cuvettes, and reagent racks and tubes were also obtained from (Horiba ABX, France). 
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3.2 Laboratory methods developed  
The following methods were used in sequential order to enable us to detect the 
isotopic enrichment of 1-13C leucine in apoB and apoA-Iin blood samples obtained 
from clinical trials as seen in Figure 3.0.  
 
Figure 3.0: I llustration of sequential steps of methods used. SDS -PAGE: sodium dodecyl 
sulphate –  polyacrylamide gel electrophoresis, GC -MS: gas chromatography –  mass 
spectrometry, AA: amino acid.  
3.2.1  Sequential flotation ultracentrifugation of blood plasma samples to obtain 
CMs &VLDL (TRL) and HDL fractions 
For obtaining a TRL ( Sf 20-400) lipoprotein fraction (CMs and VLDL) from plasma, three ml 
from each time point was placed into the respective labelled Optiseal tubes (Beckman, USA) 
pre-coated with polyvinyl alcohol (PVA), then the sample was carefully overlaid with a 
density 1.006 g/dl solution of Saline (sodium chloride) / ethylenediaminetetraacetic acid 
Data Modelling for calculation of apoB and apoA-I Kinetics 
Determination of isotopic enrichment of apoB and apoA-I by GC-MS 
Sample derivatization to convert Leucine into a volatile and thermally stable Oxazolinone derivative 
Ion exchange chromatography for AA purification  
Protein hydrolysis into AA by HCL at 120°C  
SDS-PAGE for separation of either apoB or apoA-I from other proteins in the fraction   
Delipidation for removing the lipid content of the fraction 
Ultracentrifugation for separation of either TRL or HDL fractions by density 
Plasma obtained from collected blood samples during the clinical trial 
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(EDTA) up to 4.5 ml. The tubes were transferred to a pre-chilled rotor (Type 50.4 Ti rotor, 
Beckman Coulter, USA) for ultracentrifugation for 16 hours at 4°C at 37,000 revolutions per 
minute (rpm), corresponding to average relative centrifugal force (RCF) of 183, 935 x g for 
the inner row and 218, 180 x g for the outer row of the rotor respectively. The lipoprotein 
fraction in the top of the ultra-tube was isolated by the use of a tube cutting apparatus. The 
blade of this apparatus acts as a physical barrier, preventing upper and bottom fractions to 
mix inside the tube. The one ml retrieved was transferred into a two ml volumetric flask and 
accurately adjusted to two ml using 1.006 g/dl Saline/EDTA density solution. Only one ml 
was transferred to a 10ml hydrolysis tube for apo-B100 and apo-B48 protein precipitation. 
New Optiseal tubes were prepared (not PVA coated) with 0.5 ml of 1.519 g/dl density 
solution. Then, the remaining sample in the previous Optiseal tube (TRL PVA Optiseal tube), 
after cutting the TRL fraction, was added and mixed well. The mixed solution was overlaid 
with 1.063 density solution to the top of the newly prepared Optiseal tube, and the tube 
transferred into the pre-chilled rotor for ultracentrifugation for 22 hours at 4°C at 37,000 
rpm. 
The next day, IDL and LDL was removed from the obtained fraction using the tube cutting 
apparatus. Then new Optiseal tubes were prepared, with 1.5 ml of 1.504 g/dl density 
solution. The remaining sample in the current Optiseal tube was mixed (IDL and LDL Optiseal 
tube after cutting) ensuring that the jelly-sediment at the bottom of the tube is moving 
freely. Three ml was taken from the remaining sample from the current Optiseal tube 
(including the sediment) and mixed with the 1.5 ml solution in the newly prepared Optiseal 
tube. The total mixture was overlaid with 1.21 g/dl density solution. These tubes were 
transferred into the pre-chilled rotor for the last ultracentrifugation for 24 hours at 4°C at 
40,000 rpm. 
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The next day, the top one ml which contained the HDL fraction was removed, and the 
remaining solution in the Optiseal tube was discarded. The HDL fraction was transferred into 
a two ml volumetric flask and accurately adjusted to two ml using 1.006 g/dl Saline/EDTA 
density solution. Five hundred µl was transferred into a 10 ml hydrolysis tube and stored at -
80°C for apoA-I delipidation and precipitation. The remaining amount in the flask was 
divided into two sets of two ml Eppendorf tubes for the measurements of apoA-I 
concentration and storage purposes. 
3.2.2 TRL-apoB and HDL-apoA-I delipidation, precipitation and isolation. 
3.2.2.1 TRL-ApoB-100 and B-48 
This method was modified from (Egusa et al., 1983). To precipitate apolipoprotein B from a 
TRL fraction, one ml of the retrieved TRL fraction was mixed with 1 ml of propan-2ol 
(isopropanol) in hydrolysis tubes. The samples were mixed by pulse vortexing, then further 
vortexed using a multi vortexer for 1.5 minutes.  These samples were stored at 4°C in a 
spark-free fridge/cold cabinet overnight or for at least 16 h. The samples were then 
centrifuged for 60 minutes at 4° C at 4000 rpm (corresponding to RCF of 1,792 x g) (Centra 
GP8R, Thermo UK). The supernatant was removed, and the precipitate from each sample 
was kept for further purification of apo B from lipids. Three ml Ethanol: diethyl Ether (in a 
ratio of 3:1) was added to each sample tube and stored in a spark-free -20°C freezer for at 
least 48 hours. The samples were then centrifuged at 4000 rpm (RCF of 1,792 x g) for 60 
minutes at 4°C. The solvent was removed from each tube, and 3ml of diethyl Ether was 
added as a final step for complete delipidation. The samples were stored at -20°C for a 
minimum of 48 hours. The purified protein moiety of the particles was then centrifuged at 
4000 rpm (RCF of 1792 x g) for 60 minutes. After centrifugation, samples were left to dry. If 
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necessary, Oxygen Free Nitrogen (OFN) (Nitroflow, Parker Filtration, and separation, Parker 
Hannifin Ltd, Maidstone, UK) was used for complete dryness. The dried pellet was 
reconstituted in sample buffer, and the samples were ready for preparation for separation 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
3.2.2.2 HDL-apoA-I 
This method was obtained from a previous study in which the kinetics of HDL-apoA-I was 
measured (Li et al., 2012). To specifically precipitate apolipoprotein A-I from the fraction, 
400 µl of the isolated HDL fraction was mixed with pre-cooled 8 ml mixture of Methanol and 
Diethyl Ether (4 ml each added separately) in hydrolysis tubes. Then the samples were mixed 
vigorously by pulse vortexing and multi vortexer for 1.5 minutes. These samples were then 
centrifuged at 4000 rpm (RCF of 1,792 x g) for 40 minutes at 1°C, the supernatant was 
removed, and the precipitate from each sample was kept. Another 4 ml of pre-cooled 
Diethyl Ether was added to each sample tube which was mixed vigorously by pulse 
vortexing. Then the samples were centrifuged at 4000 rpm (RCF of 1,792 x g) for 20 minutes 
at 1°C. After centrifugation, the solvent was removed from each tube, and the remaining 
precipitate in each sample tube was left to dry. If necessary, OFN was used for complete 
dryness. The dried pellet was reconstituted in sample buffer ready for preparation for 
separation by SDS-PAGE. 
3.2.3 Preparation of protein samples in sample buffer for SDS-PAGE 
The dried apoB and apoA-I pellets in hydrolysis tubes were reconstituted in 200µl and 75µl 
sample buffer PH 6.8 respectively for SDS-PAGE. The sample buffer contained 0.15 M sodium 
phosphate, 12.5% glycerol, 2% SDS, 5% β-mercaptoethanol and 0.001% bromophenol blue. 
The samples were left in sample buffer for a minimum of 24 hours at 4°C prior SDS-PAGE. 
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ApoB sample tubes were then heated on a heating block for 10 minutes at 100°C for protein 
denaturation while apoA-I sample tubes were denatured for five minutes at 120°C. After 
heating, samples were immediately placed on ice for 10 minutes to stop further protein 
denaturation and structural damage. The samples were then centrifuged at 2500 rpm (RCF 
of 1,400 x g) for 15 seconds to spin down the condensation in the tubes after the heating 
stage. Following this, the samples were ready to be loaded on the SDS-PAGE.  
3.2.4 Separation of TRL-apoB and HDL-apoA-I using SDS-PAGE  
3.2.4.1 Resolving gel 
Glass plates with 1.5 mm thick vertical slab gel separators were mounted on the apparatus 
for the preparation of the gels. The glass plates, slab gel separators, and Combs were soaked 
in 4M HCL or Decon Solution and cleaned with 70% ethanol/ deionized H2O before the start 
of gel electrophoresis. The resolving gel for apoB and apoA-I was prepared by adding the 
components shown in Table 3.0 and 3.1 respectively which show specific amounts and the 
total volume per one gel. The gel was poured immediately after preparation taking care not 
to make bubbles. A thin layer of Isoamyl alcohol was placed across the top of the gel to seal 
the gel from oxidation and helped to remove any bubbles formed. The resolving gel for apoB 
was allowed to set for 1-1.5 hours at room temperature while the resolving gel for apoA-I 
took 15-25 minutes to settle as it contained a higher percentage of acrylamide which 
solidifies quicker than the apoB gel.  
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Table 3.0: Composition of a resolving gel solution for apoB gel electrophoresis 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
SDS: sodium dodecyl sulphate; TEMED: Tetramethylethylenediamine; APS: Ammonium 
persulfate.  
 
Table 3.1: Composition of a resolving gel solution for apoA-I gel electrophoresis 
 
 
 
 
 
 
SDS: sodium dodecyl sulphate; TEMED: Tetramethylethylenediamine; APS: Ammonium 
persulfate.  
3.2.4.2 Stacking gel procedure 
The Isoamyl alcohol was poured off the top of the gel and washed twice with Buffer B of 
either apoB or apoA-I as shown in Table 3.2 and 3.3 respectively which show specific 
amounts and the total volume per one gel. The stacking gel was then prepared, apoB for 
(Table 3.2) and for apoA-I (Table 3.3), and poured on the freshly prepared resolving gel. A 
comb was gently inserted into the stacking gel avoiding the formation of any air bubbles. 
This comb formed fifteen 65 µl wells at the top of the stacking gel for sample loading. The 
stacking gel for apoB was left to settle for two hours at room temperature while it took 30-
Substance to add 
Volume in ml for 
one gel preparation 
Deionized water 25.2 ml 
40% Acrylamide (Bio-Rad) added as 4% 4 ml 
Buffer A (1.5M Tris = 181.72 g/l, PH 8.8) 10 ml 
10% SDS 0.4 ml 
10% Ammonium persulfate (APS) 0.1 g/ml. Freshly made 
and added before use 
0.4 ml 
Tetramethylethylenediamine (TEMED). To be added as 
the last component before use. 
0.032  ml 
Total Volume 40 ml 
Substance to add Volume in ml for 
one gel preparation 
Deionized water 10 ml 
40% Acrylamide (Bio-Rad) added as 10% 10 ml 
Buffer A (Tris base 0.75M = 90.86 g/l, SDS 0.2%,PH 8.8) 20.2 ml 
10% APS 0.1 g/ml. Freshly made and added before use 200 µl 
TEMED. To be added as the last component before use 112 µl 
Total Volume 40.5 ml 
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50 minutes for the apoA-I stacking gel to settle. Both the resolving and stacking gels were set 
up at room temperature, and they could be stored at 4°C until usage for a duration up to 24 
hours. 
  Table 3.2: Composition of one stacking gel solution for apoB gel electrophoresis 
SDS: sodium dodecyl sulphate; TEMED: Tetramethylethylenediamine; APS: Ammonium 
persulfate.  
 
Table 3.3: Composition of one stacking gel solution for apoA-I gel electrophoresis 
SDS: sodium dodecyl sulphate; TEMED : Tetramethylethylenediamine; APS: Ammonium 
persulfate.  
3.2.4.3 Sample loading and SDS-PAGE initiation 
It is important to note that apoB and apoA-I were separated using two separate gels which 
had different compositions. After the stacking gel settlement, the complete SDS-PAGE 
apparatus was taken to be uploaded inside a tank. The Running buffer containing Glycine 
10%, Tris 5%, SDS 1.0% (Bio-Rad, USA) was added to the reservoir to saturate negative and 
positive electrodes to generate an electric current required for the SDS-PAGE. Electrode 
saturation took place by filling both inner and outer compartments of the SDS-PAGE gel 
apparatus. After assuring that the gel apparatus was not leaking, the green Combs in the top 
of the stacking gel were removed carefully. The generated 15 wells were rinsed with the 
Substance to add 
Volume in ml for one 
gel preparation 
Deionized water 7.35 ml 
40% Acrylamide (Bio-Rad) added as 0.75% 0.75 ml 
Buffer B (1.0M Tris = 121.14 g/l, PH 6.8) 1.67 ml 
10% SDS 0.1 ml 
10% APS 0.1 g/ml. Freshly made and added before use 0.1 ml 
TEMED.  To be added as the last component before use. 0.01 ml 
Total volume 10 ml 
Substance to add 
Volume in ml for one 
gel preparation 
Deionized water 3.9 ml 
40% Acrylamide (Bio-Rad) added as 1% 1.05 ml 
Buffer B (Tris base 0.25M = 30.29 g/l, SDS 0.2%,PH 6.8) 5.0 ml 
10% APS 0.1 g/ml. Freshly made and added before use 50 µl 
TEMED.  To be added as the last component before use. 20 µl 
Total volume 10 ml 
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running buffer to remove any solid particles which could interfere with sample loading and 
sample adhering to the stacking gel. Twenty µl of pre-stained ladder proteins (Bio-Rad, USA) 
with known molecular weight were loaded into the gel as markers for protein bands (Figure 
3.1B). Then 55µl of TRL-ApoB or HDL-ApoA-I fraction proteins in sample buffer were pipetted 
into the wells. Spare wells also received 60 µl of sample buffer. This helped the samples run 
down the gel in straight columns when the electrophoresis was performed. ApoA-I samples 
were loaded in every other well to avoid overlapping of large apoA-I protein bands, and the 
SDS-PAGE run was at 80v for 16-20 hours overnight using a PowerPac basic power supply 
(Bio-Rad, USA). SDS-PAGE for apoB samples was run at 80v for 1 hour using the same 
PowerPac supply (Bio-Rad, USA) (Figure 3.1A) and then the voltage was changed to 60V to 
run for 18-20 hours overnight. The SDS-PAGE apparatus temperature was cooled using cold 
running tap water to prevent damage of separated proteins from over-heated electrodes 
during electrophoresis. 
                 
Figure 3.1: SDS-PAGE for TRL-apoB and HDL-apoA-I separation by SDS-PAGE. (A) PowerPack 
supply used. (B) Pre-stained Control ladder protein (250-10 kDa).  
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Figure 3.2: TRL-apoB-100, TRL-apoB-48 and HDL-apoA-I separation using the SDS -PAGE 
method. (A) A black arrow indicates HDL -apoA-I bands. (B) other black arrows indicate TRL-
apoB-100 and TRL-apoB-48. The standard control ladder which starts at 250 kDa is also 
indicated in bold.  
Total HDL 
apoA-I 
Unstained 
Control Std. 
ladder 
Unstained 
Control Std. 
ladder 
Apo B-100 
Apo B-48 
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3.2.5 Silver stain and protein hydrolysis 
After the completion of the SDS-PAGE, the gel was washed off the plate into the staining 
container using 200 ml of fixative solution (Methanol 50%, Acetic Acid 10%, Fixative 
enhancer concentrate (Bio-Rad, USA) 10%, deionised H2O 30%) for 20 minutes. Then the gel 
was washed three times with 400 ml of deionized water. Finally, the gel was stained with 
100 ml of freshly prepared staining solution (development accelerator solution (Bio-Rad, 
USA) 50%, Silver complex solution, Reduction moderator solution, and Image development 
reagent (Bio-Rad, USA) as 5% each, deionised H2O 35 %). Once the bands on the gel were 
developed and visible after approximately 10-20 minutes, the staining was stopped by 
addition of 5% acetic acid (50ml) for a minimum of 15 minutes. The gel was photographed, 
and the bands were cut using a special gel cutter. Each sample band was then placed in a 
labelled hydrolysis tube, and 1ml of 6M HCL was then added. The tubes were then capped, 
vortexed and placed into a heating block for 24 hours. Protein moieties from the gel bands 
were hydrolyzed into AAs by incubation at 120 °C for 24 hours in the presence of 6M HCL. 
3.2.6 Identification of apoB and apoA-I protein by western immunoblotting 
3.2.6.1 Electrophoretic transfer procedure (wet transfer) 
After SDS-PAGE, the bands were identified by Western immunoblotting. This procedure was 
followed immediately by electrophoresis. Two rectangular pieces of filter paper and one 
piece of 0.2um nitrocellulose membrane were prepared. The membrane and filter paper 
were soaked together with the fibre pads in transfer buffer pH 8.3 (Glycine 0.29%, Tris base 
0.58%, SDS 0.037%, Methanol 20%) for 10 minutes, and the gel was immersed in the transfer 
buffer immediately. Then a wet sandwich was prepared for the transfer as follows; two 
pieces of filter paper were firstly put on a fibre pad, and the gel was then gently placed onto 
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the filter paper, then the wet nitrocellulose membrane was overlaid onto the gel and then 
covered with another piece of filter paper (Figure 3.2), and finally, another fibre pad was put 
on top to complete the sandwich. Then the sandwich was placed into a plastic sandwiching 
cassette which was fitted into the mini transfer-blotting cell (Bio-Rad) as seen in Figure 3.3.  
The gel has been put on negative polarity and the membrane on the positive polarity. The 
electrophoretic transfer was run at 30v for 24 hours with running water to maintain a cold 
temperature. 
 
Figure 3.3: Wet transfer “Sandwich” set -up. The pictures were obtained from Bio-Rad website 
(http://www.bio-rad.com/en-us/product/tetra-blotting-module).  
3.2.6.2 Immunolocalisation procedure; 
Once the transfer of proteins onto the nitrocellulose membrane was completed, the 
membrane was placed into a clear plastic box containing 100 ml of blocking buffer pH 7.5 
(dried non-fat milk 5%, Tris base 10mM, NaCl 0.05M, Tween 20 0.5%) and shaken for 1 hour 
at room temperature. This has been shown to reduce nonspecific binding of the antibody to 
the membrane. Then the blocking buffer was poured off, and the membrane was washed 
with 100 ml PBST solution pH 7.4 (PBS (phosphate buffered saline) 1pack (sigma), Tween 20 
0.05%) for 10 minutes. Table 3.4 shows the primary (1°) and secondary (2°) antibodies (AB) 
with their concentration to detect: total apoB, apoB-100, apoB-48 and apoA-1 protein bands 
by western immunoblotting. The membrane was incubated with a primary antibody AB 
prepared in the blocking buffer for 1 hour at room temperature (Table 3.4). The membrane 
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was then washed with 100 ml PBST solution for 10 minutes, and the wash repeated three 
times to remove excess antibody. The membrane was then incubated with a secondary 
antibody prepared in the blocking buffer for 1 hour at room temperature (Table 3.4). The 
membrane was then washed with 100 ml PBST solution for 10 minutes, and the wash was 
repeated three times to remove excess secondary antibody. The final step was staining the 
membrane with 50 ml alkaline phosphatase (AP) staining reagent (AP colour development 
buffer 25x 4% + AP colour Reagent A 2% + AP colour Reagent B 2% + H₂O). The 
apolipoprotein bands (either apoB-100, apoB-48 or apoA-I) appeared and were identified 
after 2-10 minutes. Upon visualisation of the bands, the staining reaction was terminated by 
adding 50 ml deionized H2O (Figure 3.4). 
Table 3.4: Primary and secondary antibody (AB) used in Western Immunoblotting to identify 
total apoB, apoB-100, apoB-48, and apoA-I. 
AB used Total ApoB ApoB-100 ApoB-48 ApoA-I 
1° AB and 
concentration 
used 
1D1 mouse anti-
apoB monoclonal. 
Used at 1mg/ml 
as 10µl in 80ml 
blocking buffer. 
4G3 mouse anti-
apoB-100. Used 
at 1mg/ml as 10µl 
in 100ml blocking 
buffer. 
151 JAP mouse 
anti-apoB-48. Used 
at 0.2mg/ml as 75µl 
in 100ml blocking 
buffer. 
1. 4H1 mouse anti-apoA-I. 
Used at 0.5mg/ml. 
2. AB6713 goat anti-apoA-
I at 1mg/ml. 
Both prepared as 10µl in 
100ml blocking buffer. 
2° AB and 
concentration 
used 
Donkey anti-
mouse AP. Used 
at 1mg/ml as 
200µl in 100ml 
blocking buffer. 
Donkey anti-
mouse AP. Used 
at 1mg/ml as 
200µl in 100ml 
blocking buffer. 
Donkey anti-mouse 
AP. Used at 1mg/ml 
as 200µl in 100ml 
blocking buffer. 
Donkey anti-mouse AP at 
and Donkey anti-goat AP. 
Both used at 1mg/ml as 
200µl in 100ml blocking 
buffer. 
1°: primary; 2°: secondary; AB: antibody; apo: apolipoprotein; AP: Alkaline Phosphatase. 
3.2.7 Purification of AAs by ion exchange chromatography (IEC) 
AAs from hydrolysed apoB-100, apoB-48 and apoA-I were purified by ion exchange 
chromatography (IEC). IEC is based on the ionic interactions between the charged molecules 
in the mobile phase and the charged solid support in the immobile phase. Regarding cation 
exchange chromatography which was used, positively charged AAs in 6M HCl (at low pH) 
bound to the negatively charged solid support AG-50W Resin (Bio- 
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Figure 3.4: TRL-apoB-100, apoB-48 and HDL-apoA-I characterisation using western 
immunoblotting method. HDL -apoA-I bands identified and characterised using (A) AB6713 
apoA-I specific antibodies, (B) 4H1 apoA -I antibodies. TRL-apoB bands identified and 
characterised using (C) TRL-apoB-100 using 4G3 mouse anti -apoB-100 and (D) TRL-apoB-48 
using 151 JAP antibodies. SDS-PAGE and western immunoblotting methods were used 
respectively. The standard control  ladder which starts at 250 kDa is also indicated in bold.  
 
HDL apoA-I 
Stained control 
ladder  
Apo B-100 
Apo B-48 
Stained 
control ladder  
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Rad). To elute the AAs, 4M ammonium hydroxide (NH4OH) was added to increase the pH of 
the mobile phase which results in an ultimate reduction of the ionic interaction between AAs 
and the resin. As a result, the AAs were released from the resin, and all unwanted materials 
were removed. 
The hydrolyzed samples from SDS-PAGE were cooled on ice before they were applied to IEC 
columns (Evergreen, UK). Then they were centrifuged at 2500 rpm (RCF of 1400 x g) rpm at 
4°C to precipitate unwanted gel material which can block the column during IEC. Samples 
were then loaded onto the IEC columns with 1ml acid washed resin at pH 7.0 measured by 
instant pH 0-14 indicator paper (GE-Whatman, UK). The low pH which developed in the IEC 
column after sample pouring was restored to pH 7.0 by washing the column three to four 
times with 1ml deionised H2O. The samples were eluted by the addition of 3 ml of 4M 
NH4OH. The eluted samples were collected in labelled glass vials, and then frozen and 
concentrated by freeze-drying (ModulyoD Freeze Dryer, Thermo Electron Corporation, UK) 
to remove the solvent. 
3.2.8 Leucine derivatisation 
Freeze dried samples containing purified AAs were derivatized for the determination of 1-13C 
leucine enrichment by gas chromatography-mass spectrometry (GC-MS). Leucine was 
converted into a volatile and thermally stable trifluoromethyl oxazolinone (Oxazolinone) 
derivative (Figure 3.5) (Dwyer et al., 2002). The oxazolinone derivative was analysed by 
negative ion chemical ionisation GC-MS. Oxazolinone was formed in a rapid single step 
procedure by adding a mixture of 50µl TFAA and 50µl TFA. The samples were then mixed by 
vigorous vortexing and heated at 110°C for five minutes. Then 500µl toluene and 1ml 
deionised H2O were added respectively for the extraction of the volatile oxazolinone 
derivative. The samples were then capped, vortexed, and centrifuged at 2500 rpm (RCF of 
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1,400 × g) for 10 minutes at 4°C to separate the mixture into two layers. Finally, the top 
toluene layer in each sample was taken into a GC vial (03-FIV C201 Chromacol LTD, UK) and 
capped for GC-MS analysis which contained the oxazolinone leucine derivative. 
 
Figure 3.5: Chemical structure of oxazolinone derivative of leucine obtained from (Dwyer et 
al.,  2002).  
3.2.9 Determination of leucine isotopic enrichment of apo B-100, apo B-48, and 
apoA-I by GC-MS 
3.2.9.1 Standard Curve for Leucine enrichment 
It was essential to confirm and verify that the GC-MS detector was functioning properly 
before analysing any samples on the GC-MS. Therefore, a range of standards with different 
enrichment was prepared to determine the sensitivity, linearity, and accuracy of GC-MS. 
Both 1-¹²C-leucine and 1-¹³C-leucine were used for the preparation of standards. The 
standard curve was made with a constant ¹²C-leucine concentration, but increasing 1-¹³C-
leucine concentrations in eight different concentrations. These were derivatized and 
analysed by the GC-MS. The theoretical ratio was plotted against observed (area ratio) AR 
from the GC-MS.  
The preparation of the standard curve is shown in Table 3.5 which shows the concentrations, 
theoretical and observed ratios of tracer (12C) and tracee (13C) respectively. The standard 
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curve is demonstrated as the measured 13C/12C peak tracer: tracee ratio (TTR) plotted 
against the theoretical TTR. A linear relationship was indicated by a slope approximating to 
unity (0.9731) (Figure 3.6). It was essential to check that the range of TTRs in the standard 
curve was appropriate for the sample TTRs. Also, three sets of QCs was prepared and 
included in beginning and end of each assay which would imply that any subsequent sample 
run was accurately measured. The QCs for each assay were represented as QC1 (low), QC2 
(middle), and QC3 (high) with AR mean ± standard error of the mean (SEM), and the intra-
assay Coefficient of Variations (CVs) were (0.62%, 0.74%, and 0.42%) respectively (n=6). 
Table 3.5: Preparation of standards for TRL-apoB and HDL-apoA-I leucine samples 
standards 
Tracer 
13C (µg) 
Tracee 
12C (µg) 
Theoretical TTR 
13C /
12C 
Observed ratio 
13C /
12C 
1 0 0.0015 0.00000 0.09110 
2 0.000005 0.0015 0.00335 0.09514 
3 0.000010 0.0015 0.00669 0.09662 
4 0.000030 0.0015 0.02008 0.10975 
5 0.000050 0.0015 0.03346 0.12291 
6 0.000075 0.0015 0.05019 0.13929 
7 0.000101 0.0015 0.06693 0.15750 
8 0.000151 0.0015 0.10039 0.18800 
¹³C, levorotary labelled leucine; 
1 2
C, unlabeled leucine; TTR: tracer/tracee ratio.  
 
 
Figure 3.6: Leucine standard curve for TRL-apoB and HDL-apoA-I fractions. Calibration graph 
showing the ratio of labelled  (L¹³C6) to unlabelled Leucine (¹
2
C6). Results are mean ± SEM 
(n=6).  
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3.2.9.2 Measurement of 13C leucine isotope enrichment 
Isotopic enrichment of apoB-100, apoB-48 and apoA-I were measured by the GC-MS (GC 
system, Agilent 5973C inert XL EI/CI network MSD, Agilent Technologies, Wokingham, 
Berkshire, UK) (Ackermans et al., 1998). The GC was equipped with a capillary column of 30 
meters 0.25 mm inner diameter (J&W Scientific, Inc. CA, USA) in which helium was used as 
the carrier gas. The GC-MS was operated in a negative chemical ionisation (NCI) mode using 
methane as the reagent gas. The initial temperature of the GC oven was 50°C for one 
minute, and the ramp was 6°C/minute to 90°C, 30°C/minute to 280C. Samples were loaded 
in the sequential order and injected with an Agilent 7683 autosampler.  
The oxazolinone derivatives of 12C leucine and 1-13C leucine have a molecular mass of 209 
and 210 respectively. Therefore, the AR of ions at m/z 210 (ion fragment of 1-¹³C Leucine), 
representing the tracer, and m/z 209 (ion fragment of ¹²C Leucine) representing the tracee, 
were calculated at each time point as TTR of 210/209. This specifies the concentration of 
enrichment after the initiation of tracer infusion at t=0. TTR at each time point after the start 
of tracer infusion was calculated by subtracting the background AR at t=0 multiplied by 100 
(Dwyer et al., 2002) as: TTR = AR 210/209 after infusion – AR 210/209 baseline (t=0). 
The calculation of TTR was used for the calculation of apoB-100, apoB-48 and apoA-I kinetics 
(Dwyer et al., 2002). 
3.2.10 Determination of α-ketoisocaproate (α-KIC) isotope enrichment 
Plasma samples obtained for the measurement of α-KIC isotopic enrichment were kept at -
80C until analysis. Plasma samples were thawed, vortexed and then centrifuged at 2500 
rpm (RCF of 1400 × g) for 10 minutes at 4C to precipitate any proteins. One hundred l of 
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the plasma was added into a small glass test tube containing 1 ml ethyl alcohol. Samples 
were vortexed and centrifuged at 2500 rpm (RCF of 1400 × g) for 10 minutes at 4C. The 
supernatant was transferred to new vials by glass pipettes and dried under OFN at 50C. The 
remainder was dissolved in a mixture of 200 l deionized H20 and 100 l O-
phenylenediamine (2%) dissolved in 4M HCl, and placed on the heating block at 90C for 1 
hour. Samples were left to cool down to room temperature. One ml of ethyl acetate was 
added to extract the keto-acid. The top layer containing the keto-acid was collected in 
another tube. The extraction process was repeated by adding another 1 ml ethyl acetate. 
The extracts were dried over sodium sulphate followed by evaporation under OFN at room 
temperature. The remainder was derivatized by 100 l acetonitrile and 100 l N-Methyl-N-
(tertbutyldimethylsilyl) trifluoroacetamide (MTBSTFA) with 1% trimethylchlorosilane. 
Samples were placed on a heating block at 120C for 45 minutes. The excess derivatizing 
reagent was removed by using OFN at room temperature. One hundred l decane was 
added to the derivative 4-methyl-2-Oxpentanoic acid sodium salt, and the whole mixture 
was collected in GC vials. 
The preparation of α-KIC standard curve is shown in Table 3.6 which shows the 
concentrations, theoretical and observed ratios of D1 tracer (12C) and D0 tracee (13C) 
respectively and Figure 3.7. The α-KIC derivative 4-methyl-2-Oxpentanoic acid sodium salt 
was analysed as D1 and D0. D1 represents the labelled 4-methyl-2-oxpentanoic-1-13C acid 
sodium salt tracer, and D0 was the unlabelled 4-methyl-2-oxpentanoic-1-12C acid sodium salt 
tracee. D1 and D0 have a molecular mass of 260 and 259 respectively. A-KIC isotopic 
enrichment (Figure 3.5) was measured by electron ionisation (EI) GC-MS by the selected ion 
monitoring of D0 fragments at m/z 259 (m) and D1 fragments m/z 260 (m+1). 
Chromatographic peaks were determined, and the TTR of α-KIC (D1 13C/ D0 12C) was 
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calculated. The α-KIC observed isotope TTR enrichment was plotted against the theoretical 
TTR. Also, three sets of QCs was prepared and included in beginning and end of each assay 
which would imply that any subsequent sample run was accurately measured. The QCs were 
represented as QC1 (low), QC2 (middle), and QC3 (high) with AR mean ± SEM with an intra-
assay CVs of (0.67%, 0.66%, and 0.58%) respectively (n=6). 
Table 3.6: Preparation of standards for TRL-apoB and HDL-apoA-I α-KIC samples 
Standards 
D1 Tracer 
¹³C (µg) 
D0 Tracee 
¹2C (µg) 
Theoretical TTR 
¹³C/ ¹2C 
Observed ratio 
¹³C/ ¹2C 
1 0 1.00 0 0.22716 
2 0.1000 1.00 0.010513 0.24115 
3 0.02500 1.00 0.026283 0.25756 
4 0.05000 1.00 0.052566 0.28639 
5 0.07500 1.00 0.078849 0.31540 
6 0.10000 1.00 0.105132 0.34485 
D1 ¹³C, labelled 4-methyl-2-oxpentanoic-1-
13
C acid sodium salt;  D0 
1 2
C, unlabelled 4-methyl-2-
oxpentanoic 
12
C acid sodium saline. TTR: tracer/tracee ratio.  
 
Figure 3.7 : α-KIC standard curve for TRL -apoB and HDL-apoA-I fractions. Calibration graph 
showing labelled (D1 
1 3
C5) to unlabelled α -KIC (D0 
12
C5) ratio. Data are mean ± SEM (n=6).  
3.2.11 Measurement of TRL-apoB-100 and TRL-apoB48 by competitive Enzyme-
linked immunosorbent assays (ELISA) 
3.2.11.1 TRL-apoB-100 ELISA 
This was an in-house assay used to measure TRL-apoB-100 concentration from the obtained 
TRL fraction. This quantitative sandwich enzyme immunoassay was prepared along with a 
set of standards and QCs to check the accuracy of the assay every time it was used. The main 
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idea behind this assay was to capture the apoB-100 antigen in the sample by creating a 
sandwich between the primary antibody, a polyclonal anti apoB, and the secondary 
antibody, biotinylated monoclonal 4G3 antibody, specific to apoB-100. The excess of both 
antibodies along with the sample were washed off inside the well and nothing remained but 
the sandwich. Streptavidin was added to the wells as an enzyme to facilitate a colour 
producing reaction. Finally, a substrate was added in the end to produce a colour, and the 
colour intensity was measured by reading at 540nm in a plate reader (DYNEX Technologies, 
Opsys ELISA microplate reader, UK). A standard curve of the known standards concentration 
and optical densities (ODs), which is also known as absorbance, was used to calculate the 
concentration of the unknown sample concentration using its absorbance. The standards 
were prepared as eight standards with a gradual increase in concentration (S1-S8), and 
stored in -80°C to be used as slots for the assay as shown in Table 3.7 which shows the 
optical density (OD) and concertation of each standard prepared. In each assay, a freshly 
defrosted set of eight standards and QC were used. The plate reader software (DYNEX 
Technologies Revelation software version 4.25, UK) was used to calculate and create the 
best curve fitting for the standards based on the concentrations uploaded and measured 
ODs (Linear/Linear axes scaling by cubic regression was used as the standards curve fit for 
this assay). The standard curve was then used to calculate the TRL-apoB-100 concentrations 
based on their measured ODs (Figure 3.8). The QC used in this assay was an isolated in-
house LDL fraction which was used as a positive QC for this assay to ensure that the assay 
was working properly.  
 
 
 
  102  
 
 
     Table 3.7: Preparation of standards for TRL-apoB-100 ELISA assay. 
Standards OD (mean) n=4 Concentration (mg/ml) 
1 0.02025 0 
2 0.13175 0.02 
3 0.255 0.05 
4 0.58625 0.1 
5 0.85825 0.133 
6 1.15475 0.2 
7 1.816 0.4 
8 2.259 1 
    OD; optical density.  
 
Figure 3.8: ELISA standard curve for TRL-apoB-100 assay. Results are mean ± SEM (n=3)  
3.2.11.2 Method of TRL-apoB-100 ELISA 
Microplate wells are coated with primary antibody; sheep Anti-human apoB (IgG fraction) 
(Binding site, UK) in 100 µl coating phosphate buffer (PBS 1 pack, pH7.5) 2-3 days before the 
assay, covered and stored at 4°C in a designated box. TRL-apoB-100 samples were diluted 
with dilution buffer A (phosphate buffer + 0.02% Thimerosal (VWR International LTD., UK) as 
1:700, and the QC was diluted as to 1:35,000.  On the day of the assay, the plate is allowed 
to warm up to the room temperature (R/T), washed three times with the washing buffer 
(0.02 % thiomersal and 0.1% Triton (Triton X-100, Merck Millipore, Germany)) in which each 
wash took 300µl/well. The plate was then blocked with the blocking buffer (Phosphate 
buffer + 1% bovine serum albumin (BSA) (Sigma, UK), 0.02 % thiomersal) at R/T for one hour 
and then washed three times as before.  Standards and diluted samples were pipetted 
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(100µl) to the well and incubated at R/T for two hours. The plate was then washed three 
times followed by addition of secondary antibody B-4G3 (biotinylated monoclonal anti-apoB-
100, prepared in-house) in 100µl diluting buffer B (Phosphate buffer, 0.01% thiomersal, 0.5% 
BSA) and incubated at R/T for two hours. Then the plate was washed three times as before, 
and a streptavidin-Alkaline Phosphatase dilutes at 1:30,000 in 100µl diluting buffer B and 
incubated either at R/T for one hour or overnight at 4°C. The plate was then washed three 
times as before, and a 100µl substrate solution (Phenolphthalein monophosphate di 
(Cyclohexylammonium) salt (Sigma, UK) was dissolved in 8mg/ml in substrate buffer 
(Diethanolamine, NaN3, MgCl2 (Sigma, UK), HCl in H2O, pH 9.8) was added to the wells and 
incubated at R/T up to 45-60 minutes. Once a good intensity of pink colour was achieved in 
the most concentrated standard well, the reaction was stopped by addition of 200µl stop 
buffer (Glycine, EDTA, NaOH (Sigma, UK) at pH 10.4).  The plate was then read immediately 
in the plate reader at 540nm, and TRL-apoB-100 concentrations were calculated in mg/ml by 
the plate reader revelation software. 
3.2.11.3 TRL-apoB-48 ELISA assay 
This assay was purchased commercially as an ELISA kit (Human apoB-48 ELISA Kit, AKHB48, 
Shibayagi Co., LTD. Japan, facilitated by Oxford Biosystems, UK). Therefore, all materials 
used for this assay such as buffers for dilution, washing, enzyme and substrate solution was 
obtained from the commercial kit, and only the QCs and microplate reader and its software 
were used for the calculation of TRL-apoB-48 concentrations. The assay performance 
characteristics such as the assay range, specificity, precision and reproducibility are shown in 
Table 3.8. The assay principle was that provided standards and samples were incubated in 
monoclonal antibody-coated wells to capture apoB-48. After an hour of incubation and 
proper washing, the biotin-conjugated anti-apoB-48 antibody was added and incubated for 
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one hour. After proper washing, horseradish peroxidase (HRP) conjugated avidin was added 
to react with a chromogenic substrate reagent (TMB) for 20 minutes, and the reaction was 
stopped by addition of acidic solution, and absorbance of yellow product was measured 
spectrophotometrically at 450nm using the plate reader used with the previous assay. The 
absorbance was proportional to aboB-48 concentration. The standards were freshly 
prepared on the assay day as eight standards with gradual increase in concentration (S1-S8) 
as seen in Table 3.9 which shows the optical density (OD) and concertation of each standard 
prepared. Plate reader software (DYNEX Technologies Revelation software version 4.25, UK) 
was used to calculate and create the best curve fitting for the standards based on the 
concentrations uploaded and measured ODs (Logarithmic/Logarithmic axes scaling by cubic 
spline was used as the standards curve fit for this assay). The standard curve was then used 
to calculate the TRL-apo-B-48 concentrations based on their measured ODs as seen in Figure 
3.9. In terms of QC, positive and negative QCs was used in this assay; positive QCs were the 
lymph fractions which were full of chylomicrons-apoB-48 (batch 2, in-house prepared), and 
the negative QC was the LDL fraction (In-house prepared, used for the TRL-apoB-100 ELISA 
assay) to make sure that the assay was working properly. 
Table 3.8: performance characteristics and values of TRL-apoB-48 ELISA commercial Kit. 
Performance characteristics Value information* 
Assay range 2.5 ng/ml - 160 ng/ml 
Specificity 
All antibodies in this kit were specific to human 
apoB-48 and had no crossreactivity with human 
apoB-100 
Precision of the Assay 
Assay of 3 samples with five replicates gave a 
Mean CV of 3.5% 
Reproducibility 
Assay of 3 samples with five replicates repeated 
for three days gave a CV of 2.8-8.6% 
*All values were obtained from the instruction manual included in the ELISA kit version 9 
issued on December 3, 2012.  
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Table 3.9: Preparation of standards for TRL-apoB-48 ELISA assay 
Standards OD (mean) n=4 Concentration (ng/ml) 
1 0.1345 0 
2 0.175 2.5 
3 0.2215 5 
4 0.269 10 
5 0.5085 20 
6 0.915 40 
7 1.557 80 
8 2.29 160 
     OD; optical density.  
 
    Figure 3.9: ELISA standard curve for TRL -apoB-48 assay. Results are mean ± SEM (n=3)  
3.2.11.4 TRL-apoB-48 ELISA assay method 
TRL-apoB-48 samples were diluted with assay dilution buffer as 1:250, and the QCs were 
diluted as 1:300.  On the day of the assay, the plate is brought up to warm up to the R/T, 
washed four times with the assay washing buffer in which each wash took 300µl/well..  
Standards and diluted samples were pipetted (50µl) to the well, shaken and incubated at R/T 
for one hour. The plate was then washed four times as before followed by addition of 50µl 
biotin-conjugated anti-apoB-48 antibody assay solution, shaken and incubated at R/T for one 
hour. Then the plate was washed four times as previously and 50µl Peroxidase-conjugated 
streptavidin assay solution were added, shaken and incubated either at R/T for 30 minutes 
at R/T.  The plate was then washed six times as before, and 50µl Chromogenic substrate 
assay reagent solution were added to the wells and incubated at R/T up to 20 minutes. The 
reaction was stopped by addition of 50µl of the reaction stopper assay buffer.  The plate was 
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then read immediately in the plate reader at 450nm within a maximum period of 30-40 
minutes, and TRL-apoB-48 concentrations were calculated in ng/ml by the microplate reader 
revelation software. 
3.2.12 Measurement of TG, cholesterol and HDL-Cholesterol (HDL-C) concentration 
Blood samples were collected in EDTA, lithium heparin, and plain tubes, and then they were 
separated by centrifugation at 2500 rpm (RCF of 1400 × g) for 10 minutes at 4°C to obtain 
either serum or plasma. The concentration of plasma TG, TRL-TG-F (TG concentration on 
CMs and VLDL fraction samples), plasma total cholesterol and total cholesterol fractions 
were measured. 
The plasma TG and TRL-TG-F concentrations were determined by the ABX Mira analyser 
(Triacylglycerols CP, kit ref: A11A01640; Horiba ABX, France). The TG assay kit was used, and 
the measurement was based on an enzymatic photometric method. TGs in the sample 
underwent few enzymatic reactions to produce a colorimetric indicator ‘’Quinoneimine’’ 
which was detected by a colorimetry spectrometry. The concentration of TGs was calculated 
by measuring the absorbance of quinoneimine at 500 nm wavelength. The QCs were 
represented as N (low) and P (high) with an intra-assay CVs of 1.98% and 2.23% respectively 
(n=3).  
The plasma and fraction cholesterol concentrations were measured by the ABX Mira 
analyser using enzymatic cholesterol assay kits (kit ref: A11A01634; Horiba ABX, France) as 
prescribed previously to produce Quinoneimine. The concentration of cholesterol was 
calculated by measuring the absorbance of Quinoneimine at 500 nm wavelength. QCs were 
prepared and represented as N (low) and P (high) with an intra-assay CVs of 3.53 % and 
1.45% respectively (n=3). 
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HDL-C concentrations in plasma and fractions were also measured by the ABX Mira analyser 
using HDL enzymatic kit (Horiba ABX, Northampton, UK). The method was based on 
accelerating the reaction of cholesterol oxidase (CO) with non-HDL unesterified cholesterol 
and dissolving HDL selectively using a particular detergent; ‘Accelerator Selective Detergent’ 
(kit ref: A11A01636; Horiba ABX, France). Two main enzymatic reagents were used; one was 
responsible for the solubilization of HDL specifically, and the other one was used to develop 
a colour for the quantitative determination of HDL-C which was measured at a wavelength 
of 600 nm. QCs were prepared with N (low) and P (high) with an intra-assay CVs of 8.48% 
and 7.35% respectively (n=3). 
3.2.13 Measurement of apoA-I concentration in plasma and total HDL fractions 
ApoA-I concentration in the HDL fraction was measured by an automatic ABX Mira analyser 
(Horiba ABX, France) using an immunoturbidimetric method. Two reagents from one kit (kit 
ref: A11A01687; Horiba ABX, France) were used for the assay; apoA-I specific reagent which 
is a fraction of purified immunoglobulins from rabbit antiserum and apoA-I immunogen from 
human HDL. ApoA-I reacts with its specific antibody and generates the immune complexes. 
The produced substance was subjected to a beam of light. The proportion of apoA-I 
concentration in the samples was represented by the intensity of the scattered light. The low 
and high-quality controls (QCs) with an inter-assay CVs of 7.531% and 3.173% respectively 
(n=3). 
3.2.14  Measurement of glucose and insulin concentration 
Plasma glucose concentrations were measured by an auto glucose analyser (YSI 2300 STAT 
Plus. Analytical @ Technologies, UK). The enzymatic reaction resulted in the production of 
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hydrogen peroxidase H2O2, which is used to determine the glucose concentration. Each 
sample was measured twice, and the average value was used. 
Plasma insulin was measured using a double-antibody radioimmunoassay (RIA) called 
Millipore Human Insulin assay (Merck Millipore, MA, USA) using the double antibody/PEG 
technique (Desbuquois and Aurbach, 1971). This method was incubating the plasma sample 
with an antibody-bound tracer overnight. Then the sample was incubated with a second 
antibody for further 2 hours. The Labelled human insulin was determined by a radioactivity 
gamma counter which can distinguish the bound from the unbound tracer using the kit (Kit 
ref: HI-1AK; Merck Millipore, MA, USA). Also, a standard curve was prepared and included in 
each assay which would indicate that any subsequent sample run was accurately measured. 
3.2.15 Anthropometrics 
Body weight, body fat and BMI were measured using a body Composition Scale (Tanita Body 
Composition Analyzer BC-418MA) by applying electrical bio-impedance. 
3.2.16 Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy 
(MRS) for the measurement of liver, muscle and whole body fat 
Visceral and total fat mass was determined by MRI. Intrahepatocellular lipid (IHCL) and 
intramyocellular lipids (IMCL) were measured by 1H-magnetic resonance spectroscopy (1H-
MRS), and the spectra were acquired using a 1.5 T multinuclear system (Philips Medical 
Systems, Best, the Netherlands). All the measurements were performed in the Robert 
Steiner, MRI Unit at the Hammersmith Hospital in London, and participants were asked to 
fast for about 6 hours before they visit the unit. 1H-MRS has been used instead of a liver 
biopsy, ultrasound or CT as it safe to use (non-invasive), reliable and sensitive. It can detect a 
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low hepatic steatosis fat percentage down to less than 5% (Springer et al., 2010, Cowin et al., 
2008, Dutour et al., 2016, Reeder et al., 2011). 
3.2.17  HDL-apoA-I kinetics measurements  
HDL-apoA-I kinetics (production rate (PR) and fractional clearance rate (FCR)) were 
calculated using the following variables;  
 
a. ApoA-I TTR of each hourly time point throughout the study. 
b. KIC TTR of each time points throughout the study. 
c. Apo-A-I concentration from obtained HDL fraction of each time point. 
d. Plasma volume (PV) of each participant at each visit which is determined by body weight (BW) 
and height. 
The equations were applied as follows; 
Equation 1: Fractional secretion rate (FSR) of HDL-apoA-I was calculated by linear regression as used 
in a previous study for the measurement of HDL apoA-I kinetics (Li et al., 2012). 
FSR (pools/day) = (Slope of the apoA-I TTR time curve/KICTTR) × 24 x 60. 
Equation 2: In a steady state, the FSR is equal to the fractional catabolic rate (FCR). The production 
rate (PR) was calculated from the FSR and the pool size as follows;  
PR (mg/kg/day) = FSR × HDL apoA-I pool size 
Equation 3: ApoA-I pool size was calculated by the concentration of apoA-I and plasma volume (PV) 
divided by body weight (BW) as follows;  
ApoA-I pool size (mg/kg) = HDL apoA-I concentration × PV / BW 
Equation 4: Apo-AI PV was calculated (Pearson et al., 1995) as follows; 
PV (ml) = 1578 × Surface area m2 (SA) 
Equation 5: The surface area (SA) was calculated (Du Bois and Du Bois, 1989) as follows; 
SA (m2) = BW 0.425 × Height 0.725 × 0.007184 
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3.2.18  TRL-apoB-100 and B-48 kinetics 
TRL-apoB kinetics was calculated using computer modelling software SAAM II (SAAM 
Institute, Seattle, WA, USA) in which a model developed by Dr Roman Hovorka (University of 
Cambridge, UK) was used to obtain the best-fit curves using TRL-apoB-100, TRL-apoB-48, and 
α-KIC concentrations (Figure 3.10 A and B). To calculate TRL-apoB kinetics, important values 
for each time point throughout the study were requested by the programme; 
1. TTR of apoB-100 and apoB-48. 
2. TTR of α-KIC. 
3. ApoB-100 and apoB-48 concentration. 
4. ApoB-100 and B-48 pool size which was calculated using the three equations used earlier 
to calculate apoA-I kinetics; 
Equation 1: ApoB-100 and B-48 pool size were calculated from the concentration of apoB-
100, apoB-48, and PV divided by BW as follows;  
ApoB-100 pool size (mg/kg) = TRL-apoB-100 concentration × PV / BW 
ApoB-48 pool size (mg/kg) = TRL-apoB-48 concentration × PV / BW 
PV and SA were calculated using equations 4 and 5 which were used earlier to calculate 
apoA-I kinetics. 
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Figure 3.10: The compartmental model for measuring TRL -apoB-100 (A) and TRL-apoB-48 (B) 
kinetics using SAAM II model.  A-KIC: α-ketoisocaproate; VLDL: very low -density l ipoprotein; 
Apo: apolipoprotein; CM: chylomicron; K: rate of transfer of leucine.  
3.2.19 Statistical analysis 
All the statistics tests were performed using Graph Pad Prism Version 6.07, Microsoft Excel 
2010 and SPSS 22 (SPSS Inc.; Chicago USA). The distributions of all data were examined by 
checking their skewness and kurtosis, and performing Kolmogorov-Smirnov, D'Agostino & 
Pearson omnibus and Shapiro-Wilk normality tests. All data were analysed using parametric 
tests. 
3.2.19.1 Parametric tests used 
- To determine whether postprandial TG concentrations were constant in a steady state 
over time Repeated Measures ANOVA was carried out. 
- To compare repeated measurements after the two interventions in each study (exercise 
group vs. control group and post lixisenatide treatment vs. placebo) Paired-samples, 
two-tailed t-test was performed. 
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- To determine the differences (delta Δ values) and the effect of exercise within one group 
pre-intervention data values minus post-intervention data values were calculated. 
- To determine whether the effects of exercise on post intervention data  between the 
two groups are different (post-exercise versus post-control) in the NAFLD study (the end-
point test), an unpaired sample Two-tailed t-test was performed. 
- To determine whether the effects of exercise were different in the two groups in the 
NAFLD study, an unpaired sample Two-tailed t-test was performed on the Δ values. This 
test was applied to determine the effect of exercise between the two groups if the 
previous test failed to detect a significance difference due to an existing difference in the 
baseline measurements between the two groups after participant’s random distribution 
by coincidence. 
- To test whether two curves were statistically different; Area under the curve (AUC) over 
time was calculated, and the slope of each curve was tested using Linear Regression.  
- To test the difference between the baseline measurements of the NAFLD study vs. the 
lixisenatide study, unpaired samples Two-tailed t-test was performed. 
- Testing for correlations between different variables was carried out by Pearson 
correlation analysis corrected by Bonferroni correction test to exclude false positive 
results. 
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4. Chapter 4: Development of a feeding and a laboratory protocol to measure 
postprandial TRL-apoB-100 and apoB-48 kinetics 
4.1 Introduction 
Atherogenic dyslipidaemia is one of the major characteristics of T2D and NAFLD which is 
strongly associated with CVD risk (Taskinen and Boren, 2015, Alcala-Diaz et al., 2014). 
Elevated Postprandial TRL concentrations are strongly related to atherogenic dyslipidaemia 
(Tushuizen et al., 2010). Therefore, many studies have looked at possible effects of elevated 
postprandial TRL on increasing the risk of CVD and CHD in patients with T2D and NAFLD via 
atherogenic dyslipidaemia (Tushuizen et al., 2010, Taskinen and Boren, 2015, Alcala-Diaz et 
al., 2014). Some studies have investigated possible mechanisms by measuring TRL-TG and 
TRL-apoB kinetics (Sun et al., 2013, Xiao et al., 2012). Feeding protocols were developed to 
establish a postprandial TG steady state in the plasma for a long duration such as 8 hours to 
study TRL kinetics under the influence of different dietary conditions and drugs (Sun et al., 
2013, Xiao et al., 2012). These studies investigated TRL kinetics using protocols in which 
either the protein component (TRL-apoB) or the TG component (TRL-TG) of the lipoprotein 
was labelled using stable isotope technique (Sun et al., 2013, Xiao et al., 2012). Both studies 
used developed clinical and laboratory protocols to enable them to isolate and calculate TRL-
apoB-100 and TRL-apoB-48 kinetics. Therefore, the current pilot study was conducted to 
validate the developed constant feeding, clinical and laboratory protocols to enable us to 
calculate fasting and postprandial TRL-apoB-100 and TRL-apoB-48 kinetics using a stable 
isotope trace-labelling technique to be able to use these protocols in other clinical trials. 
4.2 Aims 
The aims of the present study were a) to develop and validate a feeding and clinical protocol 
that could establish a postprandial TG steady state, and b) to develop and validate a and 
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laboratory protocol that could separate TRL-apoB-100 and apoB-48, and measure their 
kinetics using a stable isotope technique. 
4.3 Methods 
This pilot study was separated into two parts; 1) development of a feeding protocol to 
establish a postprandial TG steady state, 2) development of a laboratory protocol to 
measure TRL apoB-100 and apoB-48 using a validated feeding protocol from the first part. A 
total of 4 overweight healthy men with BMI 30-35 were recruited in the study (for detailed 
study recruitment see chapter 2 section 2.2.1). In the first part of the study, participants 
were given 12 hourly high-fat liquid meals for a duration of 13 hours. The meal composition 
was CHO 22%, fat 66.1%, and 11.9% protein with a total of 2280 Kcal (See Table 2.0 Chapter 
2). Two protocols were tested to establish a postprandial TG steady state; A) using 12 hourly 
liquid meals, and 2) using 12 hourly liquid meals with bolus meal at the beginning of the 
study. Blood samples were taken hourly to measure plasma TG concentrations (Figure 2.1).  
The second part of the study used a validated feeding protocol based on plasma TG 
measurements from the first part of the study to measure the kinetics of TRL-apoB-100 and 
apoB-48 using a stable isotope technique (Chapter 2, Figure 2.0). On the study day, 12 hourly 
liquid meals without a bolus meal were given, and an injection of 1-13C leucine tracer of 
1mg/kg followed by a constant infusion of 1mg/kg/min was given after 4 hours of the start 
of the study for a duration of 8 hours to measure TRL-apoB kinetics (Figure 2.2). Blood 
samples were taken hourly during the study. The TRL fraction was separated from plasma 
using ultracentrifugation, and ApoB-100 and apoB-48 in the fraction were isolated via SDS-
PAGE (Chapter 3, Figure 3.0). After purification and derivatization, the leucine enrichment of 
apoB-100 and apoB-48 were finally determined by GC-MS (Chapter 3, Figure3.0). Plasma 
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metabolite concentration measurements throughout the study (see chapter 3 section 3.3 
and 3.5). 
4.4 Results 
4.4.1 Subjects characteristics 
Seven male subjects were screened, and four found suitable for the study. The 
characteristics of the subjects at screening in the PFS both parts are shown in Table 4.1. 
Three participants (PFS01, PFS02 and PFS05) were involved in part 1 to test the validity of 
the meal in establishing a postprandial TG steady state. The last participant PFS06 was 
involved in part 2 in which a feeding protocol was verified in part 1 then he was recruited for 
the second part to measure the TRL-apoB100 and apoB-48 kinetics. 
Table 4.1: Subject characteristics and fasting metabolite concentrations at screening.  
Subject PFS01 PFS02 PFS05 PFS06 
Mean ± SEM 
(n=4) 
Weight (kg) 97.1 83.9 93.2 85.6 89.9 ± 2.7 
Height (m) 1.8 1.7 1.7 1.7 1.7 ± 0.01 
BMI (kg/m2) 30.6 29.0 31.0 28.7 29.8 ± 0.5 
Body fat (%) 29.2 24.2 28.2 29.2 27.7 ± 1.0 
TG (mmol/L) 1.3 1.1 2.2 2.0 1.7 ± 0.2 
Cholesterol 
(mmol/L) 
4.8 6.2 4.3 5.2 5.1 ± 0.4 
Glucose 
(mmol/L) 
5.0 5.5 5.9 4.9 5.3 ± 0.2 
Data are shown as Mean ± SEM. BMI: body mass index, TG: triacylglycerols,  
4.4.2 Verification of postprandial TG steady state 
4.4.2.1 TG concentrations in plasma and TRL fraction  
The verification of the postprandial steady state reflected by TG concentrations is shown in 
Figure 4.0. Administration of 2 liquid meals at the beginning of the study, to act as a bolus, 
produced a rapid rise and fall in plasma TG concentration. On the contrary, without a bolus 
protocol resulted in a steady increase in plasma TG by 2.8 ± 0.1 mmol/L from basal, followed 
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by a plateau between 0 and 480 minutes (Figure 4.0). Repeated measures ANOVA was used 
to test if the TG concentration between 0 – 480 minutes was constant and found out no 
significant difference (P value = 0.6) over time in the three participants. This validates the 
feeding protocol in achieving a constant raised postprandial TG steady state which would 
enable an accurate stable isotope kinetic analysis. 
The results from measuring postprandial TRL-TG (TG fraction of VLDL and CM particles) are 
shown in Figure 4.1. The use of a meal bolus feeding protocol produced an irregular change 
in TRL-TG with no notable pattern; this protocol would be unsuitable for isotopic tracer 
kinetic studies as TG steady state was not maintained. However, results from the protocol 
without a bolus gave a stable increase in TRL-TG by 1.8 ± 0.1 mmol/L from basal followed by 
a plateau between 0 and 480 minutes (Figure 4.1). Repeated measures ANOVA was used to 
test if the TRL-TG concentration between 0 – 480 minutes was constant and found out no 
significant difference (P value = 0.9) over time in the three participants. This validates the 
feeding protocol in achieving a constant raised postprandial TRL-TG steady state which 
would enable an accurate, stable isotope kinetic analysis. 
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Figure 4.0 Plasma TG concentrations throughout  the study with or without the use of a meal 
bolus. Achieving a postprandial  TG steady state without using a meal bolus was a better  
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approach as indicated. Bolus protocol n=1, without bolus protocol n=3. Plasma TG 
concentrations are increased by 2.8 ± 0.1 mmol/L from basal as indicated. 
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Figure 4.1: Plasma TRL -TG (TG concentrations measured in TRL fraction) concentration  
throughout the study with or without the use of a meal bolus. Achieving a postprandial  TG 
steady state without using a meal bolus was a better approach as indicated. Bolus protocol 
n=1, without bolus protocol n=3. TRL -TG concentrations increased by 1.8 ± 0.1 mmol/L from 
basal as indicated. 
4.4.2.2 Glucose and insulin concentrations in plasma and TRL fraction  
Both plasma glucose and insulin concentrations in the bolus and non-bolus studies revealed 
a similar pattern shown for plasma TG and TRL-TG as shown in Figures 4.2 & 4.3 respectively. 
In the non-bolus meal protocol, plasma glucose concentrations were constant with a mean 
value of 5.5 ± 0.1 between 60 and 480 minutes (Figure 4.2), and plasma insulin 
concentrations were constant with a mean value of 124.0 ± 9.1 pmol/L between 0 and 480 
minutes (Figure 4.3). 
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Figure 4.2: Plasma glucose concentrations. Plasma glucose concentration with and without  the 
bolus protocol. Both methods achieved a steady state after 0-time point. Bolus protocol n=1, 
without bolus protocol n=3.  
 
Figure 4.3: Plasma insulin concentrations. Plasma insulin concentration with and without the  
bolus protocol.  The bolus method was more effective at achieving a steady state after 0 t ime 
point. With bolus protocol n=1, without bolus protocol n=3.  
4.4.3 TRL-apo B-100 and apo-B-48 separation by SDS-PAGE 
Fraction samples from subjects PFS01 and PFS02 were used to separate apolipoprotein B by 
SDS-PAGE after the precipitation process. Figure 4.4 shows the separated apo B-100 and apo 
B-48 bands from PFS01 samples. Sample order is as indicated in Figure 4.4 for the study time 
points from -240 – 480. 
Figure 4.4: TRL-apo B-100 and apo B-48 separation using the SDS -PAGE method. TRL-TG-F 
samples were used for the separation of TRL -apo B-100 and apo B-48 using SDS-PAGE method. 
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TRL-apo B-100 and apo B-48 are indicated respectively by a black arrow. The control ladder 
which starts at 250 kDa is also indicated. 
4.4.4 Characterisation of TRL-apo B-100 and apo B-48 by Western immunoblotting 
Western immunoblotting was applied using antigen-antibody detection for identifying TRL-
apo B-100 and apo B48 bands after they were separated by SDS-PAGE as shown in Figure 4.5 
using PFS01 samples. This successfully identified the apolipoprotein B bands and shows 
complete separation which is important for band removal for further sample processing by 
IEC and GC-MS. 
  
Figure 4.5: TRL-apo B-100 and apo B-48 characterisation using western immunoblotting  
method. TRL-apo B-100 and B48 bands from the PFS01 study t ime points were identified and 
characterised using  Primary AB 1D1-mouse and secondary AB AP-Anti mouse using SDS-PAGE 
and western immunoblotting methods respectively.  
4.4.5 TRL-apo B-100 and apo B-48 natural background enrichment (part 1) 
The natural occurring enrichment profile of the 1-¹³C leucine / ¹²C leucine (as AR 210/209) in 
TRL-apo B-100 and apo B-48 is shown in Figure 4.6. This demonstrates that this method can 
be used to measure the TTR of TRL-apo B-100 and apo B-48. 
Apo B-100 
Apo B-48 
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Figure 4.6 AR 210/209 of the background enrichment of TRL -apo B-100 and B-48 from PFS02 
samples in part 1. This f igure illustrates the natural occurring background enrichment of AR 
210/209 of apo B-100 and apo B48 throughout study time points between -280 –  480 minutes 
where the liquid mea l was given hourly as indicated. AR 210/209 represent areas of ions at 
m/z 210 (ion fragment of 1-¹³C Leucine) representing the tracer, and m/z 209 (ion fragment of 
¹²C Leucine) representing the tracee.  
4.4.6 TRL-apo B-100 and apo B-48 enrichment following the infusion of 1-¹³C 
Leucine (part 2) 
The enrichment profile of the incorporated 1-¹³C Leucine tracer in the synthesis of TRL-apo 
B-100 and apo B-48 is shown in Figure 4.7. There was a marked increase in leucine 
enrichment in apo B-100 and apo B-48 from 0 minutes. The TTR did not plateau; this 
indicates that the incorporation of labelled and unlabelled apo B-100 in the liver and apo B-
48 in the intestine has not completely equilibrated with the precursor pool. TRL-apo B-100 
enrichment will continue increasing until it reaches a plateau which will reflect the precursor 
pool enrichment.  
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Figure 4.7: TTR enrichment profile of TRL -apoB-100 and apo B-48 using PFS06 samples.  
4.5 Discussion 
The results from this study demonstrate successful development and verification of an 
hourly repeated feeding protocol. This protocol was validated by achieving a postprandial 
steady state of TRL. The TRL steady state was achieved after four hours, at this point, the 13C 
leucine labelled isotope infusion was given for accurate quantification of postprandial 
hepatic and intestinal TRL kinetics. Furthermore, all participants from the pilot studies 
accepted and tolerated the liquid meal which provided part of a recommended amount of a 
daily calorie allowance (2280Kcal of the 2500 Kcal). As seen in other repeated feeding 
studies shown in Table 1.2, different meal compositions of fat, proteins and carbohydrates 
have been used with the different amount of calories for each meal. As in the present study, 
most of the previous studies used meals with a large percentage of fat and meals were given 
every hour. A study conducted by Xiao et al. (2012) tried to achieve a postprandial steady 
state by administering a liquid feed via a radio-opaque polyvinyl feeding tube which had 
been placed through the nose into the duodenum under the guidance of a fluoroscope. The 
liquid formula contained 49% calories from fat, 38% from carbohydrates, and 13% from 
proteins. Also, the meal which was given at a rate of 40 mL/h for the first 2 hours and then 
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80 mL/h until the end of the study, did not achieve a good TG steady state to enable them to 
study TRL-apoB48 kinetics (Xiao et al., 2012) which was opposite results to the current study. 
Apo B-48 kinetics measurement may be difficult to measure due to the low concentrations 
of apo B-48 in the plasma compared with apo B-100 (Phillips et al., 1997). However, the 
current study was remarkably effective in developing and validating a method using 
isolation, precipitation and separation of apo B-100 and apo B-48 for accurate quantification 
of isotopic enrichment with 13C leucine.  
The method used for the isolation of the TRL fraction by ultracentrifugation was similar to 
methods used in other studies such as(Batista et al., 2004)and(Xiao et al., 2012)which was 
originally developed by(Havel et al., 1955, Welty et al., 1997, Welty et al., 2004).  
In this study, apo B-100 and B-48 were delipidated, precipitated and isolated from other 
apolipoproteins in the TRL fraction samples (CM and VLDL fractions) using Isopropanol. This 
method was validated by(Egusa et al., 1983)and used for the isolation of apo B-100 and B-
48. This method has also been used in other studies of apo B-100 and apo B-48 kinetics (Xiao 
et al., 2012, Cohn et al., 1988, Welty et al., 1997, Welty et al., 2004, Welty et al., 1999, 
Batista et al., 2004). 
Similarly, separation of apo B-100 and B-48 by SDS-PAGE has been used previously (Cohn et 
al., 1988),(Batista et al., 2004, Welty et al., 1997, Xiao et al., 2012). 
In this study, isotopic enrichment of Apo B-100 and B-48 was measured using isolated 
purified free amino acids which were derivatized to the oxazolinone derivative. This 
derivative has a small molecular weight which is the advantage of reducing the contribution 
of naturally occurring isotopes. This method requires one single reaction step using cheap 
reagents for the derivatizing procedure. Also, the derivative has been shown to be suitable 
for Gas Chromatography-Mass Spectrometry (GC-MS), and can be detected by negative 
  123  
 
chemical ionisation which allows determination of low concentrations of isotopic 
enrichment from small amounts of protein such as apo B-100 and apo B-48 (Dwyer et al., 
2002).  
1-¹³C Leucine tracer was successfully incorporated into the apo B-100 and B-48 which reflects 
the rate of VLDL assembly and synthesis in the liver, and CM assembly and synthesis in the 
intestine respectively. TRL-apo B-48 enrichment was lower than apo B-100 enrichment 
which could be due to dilution by the presence of leucine from the liquid meal which dilutes 
the precursor pool and causes a faster plateauing of the leucine enrichment. This indicates 
that the liquid meal and labelled isotope tracer protocols have been shown to be effective 
and are now validated for a further postprandial feeding study.  
Although this study provided a unique and novel insight into the enrichment of the protein 
fractions of the TRL, this study did not investigate the lipid moiety of TRL. The kinetics of 
postprandial TRL lipid moiety can be investigated as seen in the study by Sun et al. (2013) in 
which a novel immunoaffinity method that completely separated hepatic and intestinal TRL 
lipid moiety (TG part) was used (Sun et al., 2013). Despite the effectiveness of this method, 
the separation of hepatic and intestinal lipoproteins using this method is a very time-
consuming method. Also, this method is dependent on the availability of specific apoB-100 
antibodies which are costly when compared with the SDS-PAGE method. 
In conclusion, this study succeeded in developing a repeated feeding protocol that was used 
with a 1-13C leucine infusion to quantify the protein enrichment of hepatic VLDL-apo B-100 
and intestinal CM-apo B-48 in postprandial TRL. The recruitment criteria in this study were 
selected to match the criteria in the lixisenatide study. Therefore, the feeding and laboratory 
protocols were used to measure TRL-apo B-100 and apo B-48 kinetics in the lixisenatide 
study (Chapter 6). 
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5. Chapter 5: The effect of exercise training on HDL kinetics in patients with non-
alcoholic fatty liver disease (NAFLD). 
5.1 Introduction 
Patients with NAFLD are characterised by visceral obesity (Park et al., 2016, Yu et al., 2015, 
Yang and Chang, 2016, Cordeiro et al., 2015, Di Naso et al., 2015, Yoshimura et al., 2014, 
Fabbrini et al., 2010), IR (Delarue and Magnan, 2007, Samuel et al., 2010, Tang et al., 2011, 
Westphal, 2008), altered lipoprotein metabolism including hypertriglyceridaemia, reduced 
HDL-cholesterol concentrations and increased LDL-cholesterol concentrations (Corey and 
Cohen, 2000, Cohen and Fisher, 2013, Tessari et al., 2009, Katsiki et al., 2016) and 
hyperinsulinaemia (Giovannucci, 2007, Onyekwere et al., 2015). All these previous altered 
metabolic manifestations in patients with NAFLD are strongly associated with increasing the 
risk of CVD and CHD through atherogenic dyslipidaemia which is also called atherogenic 
lipoprotein phenotype (ALP) (Corey et al., 2014, Sdiri et al., 2013, Bhatia et al., 2012, Edens 
et al., 2009, Onyekwere et al., 2015). Exercise is one of the important treatment approaches 
in correcting and/or treating NAFLD (Neuman et al., 2015, Pinto et al., 2015). Various studies 
showed that physical exercise has strong effects in correcting reduced HDL-C concentrations 
in patients with metabolic syndrome of altered lipid metabolism such as T2D and NAFLD 
(Garcia Hermoso et al., 2014, Pattyn et al., 2013, Nuri et al., 2012, Hayashino et al., 2012, 
Iborra et al., 2008), and in healthy subjects (Gondim et al., 2015). Many clinical trials have 
been conducted to investigate the effect of exercise on liver fat content in patients with 
NAFLD (Cuthbertson et al., 2016, Hallsworth et al., 2011, Yoshimura et al., 2014, Sullivan et 
al., 2012, Johnson et al., 2009, van der Heijden et al., 2010). Similar studies conducted 
by(Lehmann et al., 2001)and(Kadoglou et al., 2012)investigated the effect of physical 
exercise on HDL-C and apoA-I concentrations in patients with T2D in relation with other 
lipolytic enzymes and inflammatory markers. Remarkably, the study conducted 
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by(Thompson et al., 1997)is the only study which has investigated the effect of long-term 
physical exercise on HDL-apoA-I kinetics in healthy overweight patients. A significant 
increase of HDL-C concentration after exercise was reported in the studies conducted by 
Thompson et al., 1997, Lehmann et al., 2001 and Alam et al., 2004, but not in the studies by 
Kadoglou et al., 2012, Cuthbertson et al., 2016 and Sullivan et al., 2012. Also, a significant 
increase of apoA-I concentrations after exercise were reported in the studies by Thompson 
et al., 1997, Lehmann et al., 2001 but not in Kadoglou et al., 2012. The study by Thompson et 
al., 1997 showed a significant decrease in HDL-apoA-I FCR after exercise by 8%. Also, the 
study showed a significant increase in the HDL-apoA-I PR by 11%. To the extent of our 
knowledge, to date no clinical trials were conducted on patients with NAFLD to investigate 
the effect of exercise on HDL-C concentration, and HDL-apoA-I concentration and kinetics. 
Therefore, the current study was conducted to test whether a physical exercise programme 
(4-5 times weekly moderate-high intensity exercise, 20 minutes progressing to 60 minutes 
per session under 40-60% VO2MAX equivalent to 65-80% HRMAX) can cause direct/indirect 
effects on fasting lipoprotein metabolism in patients with NAFLD by calculating VLDL-apoB-
100 and HDL-apoA-I kinetics using stable isotope trace-labelling technique. 
5.2 Hyopethsis 
It is hypothesised that physical exercise will correct altered lipoprotein metabolism and 
reduce liver fat in patients with NAFLD by increasing hepatic and peripheral insulin 
sensitivity, reducing fasting hypertriglyceridaemia and increasing low HDL-C. This will be 
achieved by the exercise action on reducing the PR of VLDL-apoB-100 or increasing VLDL-
apoB-100 FCR, and directly increasing the PR of HDL-apoA-I or indirectly reducing FCR of 
HDL-apoA-I. This will contribute to reducing CVD risk. 
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5.3 Aims 
To conduct a clinical trial that will study the effects of physical exercise programme on HDL-
apoA-I kinetics and concentration, fasting hypertriglyceridaemia, liver fat, IR and lipid profile 
in patience with NAFLD using stable isotope trace-labelling technique. 
5.4  Methods 
This study was designed with two groups; a control group and a supervised exercise group. 
Caucasian men aged 18 and over with BMI of 27-37 and diagnosed with NAFLD were 
recruited in the study (for detailed study recruitment see chapter 2 section 2.4.1). This study 
was a retrospective analysis of stored samples from the previous NAFLD study which was 
conducted two years ago. A total of 27 stored samples were used which was collected from 
the two groups; 12 stored samples from 12 subjects in the control group and 15 stored 
samples from 15 subjects in the supervised exercise group (chapter 2, Figure 2.7). The stored 
samples were collected hourly during the study day for 9 hours before and after the 
injection of the 1-¹³C leucine tracer (chapter 2, Figure 2.6) (for the detailed study protocol 
see chapter 2 section 2.4.4). The following measurements were performed before and after 
the four-month exercise intervention period (chapter 2, Figure 2.5); the measurement of 
HDL-C and HDL apoA-I concentration, and the calculation of HDL-apoA-I kinetics by following 
the verified laboratory protocol (for detailed laboratory protocol and methods see chapter 
3). Other supporting results mentioned in this chapter was collected and analysed by 
another personnel in the laboratory. Pre and post exercise intervention measurements in 
both groups were compared to elucidate the exercise effect by observing any significant 
difference within each group and between the two groups by using certain statistical tests 
(for detailed statistical analysis tests used see chapter 3 section 3.2.19). 
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5.5  Results 
5.5.1 Subjects characteristics 
The main physical and physiological characteristics of the 27 male subjects recruited in the 
study are shown in Table 5.0. Age, height, body weight, waist circumference and BMI were 
similar in both groups. The BMI of 16 out of 27 subjects indicates that they were considered 
obese (NHSUK, 2015). The mean value of ALT was higher than AST in these patients with 
NAFLD. This is considered one of the ways to differentiate NAFLD from alcoholic liver disease 
(Sattar et al., 2014). High plasma-TG and total cholesterol concentrations indicate altered 
lipid metabolism in these patients which would be expected in patients with NAFLD. 
Notably, the mean systolic blood pressure (BP) in both groups was located in the range of 
the prehypertension category (120 – 139 mmHg) (WHO, 2015a, American Diabetes 
Association, 2016). The mean diastolic BP was in the normal range.  
The main characteristics of participant’s pre and post the exercise intervention or control 
period in each group are shown in Table 5.1. Body weight, BMI, waist circumference and 
body fat percentage in the exercise group were consistently lower after the exercise period 
(P ≤0.001, ≤0.001, ≤0.005 and 0.01, respectively). The systolic and diastolic BP were 
decreased significantly after the exercise intervention within the exercise group (P= 0.01 and 
0.04 respectively). There were no significant differences between any of the pre and post 
measurements of the characteristics in the control group. The diastolic BP was decreased 
significantly (P=0.05) after exercise between the exercise and control group. The exercise 
effect observed between the two groups was calculated using pre-exercise minus post 
exercise (Δ) measurements and the P value was significant for all the above measurements 
(Table 5.1). 
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Table 5.0: Subject characteristics and fasting plasma measurements at screening visit 
Subjects 
characteristics 
Exercise group 
(n=15) 
Control group 
(n=12) 
P value 
Unpaired T-test 
Age (year) 52.4±2.5 52.8±3.2 0.9 
Height (m) 1.8±2.0 1.8±3.0 0.8 
Body weight (kg) 101.2±3.4 102.3±6.7 0.9 
Waist circumference 
(cm) 
109.3±2.4 110.0±4.3 0.9 
BMI (kg/m2) 31.5±1.0 31.7±1.1 0.9 
TG (mmol/L) 1.8±0.3 1.6±0.2 0.2 
Total CHOL 
(mmol/L) 
5.6±0.2 5.5±0.2 0.9 
IHCL (%) 27.4±6.8 19.7±4.3 0.3 
AST (IU/l) 38.4±3.9 29.0±2.2 0.1 
ALT (IU/l) 52.6±7.1 40.9±4.4 0.2 
γGT (IU/l) 55.1±13.7 37.0±4.9 0.2 
Systolic BP (mm Hg) 133.4±5.3 131.3±5.1 0.7 
Diastolic BP (mm 
Hg) 
83.4±2.8 82.7±2.7 0.9 
Data are expressed as Mean ± SEM. Data between the two groups were analysed by unpaired 
two-tailed t-test .  P values ≤0.05 are in bo ld.  BMI: body mass index; TG: triacylglycerols; IHCL: 
intrahepatocellular l ipid; AST: aspartate transferase; ALT: alanine transferase; γGT: gamma -
glutamyl transferase; CHOL: cholesterol; BP: blood pressure.  
 
Table 5.1: Main subjects characteristics and fasting measurements pre and post the 
intervention period in the exercise and the control group. 
Data are expressed as Mean ± SEM. Pre and post intervention data within the two groups 
were analysed by paired two-tailed t-test. Data after exercise intervention between the two 
groups were analysed by unpaired two -tailed t-test. Pre minus post exercise data (Δ)  values 
between the two groups were analysed by unpaired two -tailed t-test. P values ≤0.05 are in 
bold. EX: exercise; BMI: body mass index; BP: blood pressure.  
 
Pre-EX 
(n=15) 
Post EX 
(n=15) 
P value 
Paired 
T-test 
Pre-
Control 
(n=12) 
Post 
Control 
(n=12) 
P 
value 
Paired 
T-test 
P value 
Post data 
between the 
two groups 
Unpaired T-test 
Δ 
P value 
unpaire
d T-test 
Body weight (kg) 101.3±2.6 97.3±12.2 ≤0.001 102.3±6.1 102.9±6.4 0.3 0.5 ≤0.001 
BMI (kg/m2) 31.6±0.8 30.5±1.0 ≤0.001 31.7±1.0 31.6±1.2 0.4 0.4 0.02 
Waist circumference 
(cm) 
109.3±1.9 105.0±2.5 0.005 110.0±3.9 109.0±4.3 0.7 0.3 0.03 
Body fat (%) 27.8±1.2 26.4±1.1 0.01 29.5±1.5 29.8±1.6 0.6 0.1 0.02 
Systolic BP (mm Hg) 133.4±4.2 128.8±4.2 0.01 131.3±4.5 134.4±3.8 0.1 0.5 0.04 
Diastolic BP (mm 
Hg) 
83.4±2.3 78.2±0.6 0.04 83.8±3.0 86.3±3.0 0.6 0.05 0.02 
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5.5.2 The effect of exercise on TG, cholesterol and total apoA-I concentrations 
Table 5.2 shows the cholesterol, and total apoA-I measurements pre and post the exercise 
intervention for all participants in the exercise and control groups. LDL-CHOL was 
significantly decreased after the exercise period (P= 0.03), and the cholesterol concentration 
in the obtained HDL fraction (F-HDL-C) was significantly increased after the exercise 
intervention (P= 0.03) in the exercise group. Also, the cholesterol: HDL-cholesterol ratio was 
significantly reduced after the exercise intervention in the exercise group (P=0.04). There 
were no significant differences between pre and post exercise measurements for the 
participants in the control group. The exercise intervention did not cause any significant 
differences for any of the mentioned measurements between the two groups (Table 5.2). 
Table 5.2: Fasting total cholesterol, LDL and HDL cholesterol, and HDL-apoA-I concentrations 
before and after the intervention periods in the exercise and control groups.  
Data are expressed as Mean ± SEM. Pre and post intervention data within the two groups 
were analysed by paired two-tailed t-test. Data after exercise intervention between the two 
groups were analysed by unpaired two -tailed t-test. Pre minus post exercise data (Δ) values 
between the two groups were analysed by unpaired two -tailed t-test .  P values ≤0.05 are in 
bold. EX: exercise; TG: triacylglycerols; FFA: free fatty acids; CHOL: cholesterol ; LDL; low-
density  lipoprotein; HDL: high-density  lipoprotein; F-HDL-C: cholesterol in obtained HDL 
fraction; F-HDL-apoA-I: apolipoprotein A-I in obtained HDL fraction.  
 
Pre EX 
(n=15) 
Post EX 
(n=15) 
p value 
Paired 
T-test 
Pre 
Control 
(n=12) 
Post 
Control 
(n=12) 
p 
value 
Paired 
T-test 
P value 
Post data 
between the two 
groups 
Unpaired T-test 
Δ 
p value 
un-paired 
T-test 
TG (mmol/L) 2.0±0.2 1.8±0.2 0.3 1.6±0.2 1.9±0.2 0.3 0.8 0.1 
FFA (mmol/L) 0.4±0.1 0.4±0.1 0.4 0.5±0.1 0.5±0.1 0.6 0.1 0.3 
Total CHOL 
(mmol/L) 
5.0±0.2 4.7±0.2 0.1 5.1±0.2 5.1±0.2 1.0 0.2 0.3 
LDL-CHOL 
(mmol/l) 
3.8±0.1 3.3±0.2 0.03 3.6±0.2 3.2±0.2 0.1 0.7 0.7 
HDL-CHOL 
(mmol/L) 
1.01±0.
1 
1.0±0.1 0.3 1.1±0.1 1.1±0.1 0.9 0.5 0.6 
F-HDL-C 
(mmol/L) 
0.5±0.1 0.6±0.1 0.03 0.6 ± 0.1 0.6±0.1 0.6 0.1 0.2 
F-HDL-apoA-I 
(g/L) 
0.5±0.1 0.5±0.1 0.1 0.5±0.1 0.6±0.1 0.4 0.8 0.9 
CHOL:HDL 
ratio 
5.2±0.4 4.8±0.4 0.04 5.1±0.1 4.9±0.4 0.6 0.3 0.4 
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5.5.3 The effect of exercise on liver enzymes 
Table 5.3 shows the plasma liver enzyme concentrations measured pre and post the exercise 
intervention period for all participants in the exercise and control groups. ALT, AST and γGT 
were significantly decreased after the exercise intervention in the exercise group (P= 0.01, 
0.02, and 0.03 respectively). Also, ALT concentrations were lower after the intervention 
period with borderline significance in the control group (P=0.06). There were no significant 
differences caused by exercise between the two groups in all the liver transferase enzyme 
concentrations measured. 
Table 5.3: Plasma liver enzymes concentrations pre and post the intervention period in the 
exercise and control group. 
Data are expressed as Mean ± SEM. Pre and post intervention data within the two groups 
were analysed by paired two-tailed t-test. Data after exercise intervention between the two 
groups were analysed by unpaired two -tailed t-test. Pre minus post exercise data (Δ)  values 
between the two groups were analysed by unpaired two -tailed t-test. P values ≤0.05 are in 
bold. EX: exercise; ALT: alanine transferase; AST: aspartate transferase; γGT: gamma -glutamyl  
transferase.  
5.5.4 The effect of exercise on physical fitness, glucose, insulin and insulin 
sensitivity 
Table 5.4 shows the pre and post exercise intervention measurements of physical fitness (by 
VO2max physical fitness test), glucose, insulin and insulin sensitivity (as HOMA2) for 
participants in the exercise and control group. Physical fitness of the participants was 
significantly increased after exercise in the exercise group intervention (P≤0.001). Glucose 
and insulin concentrations were reduced significantly after exercise intervention in the 
exercise group (P= 0.005 and 0.007 respectively). Also, insulin sensitivity was increased 
 
Pre EX 
(n=15) 
Post EX 
(n=15) 
p value 
Paired 
T-test 
Pre 
Control 
(n=12) 
Post 
Control 
(n=12) 
p 
value 
Paired 
T-test 
P value 
Post data between 
the two groups 
Unpaired T-test 
Δ 
p value 
un-paired 
T-test 
ALT (U/L) 51.1±5.3 36.8±5.2 0.01 40.9±6.2 31.1±4.7 0.06 0.5 0.4 
AST (U/L) 36.9±3.2 29.4±3.5 0.02 29.0±2.5 26.3±1.84 0.24 0.5 0.2 
ΓGT (U/L) 53.5±10.2 36.3±7.5 0.03 37.0±4.5 33.8±4.9 0.25 0.8 0.1 
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significantly after the exercise intervention in the exercise group (P= 0.006). There were no 
significant differences in the control group after the intervention period. Significant 
differences of the exercise effect between the two groups were detected for physical fitness, 
insulin and insulin sensitivity measurements (Δ P≤0.001, 0.02 and 0.02 respectively).  
Table 5.4: Pre and post intervention measurements of physical fitness, glucose and insulin 
sensitivity in participants in the exercise and control groups. 
Data are expressed as Mean ± SEM. Pre and post intervention data  within the two groups 
were analysed by paired two-tailed t-test. Data after exercise intervention between the two 
groups were analysed by unpaired two -tailed t-test. Pre minus post exercise data (Δ)  values 
between the two groups were analysed by unpaired two -tailed t-test .  P values ≤0.05 are in 
bold. EX: exercise; VO 2 ma x: volume of maximum oxygen capacity; HOMA2 -IR: The Homeostasis 
Model Assessment for IR percentage. 
5.5.5 The effect of exercise on the body composition and fat measurements 
The participants’ measurements of liver, muscle, visceral and body fat before and after the 
exercise intervention period are shown in Table 5.5. Exercise significantly reduced body fat 
measurements in the exercise group including IHCL, abdominal and subcutaneous fat, total 
visceral and subcutaneous fat and total body fat (P≤0.001 for all measurements). Exercise, 
however, did not significantly reduce the soleus and tibialis intramyocellular lipid percentage 
(IMCL %) in the exercise group. 
There were no significant differences in these measurements in the control group as shown 
in Table 5.5. There were significant differences between the two groups for all the 
measurements except IMCL as shown in Table 5.5. 
 
Pre EX 
(n=15) 
Post EX 
(n=15) 
p value 
Paired 
T-test 
Pre Control 
(n=12) 
Post 
Control 
(n=12) 
p 
value 
Paired 
T-test 
P value 
Post data 
between the 
two groups 
Unpaired T-test 
Δ 
p value 
un-
paired 
T-test 
VO2max 
(ml kg-1 min-1) 
25.5±1.1 33.0±1.5 ≤0.001 23.3±1.0 23.8±1.3 0.5 ≤0.001 ≤0.001 
Glucose 
(mmol/L) 
6.0±0.2 5.8±0.2 0.005 5.9±0.2 5.6±0.1 0.1 0.4 0.7 
Insulin 
(pmol/L) 
183.0±17.0 
138.0±16.
0 
0.007 164.0±17.0 170.0±17.0 0.7 0.2 0.02 
HOMA2-IR 
(%) 
3.45±0.3 2.61±0.3 0.006 3.1±0.3 3.2±0.3 0.8 0.2 0.02 
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Table 5.5: The pre and post intervention measurements of liver, muscle and body fat 
composition in the exercise and control groups. 
Data are expressed as Mean ± SEM. Pre and post intervention data within the two groups 
were analysed by paired two-tailed t-test. Data after exercise intervention between the two 
groups were analysed by unpaired two -tailed t-test. Pre minus post exercise data (Δ)  values 
between the two groups were analysed by unpaired two -tailed t-test. P values ≤0.05 and are 
in bold. EX: exercise; IHCL: intrahepatocellular lipid; IMCL: intramyocellular lipid; Sol: soleus 
muscle; Tib. A: tibial is anterior muscle; Subcut: subcutane ous.  
5.5.6 The effect of exercise on dietary intake using seven days diet diaries 
The dietary intake of the participants in the exercise and control group pre and post the 
intervention is shown in Table 5.6. There were no significant differences in dietary intake in 
either the exercise or the control group. Also, there were no significant differences in 
measurements indicated between the two groups. 
 
 
 
 
 
 
 
Pre EX 
(n=15) 
Post EX 
(n=15) 
p 
value 
Paired 
T-test 
Pre 
Control 
(n=12) 
Post 
Control 
(n=12) 
p 
value 
Paired 
T-test 
P value 
Post data 
between the 
two groups 
Unpaired T-test 
Δ 
p value 
un-paired 
T-test 
IHCL (%) 27.3±5.8 17.0±5.3 ≤0.001 19.3±4.0 17.7±3.5 0.5 0.9 0.02 
IMCL (Sol) (%) 21.7±3.8 19.0±3.5 0.1 19.2±1.8 20.5±2.6 0.3 0.7 0.1 
IMCL (Tib. A) 
(%) 
8.8±1.0 8.8±1.4 1.0 13.2±5.4 8.2±1.2 0.4 0.7 0.4 
Abdominal 
visceral Fat (kg) 
5.7±0.4 4.7±0.4 ≤0.001 5.7±0.6 5.4±0.6 0.4 0.3 0.06 
Abdominal 
Subcut. Fat (kg) 
7.0±7.2 6.3±0.7 ≤0.001 7.8±1.0 7.9±1.1 0.8 0.2 0.003 
Total visceral 
fat (kg) 
9.5±0.6 7.9±0.6 ≤0.001 9.9±0.9 9.6±0.9 0.6 0.1 0.03 
Total Subcut. 
fat (kg) 
22.1±1.7 19.5±1.6 ≤0.001 24.9±2.4 24.9±2.6 1.0 0.1 0.001 
Total body fat 
(kg) 
31.6±2.0 27.3±1.9 ≤0.001 34.8±3.2 34.5±3.5 0.8 0.07 0.004 
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Table 5.6: The pre and post intervention dietary intake of participants in the exercise and 
control groups. 
 
Pre EX 
(n=15) 
Post EX 
(n=15) 
p value 
Paired 
T-test 
Pre 
Control 
(n=12) 
Post 
Control 
(n=12) 
p value 
Paired 
T-test 
P value 
Post data 
between the 
two groups 
Unpaired T-test 
Δ 
p value 
un-
paired 
T-test 
Energy 
(MJ/d) 
9.9±0.8 10.2±0.7 NS 8.7±0.5 8.2±0.5 NS NS NS 
Protein (g/d) 105.0±10.0 105.0±7.0 NS 89.0±8.0 83.0±7.0 NS NS NS 
CHO (g/d) 279.0±23.0 272.0±24.0 NS 208.0±6.0 203.0±11.0 NS NS NS 
Sugars (g) 102.0±13.0 111.0±16.0 NS 76.0±6.0 74.0±6.0 NS NS NS 
Fat (g/d) 87.0±9.0 96.0±9.0 NS 82.0±8.0 72.0±8.0 NS NS NS 
Saturated fat 
(g/d) 
33.0±4.0 32.0±4.0 NS 30.0±3.0 25.0±3.0 NS NS NS 
Fibre (g/d) 29.0±6.0 37.0±13.0 NS 17.0±2.0 18.0±1.0 NS NS NS 
Sodium (g/d) 3.5±0.4 2.9±0.5 NS 2.9±0.3 2.7±0.2 NS NS NS 
Data are expressed as Mean ± SEM. Pre and post intervention data wi thin the two groups 
were analysed by paired two-tailed t-test. Data after exercise intervention between the two 
groups were analysed by unpaired two -tailed t-test. Pre minus post exercise data (Δ)  values 
between the two groups were analysed by unpaired two -tailed t-test .  P values ≤0.05 are in 
bold. EX: exercise; CHO: carbohydrates; NS: non -significant.  
5.5.7 The effect of exercise on leucine isotopic enrichment of HDL-apoA-I in the 
exercise and control group 
The leucine isotopic enrichment of HDL-apoA-I in all the participants in the exercise group 
and the control group are shown in Figures 5.0 (A) and (B) respectively. Pre and post exercise 
intervention measurements of 13C leucine enrichment were calculated and expressed as 
TTRs. The mean area under the curve (AUC) of the leucine TTR enrichment was reduced with 
borderline significance (AUC=1.4±0.03xmin) after exercise when compared with the AUC of 
the pre-exercise TTR enrichment (AUC=1.8±0.03xmin) in the exercise group (P=0.05). The 
AUC of pre and post exercise leucine TTR enrichment in the control group was significantly 
difference (pre-exercise AUC= 1.7±0.03xmin and post-AUC= 1.5±0.03xmin, P=0.09). The 
slopes of pre and post-TTR enrichment in the exercise group were compared using Linear 
regression and showed a significant difference (P=0.006) (Figure 5.0 (A)). The slopes of pre 
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and post-TTR enrichment showed no significant difference in the control group (P=0.5) 
(Figure 5.0 (B)). 
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Figure 5.0: 
1 3
C Leucine TTR enrichment data are expressed as Mean ± SEM. Pre and post 16 
weeks intervention measurements of 
1 3
C leucine TTR enrichment of HDL -apoA-I in the exercise 
group (A) and control group (B) across study t ime points.  
5.5.8 The effect of exercise on HDL-apoA-I kinetics 
Table 5.6 shows the HDL-apoA-I kinetics measurements pre and post exercise intervention in 
the participants of the exercise and control groups. HDL-apoA-I PS was increased 
significantly after the exercise intervention in the exercise group (P=0.05) as shown in Table 
5.6. The kinetic measurements in the control group and between the two groups did not 
show significant differences. 
 
 
Table 5.6: HDL-apoA-I kinetics measurements before and after the intervention period in the 
exercise and control group. 
 Pre EX Post EX p value Pre Post p value P value Δ 
A 
B 
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(n=15) (n=15) Paired 
T-test 
Control 
(n=12) 
Control 
(n=12 
Paired 
T-test 
Post data 
between the 
two groups 
Unpaired T-test 
p value 
un-paired 
T-test 
HDL-apoA-I PS 
(mg/kg) 
17.4±0.8 18.9±0.75 0.05 17.9±2.0 19.3±2.0 0.4 0.8 1.0 
HDL-apoA-I 
FCR 
(pools/day) 
0.3±0.02 0.2±0.02 0.4 0.2±0.02 0.2±0.02 0.9 0.9 0.6 
HDL-apoA-I PR 
(mg/kg/day) 
4.4±0.3 4.5±0.3 1.0 3.3±0.5 3.5±0.5 0.6 0.4 0.7 
Data are expressed as Mean ± SEM. Pre and post intervention data within the two groups 
were analysed by paired two-tailed t-test. Data after exercise intervention between the two 
groups were analysed by unpaired two -tailed t-test. Pre minus post exerci se data (Δ)  values 
between the two groups were analysed by unpaired two -tailed t-test. P values ≤0.05 are in 
bold. EX: exercise; HDL: high-density lipoprotein; apoA-I: apolipoprotein A-I; PS: pool size; 
FCR: fractional catabolic rate; PR: production rate.  
5.5.9 The effect of exercise on VLDL1-apoB-100 and VLDL2-apoB-100 kinetics. 
Table 5.7 show that total VLDL-apoB-100 PR was increased significantly after the exercise 
intervention in the exercise group (P= 0.004). VLDL1-apoB-100 FCR was increased 
significantly after the exercise intervention in the exercise group (P=0.02).  Also, VLDL1-apoB-
100 PR was increased significantly after the exercise intervention in the exercise group 
(P=0.003). VLDL2-apoB-100 PS was reduced significantly after the exercise intervention in the 
exercise group (P=0.02). The kinetics measurements in the control group did not show 
significant differences before and after the intervention period. However, the Δ values 
between the two groups showed significant differences in total VLDL-apoB-100 PR, VLDL1-
apoB-100 FCR and VLDL1-apoB-100 PR (Δ P= 0.02, 0.006 and 0.01 respectively).  
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Table 5.7: VLDL1-apoB-100 and VLDL2-apoB-100 kinetics measurements before and after the 
intervention period in the exercise and control group. 
Data are expressed as Mean ± SEM. Pre and post intervention data within the two groups 
were analysed by paired two-tailed t-test. Data after exercise intervention between the two 
groups were analysed by unpaired two -tailed t-test. Pre minus post exercise data (Δ)  values 
between the two groups were analysed by unpaired two -tailed t-test .  P values ≤0.05 are in 
bold. EX: exercise; VLDL: very low density lipoprotein; apoB -100: apolipoprotein B-100; PS: 
pool size; FCR: fractional catabolic rate; PR: production rate.  
5.5.10 Interrelationships between HDL-apoA-I and VLDL1-apoB-100, VLDL2-apoB-100 
kinetics before and after the intervention. 
Pearson correlation coefficient analysis was performed between the baseline HDL-apoA-I PS, 
FCR and PR and VLDL1-apoB-100 and VLDL2-apoB-100 kinetics and other variables after the 
intervention for all participants as shown in Table 5.8 in which there were analysed. HDL-
apoA-I PS was directly correlated with VLDL1-apoB-100 FCR (r=0.42; P=0.03), F-HDL-C 
concentration (r=0.49; P=0.003) and F-HDL-apoA-I (r=0.99; P=<0.0001), and inversely 
correlated with, VLDL2-apoB-100 PS (r=-0.50; P= 0.01) and total VLDL-apoB-100 PS (r=-0.47; 
P=0.01). Also, HDL-apoA-I FCR was directly related with HDL-apoA-I PR (r=0.81; P=<0.001), 
ALT concentration (r=0.50; P=0.007) (Figure 5.1(C)), and AST concentration (r=0.44; P=0.02) 
 
Pre EX 
(n=15) 
Post EX 
(n=15) 
p 
value 
Paired 
T-test 
Pre 
Control 
(n=12) 
Post 
Control 
(n=12 
p 
value 
Paired 
T-test 
P value 
Post data 
between the 
two groups 
Unpaired T-
test 
Δ 
p value 
un-
paired 
T-test 
VLDL1-apoB-100 PS 
(mg/kg) 
52.1±5.9 57.6±7.5 0.3 48.7±5.4 50.7±7.3 0.8 0.8 0.7 
VLDL2-apoB-100 PS 
(mg/kg) 
36.5±3.8 28.1±3.1 0.05 32.9±4.6 32.7±3.3 0.9 0.2 0.1 
Total VLDL-apoB-100 
PS (mg/kg) 
88.6±8.1 85.6±8.2 0.6 80.7±7.9 83.4±9.9 0.8 0.9 0.6 
VLDL1-apoB-100 FCR 
(pools/day) 
7.2±0.6 10.9±1.5 0.02 10.9±1.8 8.9±1.1 0.3 0.5 0.01 
VLDL2 –apoB-100 FCR 
(pools/day) 
12.3±1.3 11.8±1.3 0.7 16.9±3.0 12.9±1.8 0.1 0.7 0.2 
VLDL1-apoB-100 PR 
(mg/kg/day) 
3.7±0.7 5.5±0.5 0.003 4.9±0.8 3.9±0.6 0.3 0.02 0.006 
VLDL2-apoB-100 PR 
(mg/kg/day) 
4.1±0.4 3.2±0.4 0.2 4.9±1.0 3.9±0.6 0.3 0.2 0.9 
Total VLDL-apoB-100 
PR (mg/kg/day) 
4.2±0.7 6.04±0.5 0.004 5.7±0.9 4.9±0.5 0.5 0.6 0.02 
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(Figure 5.1(D)), and inversely correlated with VLDL2-apoB-100 FCR (r=-0.43; P=0.02) (Figure 
5.1(A)), VLDL2-apoB-100 PR (r=-0.47; P=0.01) (Figure 5.1(B)) and F-HDL-C concentration (r=-
0.42; P=0.03). HDL-apoA-I PR inversely correlated with VLDL2-apoB-100 PR (r=-0.45; P=0.02). 
Table 5.8: Correlation between the exercise kinetic measurements of HDL-apoA-I, VLDL1-
apoB-100 and VLDL2-apoB-100 at baseline (pre-exercise intervention) (n=27). 
Correlations HDL-apoA-I PS HDL-apoA-I FCR HDL-apoA-I PR 
HDL-apoA-I PS (mg/kg)  -0.037 0.48** 
HDL-apoA-I FCR (pools/day) -0.037  0.81*** 
HDL-apoA-I PR (mg/kg/day) 0.48** 0.81***  
VLDL1-apoB-100 PS (mg/kg) -0.25 0.12 -0.22 
VLDL2-apoB-100 PS (mg/kg) -0.50** -0.22 -0.34 
Total VLDL-apoB-100 PS (mg/kg) -0.47* -0.22 -0.36 
VLDL1-apoB-100 FCR (pools/day) 0.42* -0.20 0.034 
VLDL2-apoB-100 FCR (pools/day) 0.47* -0.43* -0.31 
VLDL1-apoB-100 PR (mg/kg/day) 0.16 0.29 -0.02 
VLDL2-apoB-100 PR (mg/kg/day) -0.2 -0.47* -0.42* 
Total VLDL-apoB-100 PR (mg/kg/day) 0.13 -0.13 -0.17 
Total CHOL -0.05 0.17 0.03 
LDL-CHOL (mmol/L) -0.03 0.15 0.01 
Plasma TG (mmol/L) -0.24 0.31 -0.09 
F-HDL-C  (mmol/L) 0.49** -0.42* -0.06 
HDL-F-apo-A-I  (g/L) 0.99*** -0.09 0.39 
ALT (U/L) 0.19 0.50** 0.33 
AST (U/L) 0.01 0.44* 0.39 
IHCL% -0.05 0.36 0.18 
Data expressed and the r  values using two-tailed Pearson Correlation and corrected by 
Bonferroni correction test . P  values ≤ 0.05 were marked as; *P≤0.05. **P≤0.01 and 
***P≤0.001. VLDL: very low density lipoprotein; LDL: low -density lipoprotein; HDL: high 
density l ipoprotein; apo : apolipoprotein ; PS: pool size; FCR: fractional catabolic rate; PR: 
production rate; CHOL: cholesterol;  TG: triacylglycerols; F-HDL-C: cholesterol in obtained HDL 
fraction; F-HDL-apoA-I: apolipoprotein A-I in obtained HDL fraction; ALT: alanine transferase; 
AST: aspartate transferase; IHCL%: intrahepatocellular l ipid percentag e. 
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Figure 5.1: Baseline correlations analysis by Pearson correlation test and corrected by Bonferroni correction test  in all  participants (n=27) of A: 
baseline HDL-apoA-I FCR versus baseline VLDL2-apoB-100 FCR (r=-0.43; P=0.02), B: baseline  HDL-apoA-I PS versus baseline VLDL2-apoB-100 PR (r=-
0.47; P=0.01), C: baseline HDL-apoA-I FCR versus ALT (r=0.50; P=0.007), and D: baseline HDL-apoA-I FCR versus AST (r=0.44; P=0.02). VLDL: very low 
density lipoprotein; HDL: high density lipoprotein; apo B-100: apolipoprotein B-100; apoA-I:  apolipoprotein A-I;  PS: pool size; FCR: fractional catabolic 
rate; PR: production rate; TG: triacylglycerols; IHCL%: intra hepatocellular l ipid percentage ; ALT: alanine transferase; AST: aspartate transferase.  
A B 
C D 
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The relationship between the change of pre minus post exercise (delta (Δ)) in HDL-apoA-I PS, 
FCR and PR with Δ VLDL1-apoB-100 and Δ VLDL2-apoB-100 kinetics and other variables after 
the intervention for all participants was analysed as shown in Table 5.9. The Δ HDL-apoA-I PS 
was positively correlated with Δ HDL-apoA-I PR (r=0.40; P= 0.02), Δ VLDL1-apoB-100 FCR (r= 
0.41; P= 0.03) (Figure 5.2 (D)), and the Δ F-HDL-apoA-I (r= 0.98; P=<0.0001), and inversely 
correlated with Δ VLDL1-apoB-100 PS (r=-0.43; P=0.03), Δ VLDL2-apoB-100 PS (r=-0.41; P= 
0.03) and Δ total VLDL-apoB-100 PS (r=-0.63; P=0.0004) as shown in Figure 5.2 (A, B and C) 
respectively. There was a positive correlation between HDL-apoA-I FCR and HDL-apoA-I PR 
(r=0.80; P=<0.001). HDL-apoA-I PR inversely correlated with total VLDL-apoB-100 PS (r=-0.45; 
P=0.02) (Figure 5.2 (E)), and directly correlated with F-HDL-apoA-I concentration (r=0.48; 
P=0.01). 
Table 5.9: Interrelationships correlation between the Δ HDL-apoA-I measurements and Δ 
VLDL1-apoB-100 and Δ VLDL2-apoB-100 kinetic measurements (n=27). 
Correlations Δ HDL-apoA-I PS Δ HDL-apoA-I FCR Δ HDL-apoA-I PR 
Δ HDL-apoA-I PS (mg/kg)  -0.04 0.40* 
Δ HDL-apoA-I FCR (pools/day) -0.04  0.80*** 
Δ HDL-apoA-I PR (mg/kg/day) 0.40* 0.80***  
Δ VLDL1-apoB-100 PS (mg/kg) -0.43* -0.12 -0.21 
Δ VLDL2-apoB-100 PS (mg/kg) -0.41* -0.21 -0.31 
Δ Total VLDL-apoB-100 PS (mg/kg) -0.63*** -0.17 -0.45* 
Δ VLDL1-apoB-100 FCR (pools/day) 0.41* -0.19 0.06 
Δ VLDL2-apoB-100 FCR (pools/day) 0.15 0.25 0.33 
Δ VLDL1-apoB-100 PR (mg/kg/day) 0.16 -0.10 -0.04 
Δ VLDL2-apoB-100 PR (mg/kg/day) -0.27 0.13 -0.02 
Δ Total VLDL-apoB-100 PR (mg/kg/day) 0.1 -0.13 -0.04 
Δ Total CHOL -0.17 0.14 0.15 
Δ LDL-CHOL (mmol/L) -0.03 0.19 0.74 
Δ Plasma TG (mmol/L) -0.08 -0.18 -0.09 
Δ F-HDL-C  (mmol/L) 0.39 -0.16 -0.05 
Δ HDL-F-apo-A-I  (g/L) 0.98*** 0.15 0.5* 
Δ IHCL (%) -0.04 0.13 0.2 
Data expressed and the r  values using two-tai led Pearson Correlation corrected by Bonferroni 
correction test.  P  values ≤ 0.05 were marked as;  *P≤0 .05.  **P≤0.01 and ***P≤0.001. Δ: Delta (the 
change); VLDL: very low density lipoprotein; LDL: low -density lipoprotein; HDL: high density  
lipoprotein; apo: apolipoprotein; PS: pool size; FCR: fractional catabolic rat e; PR: production rate; 
CHOL: cholesterol; TG: tr iacylglycerols; F-HDL-C: cholesterol in obtained HDL fraction; F -HDL-
apoA-I: apolipoprotein A-I  in obtained HDL fraction; IHCL%: intrahepatocellular lipid percentage.  
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Figure 5.2: Delta correlations analysis by Pearson correlation test and corrected by Bonferroni correction test  in al l participants (n=27)  of A: Δ HDL-
apoA-I  PS versus Δ VLDL 1-apoB-100 PS (r=-0.43; P=0.03), B: Δ HDL-apoA-I  PS versus Δ VLDL 2-apoB-100 PS (r=-0.41; P=0.03), C: Δ HDL -apoA-I  PS versus Δ 
total VLDL-apoB-100 PS (r=-0.63; P=<0.001), D: Δ HDL -apoA- I  PS versus Δ VLDL1-apoB-100 FCR (r=0.41; P=0.03), and E: Δ HDL-apoA-I  PR versus Δ total 
VLDL-apoB-100 PS (r=-0.45; P=0.02). VLDL: very low density l ipoprotein; HDL: high density lipoprotein; apoA -I: apolipoprotein A-I; apoB-100: 
apolipoprotein B-100; PS: pool size; FCR: fractional catabolic rate; PR: production rate.   
E 
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5.6 Discussion 
This study investigated the effect of a four-month moderate-intensity exercise intervention 
on HDL kinetics in patients with NAFLD. The current study in addition to other studies 
conducted by Thompson et al., 1997, Cuthbertson et al., 2016, Kadoglou et al., 2012, 
Lehmann et al., 2001, Sullivan et al., 2012 and Alam et al., 2004 in which participants were 
required to exercise at a range between 40-50% VO2max (equivalent to 20-30% change in 
maximum heart rate (HRMAX)) (Lounana et al., 2007, Swain et al., 1994) in each study as 
shown in Table 5.10. The American College of Sports and Medicine (ACSM) (Garber et al., 
2011) and the U.S. Office of Disease Prevention and Health Promotions (ODPHP) (ODPHP, 
2016) both states that in order to gain health benefits, adults must perform a weekly 150-
300 minutes of moderate-intensity physical activity equals to 5 days of 30-60 minute 
exercise as seen in the previous studies.  
There was no significant change in HDL-apoA-I kinetics after the exercise intervention in 
either group. Neither plasma HDL-C concentrations nor apoA-I fraction concentrations were 
significantly changed. However, HDL-C concentrations measured in the isolated HDL fraction 
(different samples from plasma) were increased significantly after exercise in the exercise 
group.  
The only published study to date which has previously investigated the effect of exercise on 
HDL-apoA-I kinetics was by Thompson et al., 1997. This study with other studies which 
investigated the effect of exercise on HDL-apoA-I concentration and HDL-cholesterol but not 
kinetics (Kadoglou et al., 2012 and Lehmann et al., 2001) are shown in Table 5.10 which 
illustrates key information from each study (including the current study) such as the number 
of participants recruited, healthy or with a metabolic disease, period and type of exercise 
used. Sullivan et al., 2012 and Alam et al., 2004 investigated the effect of a similar exercise 
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programme on liver fat content, and they measured the concentrations of HDL-cholesterol 
after exercise (Table 5.10). Table 5.11 shows key information from some previous clinical 
studies that looked at the effect of different interventions on HDL-apoA-I kinetics (FCR and 
PR calculated before and after each intervention) in patients with altered lipid metabolism 
either healthy or with T2D. 
Table 5.10: Comparison of the current study with previous studies which investigated the 
effect of exercise on HDL metabolism. 
Study 
Number of 
participants 
Health and 
disease 
status 
Period 
of 
exercise 
Measurements 
of 
Type of exercise programme 
Current 
study 
27 males (12 
control and 
15 exercise) 
NAFLD 
16 
weeks 
HDL-apoA-I 
kinetics, apoA-I 
and HDL-C 
concentrations 
4-5X weekly moderate-high intensity 
exercise, 20 minutes progressing to 60 
minutes per session (40-60% VO2MAX) 
equivalent to 65-80% HRMAX. approved 
by ACSM guidelines 
(Thompson 
et al., 1997) 
17 males 
Healthy 
overweight 
12 
Months 
HDL-apoA-I 
kinetics, apoA-I 
and HDL-C 
concentrations 
3 progressing to 5X weekly moderate-
high intensity exercise, 30 minutes 
progressing to 45 minutes including 
warm-up and cooling down per session 
(60-80% 6-7 HRMAX). Own protocol. 
(Cuthbertson 
et al., 2016) 
39 males and 
11 females 
NAFLD 
16 
weeks 
HDL-C 
concentrations 
4-5X weekly moderate-high intensity 
exercise, 20 minutes progressing to 60 
minutes per session (30-60% HRR) 
equivalent to 65-80% HRMAX. approved 
by ACSM guidelines 
(Kadoglou et 
al., 2012) 
12 males and 
35 females)  
T2D 
12 
weeks 
ApoA-I and 
HDL-C 
concentrations 
3X weekly moderate-high intensity 
exercise, 60 minutes including warm-
up and cooling down per session (60-
80% HRMAX). Own protocol. 
(Lehmann et 
al., 2001) 
7 males and 
3 post-
menopausal 
Females) 
T2D 
12 
weeks 
ApoA-I and 
HDL-C 
concentrations 
Daily moderate-high intensity exercise 
aerobic exercise with 50-70% HRMAX. 
Own protocol. 
Sullivan et 
al., 2012 
18 males (6 
control and 
12 exercise) 
NAFLD 
16 
weeks 
HDL-C 
concentrations 
5X weekly moderate-high intensity 
exercise, 30-60 minutes per session 
(45-55% VO2MAX) approved by ACSM 
guidelines 
Alam et al., 
2004 
18 males T2D 
24 
weeks 
HDL-C 
concentrations 
4X weekly moderate-high intensity 
exercise, (50-85% VO2MAX) approved by 
ACSM guidelines 
NAFLD; non-alcoholic fatty liver disease, -X: how many times i.e. 5X: f ive times; VO2 MA X; the 
volume of maximum oxygen capacity by physical f itness; ACSM: American College of Sports 
and Medicine; HRM AX : maximum heart rate during exercise; HRR: Heart rate reserve (maximal 
heart rate minus resting heart rate).   HDL-C: high-density lipoprotein –  cholesterol;  apoA-I:  
apolipoprotein A-I.  
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Table 5.11: Previous studies which investigated the effect of different interventions on HDL -
apoA-I kinetics. 
Study carried 
out by 
Methodology Subjects 
Nutritional 
state 
Intervention 
investigated 
HDL-apoA-I FCR 
(pools/day) pre 
and post 
intervention 
HDL-apoA-I PR 
(mg/kg/day) pre 
and post 
intervention 
(Pang et al., 
2014) 
96 hours primed-
constant infusion of 
Leucine [(5,5,5-
2
H3)L-
Leucine] 
12 males with 
T2D aged >18 
Constant-
feeding 
Effect of niacin 
Pre= 0.37±0.02  
Post= 0.33±0.01 
Pre= 21.72±0.2 
Post= 20.93±0.2  
(Verges et 
al., 2009) 
16 hours primed-
constant infusion of L-L-
[1-
13
C] leucine 
8 subjects (5 
males and 3 
females) with 
T2D aged >40 
Constant-
feeding 
Effect of 20mg 
Rosuvastatin  
Pre= 0.32±0.02  
Post= 0.25±0.02 
Pre= 16.19±1.5 
Post= 12.79±1.4 
(Frenais et 
al., 2001b) 
14 hours primed-
constant infusion of 
Leucine [(5,5,5-
2
H3)L-
Leucine] 
5 females with 
T2D aged > 36 
Fasting 
Role of LPL 
activity  in 
patients with T2D 
Patients with 
T2D = 0.27±0.04  
Healthy control 
= 0.37±0.04 
Patients with 
T2D = 12.1±1.3 
Healthy control = 
16.1±1.5 
(Frenais et 
al., 2001a) 
14 hours primed-
constant infusion of 
Leucine [(5,5,5-
2
H3)L-
Leucine] 
14 females 
aged > 40 (7 
with T2D 
Fasting 
Effect of omega-3 
fatty acids   
Pre= 0.32±0.02 
Post= 0.23±0.01 
Pre= 15.8±0.9 
Post= 12.3±1.5 
(Frenais et 
al., 1997) 
14 hours primed-
constant infusion of 
Leucine [(5,5,5-
2
H3)L-
Leucine] 
8 patients (7 
females and 1 
male) with T2D 
aged > 40 
Fasting 
No intervention 
were investigated 
0.39±0.1 13.6±1.8 
(Thompson 
et al., 1997) 
Administration of 
radioactive 
125
I-HDL 
tracer before and after 
12 months of exercise 
17 overweight 
males aged > 40 
Constant-
feeding 
Effect of 
prolonged 
exercise training 
Pre= 0.23±0.01 
Post= 0.21±0.01 
Pre= 9.0±0.1 
Post= 10.1±0.1 
Data are expressed as Mean ± SEM. HDL: high -density lipoprotein; apoA -I:  apolipoprotein A-I;  
FCR: fractional catabolic rate; PR: production rate.  
5.6.1 Changes in TG, HDL-C, apoA-I concentrations and HDL-apoA-I kinetics and 
correlations with TG and IHCL 
The current study is the first study to investigate the effect of exercise on HDL-apoA-I 
kinetics in patients with NAFLD. Plasma TG concentrations did not reduce significantly after 
exercise and plasma HDL-C concentrations not increase significantly after exercise in the 
exercise group. However, HDL-C concentrations in HDL fraction were significantly increased 
after exercise in the exercise group which was similar to the results found in the study by 
Thompson et al., 1997. Also, exercise did not cause a significant change in apoA-I 
concentrations in the exercise groups but increased the HDL-apoA-I PS in the exercise group 
without a significant difference between the exercise and the control group. Exercise also 
reduced HDL-apoA-I FCR insignificantly in the exercise group which it was opposite to the 
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results achieved in the study by Thompson et al., 1997. The HDL-apoA-I PR did not change in 
both groups after the exercise intervention which it was opposite to the results achieved in 
the study by Thompson et al., 1997. Also, a significant increase of apoA-I concentrations 
after exercise were reported in the studies by Thompson et al., 1997, Lehmann et al., 2001 
but not in Kadoglou et al., 2012 which was similar to the results in the current study. Also, 
significant reduction of plasma TG concentrations after exercise were reported in the studies 
by Thompson et al., 1997, Lehmann et al., 2001 and Alam et al., 2004, but not in the studies 
by(Cuthbertson et al., 2016), Kadoglou et al., 2012 and Sullivan et al., 2012 which was not 
seen in the current study results. Reported significant increase in HDL-C and/or apoA-I 
concentrations after exercise is accompanied by a significant decrease in plasma TG which is 
seen in the studies by Thompson et al., 1997, Lehmann et al., 2001, Alam et al., 2004, 
Kadoglou et al., 2012 and Sullivan et al., 2012. HDL-apoA-I kinetics were reported to be 
significantly changed after 12 months exercise in healthy overweight males (Thompson et 
al., 1997) which was not seen in the current study results. 
5.6.2 Changes in VLDL metabolism and kinetics 
The study conducted by Sullivan et al., 2012 was the only study which has previously 
investigated the effect of exercise on the VLDL-apoB-100 secretion rate (SR), VLDL-TG SR 
kinetics and LDL-CHOL in patients with NAFLD. However, their results show no significant 
changes in VLDL-apoB-100 SR, VLDL-TG SR kinetics and LDL-CHOL after exercise. Alam et al., 
2004 showed that a six-month exercise intervention reduced total VLDL-apoB absolute 
secretion rate (ASR) by 51.3% and reduced VLDL-apoB PS by 47.2% with no significant 
difference in VLDL-apoB FCR. 
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5.6.3 Interrelationship between VLDL1, VLDL2-apoB100 and HDL-apoA-I kinetics 
The baseline correlations (pre-intervention) showed two important key associations; 1) 
baseline HDL-apo-A-I PS was inversely correlated with plasma TG concentration and 2) HDL-
apoA-I FCR was borderline directly correlated with IHCL% (P=0.06). The study conducted 
by(Verges et al., 2014)showed that HDL-apoA-I FCR was correlated liver fat content (IHCL) 
which was similar to our results. Our study data showed some significant correlations 
between Δ VLDL1 & Δ VLDL2-apoB-100 and Δ HDL-apoA-I Kinetics as shown in Table 5.8 
(Figure 5.1). Similar results were observed in the study conducted by(Welty et al., 2004)in 
which similar correlations were observed between HDL-apoA-I and VLDL and LDL apoB-100 
and chylomicron (CM) apoB-48 kinetics. The study showed that HDL-apoA-I PS was directly 
correlated with HDL-apoA-I PR (r=0.65; P=<0.001) but not with HDL-apoA-I FCR (r=0.24; 
P=0.272). HDL-apoA-I PR was directly correlated with HDL-apoA-I FCR (r=0.81; P=<0.001). 
The study also showed that apoA-I PS and PR correlated inversely with LDL-apoB-100 PS but 
not VLDL-apoB-100 PS. Current correlations indicate strong evidence of a connection 
between liver fat accumulation, plasma TG concentrations, and VLDL and HDL production 
and clearance rates in patients with altered lipid metabolism. Also, any significant 
improvement in the previous parameters will lead to a significant improvement in the other 
ones with time. 
5.6.4 Changes in IR and physical fitness 
Our data demonstrate that exercise caused a significant reduction in fasting insulin and 
glucose concentrations by 24.5% and 4%, HOMA2-IR (IR assessment) by 24.3%, and an 
increase in VO2MAX (physical fitness) by 22.7% in the exercise group. Similar results were 
observed in the study conducted by van der Heijden et al., 2010 which showed that a 12-
week exercise intervention caused a significant decrease in insulin concentrations by 16.5%, 
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and a significant increase in VO2MAX by 11%. Also, the study conducted by Alam et al., 2004 
showed that exercise reduces fasting insulin and glucose concentrations by 27.6% and 19% 
respectively, and also exercise decreased the HOMA-IR by 35.6% and increased the VO2MAX 
by 14%. Also, a study by Devries et al., 2008 showed that exercise reduces the HOMA-IR by 
9% and increases the VO2MAX by 11.7% in obese healthy males.(Cuthbertson et al., 2016)also 
showed similar significant reductions in fasting plasma glucose, insulin and HOMA2-IR. 
However, their results indicated that exercise intervention improved peripheral IR but not 
hepatic IR based on peripheral and hepatic glucose production (HGP) in response to high and 
low insulin doses respectively. Also, they said that improved hepatic IR could not be 
achieved due to high accumulated liver fat in their participants. A significant reduction in 
hepatic IR was seen in previous studies such as the studies conducted by(Lim et al., 2011) 
and(Petersen et al., 2005). In both studies, the percentage of accumulated liver fat was 
lower than the percentage of liver fat in our participants (12.8 and 12% respectively 
compared to 27.3%). Therefore, weight loss intervention in both studies was able to clear 
almost all accumulated liver fat and resulted in the reversal of T2D in the study by Lim et al., 
2011 and hepatic steatosis in the study by Petersen et al., 2005. As a result, an improvement 
in hepatic IR could not be achieved due to the high mean of liver fat content before the 
exercise in the exercise group 27.3%, and remained elevated even after exercise with a 
mean of 17.0%. Therefore, our data suggest that weekly physical exercise increases the 
physical fitness and improve peripheral insulin sensitivity in patients with NAFLD as the 16-
week exercise intervention could not clear all accumulated liver fat as shown in (Cuthbertson 
et al., 2016, Bojsen-Moller et al., 2014). 
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5.6.5 Changes in weight loss, body and liver fat content 
The significant reduction in body weight by 4%, BMI by 3.5% and body fat percentage by 5% 
in the exercise group is similar to the results observed in the study conducted by van der 
Heijden et al., 2010 which showed that a 12-week aerobic exercise intervention caused a 
significant reduction of body fat percentage by 2.6% in obese adolescents. Also, the study 
conducted by Alam et al., 2004 found a significant decline in body weight with 1.3%, BMI 
with 3.2% and body fat mass with a 6.5% after six-month exercise in patients with T2D. 
Sullivan et al., 2012 and Johnson et al., 2009 showed that a 16-week exercise intervention 
caused a reduction of with no significant changes in body weight, BMI and body fat 
percentage in NAFLD patients.   
Also, our data demonstrate four-month moderate exercise activity caused a significant 
decrease in IHCL with 37.7%, abdominal visceral and subcutaneous fat by 17.5% and 10% 
respectively and total visceral, subcutaneous and body fat by 16%, 11.7% and 13.6% 
respectively. Sullivan et al., 2012 showed a significant reduction of IHCL by 10.3% after a 16-
week exercise intervention. Cuthbertson et al., 2016 also showed a significant reduction in 
liver fat percentage by 4.7 % after exercise with an increased percentage of liver fat even 
after the exercise as seen in the current study. Therefore, hepatic IR could not be improved 
in the current study as shown in the study by Cuthbertson et al., 2016. 
Also, the study carried out by Johnson et al., 2009 showed a significant decrease in hepatic 
triacylglycerol concentrations (HTGC) by 20.6% and visceral adipose tissue (VAT) area 12.5% 
after exercise. Also, the study conducted by van der Heijden et al., 2010 showed a significant 
reduction in the hepatic fat percentage by 30% and visceral fat area by 10% after exercise 
among the obese group.  
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Calorie restriction without exercise is considered as independent factors with a powerful 
impact on reducing weight and liver content in patients with metabolic syndrome of altered 
lipid metabolism such as NAFLD (Koot et al., 2011, Oza et al., 2009, Lazo et al., 2010, Promrat 
et al., 2010) and T2D (Lazo et al., 2010, Tamura et al., 2005, Schafer et al., 2007, Petersen et 
al., 2005). However, the current study suggests that moderate physical exercise without 
calorie restriction can be considered as an independent therapeutic approach to reduce 
weight and body and liver fat in NAFLD patients.  
5.6.6 Changes in plasma liver enzymes 
The study data demonstrated that a four-month exercise intervention significantly 
decreased plasma liver enzymes concentrations as shown by several previous exercise 
interventions in NAFLD (Sullivan et al., 2012,(Khaoshbaten et al., 2013),(Abd El-Kader et al., 
2014)). The studies by Johnson et al., 2009, van der Heijden et al., 2010, Cuthbertson et al., 
2016 and Devries et al., 2008 showed reduction with no significance in ALT concentrations 
after exercise. 
Baseline correlation showed a significant positive correlation between HDL-apoA-I FCR and 
liver enzymes ALT, AST and IHCL% (r=0.50, P=0.007, r=0.44, P=0.02 and r=0.36, P=0.05 
respectively) (Figure 5.1 D, E and F respectively). This indicates that a decrease in HDL-C 
concentrations may be associated with increased liver enzymes and liver fat accumulation in 
patients with altered lipid metabolism, liver and cardiovascular disease due to the 
development of HDL-TG and SDLDL in the ALP (Chunming et al., 2015, Calanna et al., 2014, 
Siddiqui et al., 2013, Onat, 2011).  
Our study data also showed a direct positive correlation between Δ ALT and Δ γGT 
concentrations with Δ IHCL% after exercise (r=0.48, P=0.01 and r=0.57, P=0.001 
respectively). Similar results were observed in the study conducted by Sullivan et al., 2012 in 
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which ALT concentrations were directly associated with the IHCL% changes after exercise 
(R2=0.60, P≤0.001) in patients with NAFLD. Also, in the study conducted by van der Heijden 
et al., 2010 showed that hepatic fat content was directly correlated with ALT concentrations 
before and after exercise (baseline: R2=0.56, P=≤0.05; post: R2=0.67, P=≤0.01) in patients 
with NAFLD. 
Therefore, our data along with data from other studies suggest that regular moderate 
exercise activity reduces liver enzymes, especially ALT. The study conducted by(Bi et al., 
2014)showed that ALT, AST and GGT are strongly correlated with NAFLD disease progression 
and risk especially GGT. Therefore, studies investigated the physical activity association with 
liver enzymes in improving NAFLD conditions such as the recent study conducted 
by(Loprinzi, 2016)which showed that reduced ALT and GGT concentrations with physical 
activity were strongly associated with reduced mortality in patients with NAFLD. Also, in the 
study conducted by(Martins et al., 2015)showed that physical activity is related to central 
obesity and fatty liver markers such as ALT. As a result, all this evidence suggests that regular 
moderate physical activity improves NAFLD, as determined by fat liver content and liver 
enzymes (Omagari et al., 2011, Prati et al., 2002). 
5.6.7 The overall effect of exercise on hypertriglyceridaemia and HDL metabolism 
(Cuthbertson et al., 2016)showed that physical exercise improves peripheral insulin 
sensitivity. This would be expected to increase the activity of LPL but not HL (Zhang et al., 
2002). Increased LPL activity will lead to increased VLDL hydrolysis in peripheral tissues 
(VLDL1 and VLDL2) which increases VLDL clearance (Mead et al., 2002, Mead and Ramji, 
2002, Lafontan and Langin, 2009). 
Physical exercise increases skeletal muscle fat oxidation and blood flow which contributes to 
reducing circulating FFA (Hurren et al., 2011, Kiens, 2006). Reduced FFA release from the 
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adipose tissue due to increased insulin sensitivity (Cuthbertson et al., 2016) will also reduce 
circulating FFA. This will result in reduced hepatic FA uptake and reduced fat droplet 
accumulation in the liver (Cuthbertson et al., 2016, Gauthier et al., 2004, Alam et al., 2004). 
Increased insulin sensitivity reduces the expression of MTP, which is a protein responsible 
for VLDL assembly and intracellular stabilisation of apoB within the hepatocyte (Gordon et 
al., 1996, Taghibiglou et al., 2000, White et al., 1998). However, instead of reduced VLDL-
apoB-100 PR due to increased insulin sensitivity, VLDL1 and total VLDL-apoB-100 PR was 
increased.  This may be explained as exercise activity increases peripheral insulin sensitivity 
but not hepatic insulin sensitivity as shown in the study by(Cuthbertson et al., 2016). Also, 
there is a evidence that physical exercise causes more TG enrichment VLDL1 which increases 
VLDL1 particle size and facilitates more clearance of accumulated intracellular TG and hence 
reduces liver fat content (Aadland et al., 2013, Al-Shayji et al., 2012, Herd et al., 2001, 
Ghafouri et al., 2015). 
It has been reported that physical exercise reduced hepatic FFA accumulation by stimulation 
of hepatic FA oxidation via the activation of adenosine-monophosphate-activated protein 
kinase (AMPK) and SREBP-I to inhibit acetyl-coA carboxylase release which results in 
decreasing malonyl-CoA and results in increased mitochondrial FA oxidation (Carlson and 
Winder, 1999, Sim and Hardie, 1988, Kim et al., 1989). Increased FA oxidation and VLDL 
production will increase hepatic fat clearance (Boren et al., 2015). This however will lead to a 
decrease in plasma TG pool which will increase the exchange rate of TG and CE between HDL 
and the TG plasma pool via CETP which causes the formation of TG-enriched HDL (HDL-TG) 
as seen in Figure 5.2 (Frayn, 2010, Guerin et al., 2001, Barter, 2000). HDL-TG will be 
hydrolysed by LPL in the circulation and/or HL in the liver causing the rapid removal of HDL 
particles which will lead to a decrease in HDL-C concentrations and an increase in LDL-C and 
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SDLDL (Frayn, 2010, Guerin et al., 2001, Barter, 2000). Also, in this study HDL-apoA-I FCR was 
correlated with IHCL%, and HDL-apoA-I PS was correlated with plasma TG concentration 
which indicates that an increase in plasma TG, by increased VLDL production, will lead to a 
decrease in HDL-apoA-I concentration. This explanation fits with our study in which plasma 
TG did not decrease after four-month of exercise and hence HDL-C did not increase as seen 
in previous studies by Cuthbertson et al., 2016, Kadoglou et al., 2012 and Sullivan et al., 2012 
(Figure 5.2). 
The study conducted by Thompson et al., 1997 and Alam et al., 2004 showed a decreased 
plasma TG and improved plasma HDL-C concentrations after twelve-month and six-month 
exercise intervention respectively. This indicated that in order to reach this stage, more 
exercise duration is needed to clear most of the hepatic fat up to an optimum point in which 
VLDL production is reduced. This will lead to a reduction in plasma TG pool which reduces 
the exchange rate of TG and CE between HDL and the TG plasma pool via CETP (Frayn, 2010, 
Guerin et al., 2001, Barter, 2000) which reduces the formation of HDL-TG and hence reduced 
HDL clearance rate. Corrected associated hypertriglyceridaemia in NAFLD via improving 
peripheral IR by exercise will increase HDL-CHOL and reduce LDL-CHOL which reduces the 
ALP risk in patients with altered lipid metabolism (Cuthbertson et al., 2016, Frayn, 2010) 
(Figure 5.2 (A)). The effect of exercise on correcting hypertriglyceridaemia and HDL-C is 
shown in Figure 5.2 (B) as discussed earlier. 
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Figure 5.2: (A) Increased exchange rate of TG and CE between HDL and the TG plasma pool via 
CETP causes the formation of HDL -TG and S DLDL and reduces HDL-C due to 
hypertriglyceridaemia. (B) Exercise decreases plasma TG which decreases the exchange rate of 
TG and CE between HDL and  TG plasma pool via CETP which reduces the formation of HDL -TG 
and S DLDL and increases HDL-C. FFA: free fatty acids; TG: triacylglycerols; ApoB-100:  
apolipoprotein B-100, apoB-48: apolipoprotein B-48; ApoA-I: apolipoprotein A-I; IHCL%: 
intrahepatocellular lipid percentage; VLDL: very low -density lipoprotein; HDL: high density 
lipoprotein; CETP: cholesteryl ester transfer protein; CE: cholesteryl ester; LPL: lipoprotein 
lipase; HL: hepatic lipase; S DLDL: small dense low-density lipoprotein; HDL -C: high-density 
lipoprotein –  cholesterol;  FCR: fractional catabolic rate.  
A) 
B) 
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5.6.8 Study limitations and future work 
Extending the exercise intervention from four to six months as in the study conducted by 
(Alam et al., 2004), could show a significant decrease in the plasma TG and an increase in 
HDL-C concentrations as explained earlier (Figure 5.2 (B)). Also, this study measured total 
HDL apo-A-I fraction only; changes in HDL subclasses were not measured. Although Total 
HDL-apoA-I kinetics (PR and FCR) did not change significantly after exercise, changes in HDL 
subclasses kinetics could have occurred. Measuring the activity concentrations of enzymes 
involved in VLDL and HDL metabolism such as PLTP, CETP and LPL could provide additional 
valuable information. In addition, the measurement of VLDL-TG kinetics by 
immunochromatography (Sun et al., 2013) will provide valuable information about the 
amount of TG exported in VLDL particles instead of particle number reflected by apoB 
kinetics measurement. This will also be helpful in measuring the VLDL particle size after 
exercise as seen in other previous studies which might also be correlated with liver fat 
content (Aadland et al., 2013, Al-Shayji et al., 2012, Herd et al., 2001, Ghafouri et al., 2015). 
Hepatic fat oxidation through the measurement of certain enzymes such as AMPK, malonyl-
CoA and acetyl-coA carboxylase using liver tissue biopsies (Lim et al., 2012) could be 
assessed in the future to investigate exercise effect on hepatic fat oxidation concentration 
(Carlson and Winder, 1999, Sim and Hardie, 1988, Kim et al., 1989, Hirschey and Verdin, 
2010). The HDL-apoA-I kinetics measured (PR and FCR) as shown in Table 5.6 were lower 
than the kinetics measured in previous studies shown in Table 5.11. This could be due to 
three reasons; 
1) The apoA-I concentration, HDL-apoA-I kinetics and HDL-C measurement were analysed 
using total HDL-fraction instead of blood plasma. This fraction was obtained by a three- 
step ultracentrifugation for at least 20 hours each. The shear forces generated by the 
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high-speed ultracentrifugation field may strip off the HDL-apoA-I protein and alter the 
HDL concentration measurements (Hafiane and Genest, 2015). Causing a low detection 
of HDL-apoA-I concentration. 
2) The high salt density solution used during ultracentrifugation process may deplete HDL-
associated apolipoproteins and alter their concentration during measurements 
(Davidsson et al., 2010). 
3) The fraction samples were not used freshly as they were stored at -80 C for more than 
two years which might cause a reduction in HDL-C and HDL-apoA-I measurements 
(Nanjee and Miller, 1990, Warnick and Wood, 1995). 
5.6.9 Conclusion 
Our laboratory, exercise and study protocols were successful in detecting an effect of four-
month moderate exercise activity on HDL kinetics, VLDL1 and VLDL2-apoB-100 kinetics, liver 
fat content, and altered lipid profile in patients with NAFLD. Novel investigation of HDL-
apoA-I kinetics gave no significant differences for the total HDL-apoA-I FCR and PR before 
and after exercise. However, exercise increases the total HDL-apoA-I PS, which would 
increase the availability for more HDL particles. Moderate physical exercise corrected 
hyperinsulinaemia and increased peripheral insulin sensitivity which is associated with 
reducing liver fat content and improves overall lipoprotein kinetics in patients with NAFLD. 
Moderate exercise caused a decrease IHCL% which was explained by an increase in VLDL1 
and total VLDL-apoB-100 FCR and PS and increased VLDL1-apoB-100 PR to eliminate 
accumulated liver fat content. All the demonstrated data provided substantial evidence that 
long-term moderate physical exercise activity is beneficial and recommended for the 
management for NAFLD without calorie restriction or lifestyle-induced weight loss. 
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6. Chapter 6: The effect of lixisenatide on postprandial TRL-apoB-100, TRL-apoB-
48 and HDL-apoA-I kinetics 
6.1 Introduction 
Hyperglycaemia, IR (IR) and hypertriglyceridaemia in patients with T2D are associated with 
serious cardiovascular complications (Adiels et al., 2006, Sobenin et al., 1996, King et al., 
2011, Matikainen and Taskinen, 2013, Pettersson et al., 2011). Postprandial hyperlipidaemia 
is considered one of the factors that increase the development of CVD in patients with T2D 
via increasing the extent of the atherogenic lipoprotein phenotype (ALP) (Boren et al., 2014, 
Taskinen and Boren, 2015, Manoria et al., 2013, Suryabhan et al., 2013), i.e. increased LDL-C 
and SDLDL, and reduced HDL-C concentrations (Stefanutti et al., 2014, Manoria et al., 2013, 
Schaefer et al., 2002, Taniguchi et al., 2000). Several studies investigated the effect of 
glucagon-like peptide -1 (GLP-1) receptor agonists on postprandial hyperlipidaemia and 
triacylglycerol-rich lipoprotein (TRL) metabolism (Voukali et al., 2014, Hermansen et al., 
2013, Chiquette et al., 2012). Hermansen et al., (2013) conducted a randomized, double-
blind, placebo-controlled, cross-over clinical trial and found out that a 3 week treatment 
with once daily 1.8mg liraglutide reduced hypertriglyceridaemia and apoB-48 concentration 
versus placebo in patients with T2D. Bunck et al., (2010) illustrated that a 51-week treatment 
with twice daily 10µg exenatide period caused a reduction in postprandial 
hypertriglyceridaemia and apoB-48 concentrations but not TRL-apoB-100 concentrations, 
and a significant increase in serum HDL-C concentrations in patients with T2D. Another study 
showed similar results in which a 3-week treatment with once daily 10µg exenatide period 
also reduced postprandial increase of TG and apoB-48 concentrations (Schwartz et al., 2010). 
However, Xiao et al., (2012) was the only study to date which investigated the effect of GLP-
1 receptor agonist (exenatide) on postprandial TRL-apoB-100 and TRL-apoB-48 kinetics in 
healthy obese men and found that exenatide inhibited the production of TRL-apoB-48 which 
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was independent of reduced gastric emptying. Xiao et al., (2012) also showed that 4 to 6-
week treatment with once daily 10µg exenatide caused a significant reduction in apoB-48 
concentrations, but not TRL-apoB-100 concentrations, which was explained by a significant 
decrease in TRL-apoB-48 PR, but not FCR, and found no significant changes in TRL-apoB-100 
concentrations and kinetics. To date, there are no published studies on the effect of GLP-1 
receptor agonist on postprandial TRL-apoB-100, TRL-apoB-48 and HDL-apoA-I kinetics in 
patients with T2D. Lixisenatide, also known as Lyxumia, is a GLP-1 receptor agonist which is 
been licensed to be used as a treatment for uncontrolled hyperglycaemia associated with 
patients T2D along with metformin (EMA, 2013). Therefore, this study was conducted to test 
whether a 4 week lixisenatide treatment (once daily (10µg for 14 days followed by an 
increase to 20µg for 14 days) versus placebo can cause direct/indirect effects on 
postprandial lipoprotein metabolism in patients with T2D by calculating TRL-apoB-48, TRL-
apoB-100 and HDL-apoA-I kinetics using stable isotope trace-labelling technique. 
6.2 Hypothesis 
Lixisenatide treatment for patients with T2D will correct altered lipoprotein metabolism by 
increasing hepatic and peripheral insulin sensitivity and reducing postprandial 
hypertriglyceridaemia. This will be accomplished by reducing plasma postprandial TG 
concentration by decreasing CM-apoB-48 PR as a result of indirect and direct effects of 
lixisenatide on intestinal enterocytes, and will also reduce VLDL-apoB-100 PR from the liver 
as a consequence of an improvement in insulin sensitivity. The latter will indirectly increase 
the PR of HDL-apoA-I. These effects will contribute to reducing CVD risk. 
6.3 Aims 
To conduct a clinical trial that will study the effects of a 4-week treatment with lixisenatide 
(a GLP-1 receptor agonist) versus placebo on postprandial lipoprotein metabolism, 
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hypertriglyceridaemia, IR and lipid profile in patience with T2D using a constant feeding 
protocol and a stable isotope trace-labelling technique. 
6.4  Methods 
This study was a double-blind crossover study of a treatment with subcutaneous injections 
of once daily 10-20µg lixisenatide versus placebo for the duration of 12 weeks including the 
washout period. Six Caucasian men aged 40-65 with BMI 27-37 kg/m2 diagnosed with T2D 
were recruited in the study (for detailed study recruitment see chapter 2 section 2.3.1) 
(chapter 2, Figure 2.3). Samples from 4 out of 6 patients were used to measure HDL-C, HDL-
apoA-I concentration and HDL-apoA-I kinetics (chapter 2, Figure 2.3). Subjects were assigned 
blindly and randomly to the two treatment options; starting lixisenatide treatment for four 
weeks followed by a four-week washout period versus another four weeks of placebo or vice 
versa (chapter 2, Figure 2.4). Blood samples were collected hourly during the study before 
and after the injection of the 1-¹³C leucine tracer for 12 hours (Figure 2.2) (for detailed study 
protocol see chapter 2 section 2.3.3). The following measurements were performed at the 
end of each treatment period at visits 4 and 8 (chapter 2, Figure 2.4); plasma glucose, plasma 
lipid concentrations, TRL-apoB-100, TRL-apoB-48 and HDL-apoA-I concentrations and 
kinetics by following the verified laboratory protocol (for detailed laboratory methods and 
protocol of measurement see chapter 3). Other supporting results mentioned in this chapter 
such as insulin concentration were collected and analysed by other personnel in the 
laboratory. Data of lixisenatide treatment versus placebo were compared and analysed by 
certain statistical tests to elucidate the effect of lixisenatide (for detailed statistical analysis 
tests used see chapter 3 section 3.2.19). 
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6.5  Results 
6.5.1 Subject characteristics 
The main physical and physiological characteristics of the six male subjects recruited in the 
study are shown in Table 6.0. Age, height, body weight, BMI and body fat percentage were 
similar in both groups. The BMI of 3 out of 6 subjects indicates that they were considered 
obese (NHSUK, 2015). Elevated fasting glucose, HbA1c, TG and total cholesterol 
concentrations show hyperglycaemia and altered lipid metabolism in these patients 
respectively which would be expected in patients with T2D. Notably, the mean systolic blood 
pressure (BP) in both groups was located in the range of the prehypertension category (120 
– 139 mmHg) (WHO, 2015a, American Diabetes Association, 2016), while the mean diastolic 
BP was in the normal range. The main characteristics of the participants after lixisenatide 
treatment intervention versus placebo are shown in Table 6.1. Body weights, BMI, waist 
circumference and body fat percentage, were not significantly changed after lixisenatide 
treatment versus placebo. This indicates that lixisenatide treatment did not cause a 
significant effect on weight loss in the participants of this study, and all the following results 
occurred independently of weight loss. Plasma liver enzymes; alanine transaminase (ALT) 
and aspartate transaminase (AST) were not significantly changed after lixisenatide treatment 
versus placebo. Systolic and diastolic BP were not significantly changed after lixisenatide 
treatment versus placebo. 
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Table 6.0: Subject characteristics and fasting plasma measurements at the screening visit. 
 
 
 
 
 
 
 
 
Data are expressed as Mean ± SEM. Data between the two groups were analysed by paired 
two-tailed t-test .  P values ≤0.05 are in bold. BMI: body mass index; TG: tr iacylglycerol; HbA1c: 
haemoglobin A1C; CHOL: cholesterol; BP: blood pressure.  
 
Table 6.1: Main subjects characteristics after lixisenatide treatment versus period. 
 
 
 
 
 
 
 
 
Data are expressed as Mean ± SEM. Data after lixisenatide and placebo were compared 
between each other and analysed by paired two -tailed t-test. P values ≤0.05 are in bold. BMI: 
body mass index; BP: blood pressure.  
6.5.2 The effect of lixisenatide treatment on glucose and insulin concentrations 
and IR 
Concentrations of fasting and postprandial plasma glucose, insulin and IR calculated by the 
Homeostasis Model Assessment 2 (HOMA2-IR) after lixisenatide treatment versus placebo are 
shown in Figure 6.0 A, B and C respectively. Figure 6.0 (A) shows the mean concentrations of 
plasma glucose after lixisenatide treatment versus placebo for the six participants. Fasting 
glucose concentrations with a mean concentration of 7.6±0.6 at -240 minutes mmol/L were 
Characteristics 
Baseline measurements  
(n=6) 
Age (years) 58.8±2.2 
Height (cm) 173.2±2.7 
Body weight (kg) 91.2±4.2 
BMI (kg/m2) 30.4±1.2 
Glucose (mmol/L) 7.9±0.7 
HbA1c (mmol/mol) 57.5±3.5 
TG (mmol/L) 1.7±0.2 
Total CHOL (mmol/L) 3.5±0.4 
Body fat (%) 28.2±1.6 
Systolic BP (mm Hg) 126.5±8.9 
Diastolic BP (mm Hg) 78.7±2.2 
Characteristics 
Lixisenatide 
(n=6) 
Placebo 
(n=6) 
P value 
Paired T-test 
Body weight (kg) 91.8± 4.0 91.0±4.3 0.2 
BMI (kg/m2) 29.5±1.1 29.3±1.2 0.9 
Body fat (%) 27.5±1.3 26.8±1.6 0.7 
AST (IU/l) 30.5±6.5 34.7±10.4 0.8 
ALT (IU/l) 44.2±8.6 46.7±11.8 0.9 
Systolic BP (mm Hg) 126.3±6.6 128.6±7.1 0.7 
Diastolic BP (mm Hg) 81.8±2.6 80.3±3.6 0.8 
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significantly lower after the lixisenatide treatment (P=0.05) than placebo (8.3 ±1.0 mmol/L). 
Postprandial glucose concentrations with a mean concentration of 8.2±1.1 mmol/L between 0 – 
480 minutes after the lixisenatide treatment were significantly lower (P=0.001) than placebo 
(9.2±1.1 mmol/L) (Figure 6.0 (A)). Fasting insulin concentrations with a mean concentration of 
157.5±28.2 pmol/L at -240 minutes were not significantly different after the lixisenatide 
treatment (P=0.33) versus placebo (123.5±27.5 pmol/L) (Figure 6.0(B)). Postprandial insulin 
concentrations with a mean concentration of 264.8±52.5 pmol/L between 0 – 480 minutes after 
lixisenatide treatment were significantly higher (P=<0.001) than placebo (221.2±46.3 pmol/L) 
(Figure 6.0 (B)). The mean IR value of 2.3±0.3 after lixisenatide versus placebo was not 
significantly different (2.8±0.4) (Figure 6.0 (C)). 
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Figure 6.0: Plasma fasting glucose (A) and insulin (B) concentrations and 
HOMA2-IR (C) after lixisenatide treatment versus placebo (n=6). Data 
expressed as mean ± SEM. Fasting concentration at -240 minutes after 
lixisenatide and placebo treatments were analysed by paired two -tailed 
t-test. The mean of postprandial concentrations between 0 –  480 
minutes after l ixisenatid e and placebo treatments were analysed by 
paired two-tailed t-test.  *P≤0.05, **P<0.01 and ***P<0.001. HOMA2-IR: 
The Homeostasis Model Assessment 2 for IR calculation.  
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6.5.3 The effect of lixisenatide treatment on plasma TG, total cholesterol and FFA 
concentrations 
Plasma TG, total cholesterol and FFA concentrations after lixisenatide treatment versus 
placebo for the six participants are shown in Figure 6.1 (A, B and C respectively). A repeated 
measure ANOVA test was used to verify if the TG concentrations between 0 – 480 minutes 
were constant and in a steady state. TG concentrations were not significantly different after 
lixisenatide treatment (P= 0.4) or placebo (P= 0.5) over time in the six participants. This 
validates the feeding protocol in achieving a constant raised postprandial TG steady state 
which is necessary for the analysis of stable isotope kinetics. Fasting TG concentrations with 
a mean concentration of 1.5±0.1 mmol/L at -240 minutes were not significantly different 
(P=0.6) between the lixisenatide treatment and placebo (1.6±0.2 mmol/L) (Figure 6.1 (A)). 
Postprandial TG concentration with a mean concentration of 2.8±0.3 mmol/L between 0 – 
480 minutes after lixisenatide treatment was significantly lower (P=0.002) than placebo 
(3.3±0.3 mmol/L) (Figure 6.1 (A)). Fasting total cholesterol concentrations with a mean value 
of 3.7±0.4 mmol/L at -240 minutes after the lixisenatide treatment was not significantly 
different (P=0.09) from placebo (4.2±0.5 mmol/L) (Figure 6.1(B)). Postprandial total 
cholesterol concentration with a mean concentration of 3.8±0.4 mmol/L between 0 – 480 
minutes after the lixisenatide treatment was significantly lower (P=0.02) than placebo 
(4.1±0.5 mmol/L) (Figure 6.1 (B)). Fasting FFA concentrations with a mean concentration of 
0.7±0.1 mmol/L at -240 minutes after the lixisenatide treatment was not significantly 
different (P=0.5) from placebo (0.7±0.1 mmol/L) (Figure 6.1 (C)). Postprandial FFA 
concentration with a mean concentration of 0.5±0.1 mmol/L between 0 – 480 minutes after 
the lixisenatide treatment was significantly lower (P=0.05) than placebo (0.6±0.03 mmol/L) 
(Figure 6.1 (C)).  
 163  
 
- 2 4 0 - 1 2 0 0 1 2 0 2 4 0 3 6 0 4 8 0
1
2
3
4
5
6
T im e  ( m in )
P
la
s
m
a
 T
G
 (
m
m
o
l/
L
)
L ix is e n a t id e
P la c e b o
R e p e a te d  m e a ls
1 -¹³C  le u c in e  t r a c e r  b o lu s ; 1 m g / k g  a n d
 a  c o n s ta n t  in fu s io n  o f  1 m g / k g / m in .
***
A
        
- 2 4 0 - 1 2 0 0 1 2 0 2 4 0 3 6 0 4 8 0
3
4
5
6
T im e  ( m in )
P
la
s
a
m
 c
h
o
le
s
te
ro
l 
(m
m
o
l/
L
)
L ix is e n a t id e
P la c e b o
R e p e a te d  m e a ls
1 -¹³C  le u c in e  t r a c e r  b o lu s ; 1 m g / k g  a n d
 a  c o n s ta n t  in fu s io n  o f  1 m g / k g / m in .
**
B
 
- 2 4 0 - 1 2 0 0 1 2 0 2 4 0 3 6 0 4 8 0
0 .2
0 .4
0 .6
0 .8
1 .0
T im e  ( m in )
P
la
s
m
a
 F
F
A
 (
m
m
o
l/
L
)
L ix is e n a t id e
P la c e b o
R e p e a te d  m e a ls
1 -¹³C  le u c in e  t r a c e r  b o lu s ; 1 m g / k g  a n d
 a  c o n s ta n t  in fu s io n  o f  1 m g / k g / m in .
*
C
 
Figure 6.1: Plasma fasting TG (A), cholesterol (B) and FFA (C) concentrations after 
lixisenatide treatment versus placebo (n=6) .  Data expressed as mean ± SEM.  Fasting 
concentrations at -240 minutes after lixisenatide and placebo treatments were 
analysed by paired two-tailed t -test.  The mean of postprandial concentrations 
between 0 –  480 minutes after lixisenatide and placebo treatments were 
analysed by paired two-tailed t -test. *P≤0.05, **P<0.01 and ***P<0.001. TG: 
triacylglycerol; FFA: free fatty acids.  
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6.5.4 The effect of Lixisenatide treatment on TRL-TG and TRL-cholesterol 
concentrations. 
The TRL-TG and TRL-cholesterol concentrations after lixisenatide treatment versus placebo 
for the six participants are shown in Figure 6.2 (A and B respectively). Fasting TRL-TG 
concentrations with a mean concentration of 1.0±0.1 mmol/L at -240 minutes after the 
lixisenatide treatment were not significantly different (P=0.9) from placebo (0.9±0.2 mmol/L) 
(Figure 6.2 (A)). Postprandial TRL-TG concentrations with a mean concentration of 2.3±0.2 
mmol/L between 0 – 480 minutes after the lixisenatide treatment were significantly lower 
(P=0.05) than placebo (2.6±0.30 mmol/L) (Figure 6.2 (A)).  
Fasting TRL-cholesterol concentrations with a mean concentration of 0.3±0.02 mmol/L at -
240 minutes after the lixisenatide treatment were not significantly different (P=0.6) versus 
placebo (0.3±0.1 mmol/L) as shown in Figure 6.2 (B). Postprandial TRL-cholesterol 
concentrations with a mean concentration of 0.4±0.1 mmol/L between 0 – 480 minutes after 
the lixisenatide treatment were significantly lower (P=0.04) than placebo (0.5±0.1 mmol/L) 
(Figure 6.2 (B)).  
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Figure 6.2: TRL-TG (A) and TRL-cholesterol (B) concentrations after lixisenatide treatment versus placebo (n=6). Data expressed as mean ± SEM. Fasting 
concentrations at -240 minutes after lixisenatide and placebo treatment s were analysed by paired two -tailed t-test.  The mean of postprandial 
concentrations between 0 –  480 minutes after lixisenatide and placebo treatments were analysed by paired two -tailed t-test. *P≤0.05 .  TRL: 
triacylglycerol r ich -l ipoprotein; TG: triacylgly cerol.  
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6.5.5 The effect of Lixisenatide treatment on fasting plasma HDL-C, F-HDL-C and F-
HDL-apoA-I concentrations. 
Figure 6.3 (A and B) shows the cholesterol and apoA-I concentrations in the HDL fraction (F-
HDL-C) and (F-HDL-apoA-I) respectively after lixisenatide treatment versus placebo for the 
six participants. Fasting F-HDL-C concentration with a mean concentration of 0.57±0.1 g/L at 
-240 minutes after lixisenatide treatment was not significantly different (P=0.4) versus 
placebo (0.63±0.1 g/L) as shown in Figure 6.3 (A). Postprandial F-HDL-C concentration with a 
mean concentration of 0.6±0.1 g/L between 0 – 480 minutes after the lixisenatide treatment 
was lower, but not statistically significant (P=0.07) versus placebo (0.5±0.1 g/L) (Figure 6.3 
(A)).  
Fasting plasma HDL-C concentration with a mean concentration of 1.1±0.06 g/L at -240 
minutes after lixisenatide treatment was not significantly different (P=0.4) versus placebo 
(1.1±0.1 g/L) as shown in Figure 6.3 (B). 
Fasting F-HDL-apoA-I concentration with a mean concentration of 0.5±0.03 g/L at -240 
minutes after the lixisenatide treatment was not significantly different (P=0.6) versus 
placebo (0.5±0.1 g/L) as shown in Figure 6.3 (C). Postprandial F-HDL-apoA-I concentrations 
with a mean concentration of 0.5±0.03 g/L between 0 – 480 minutes after the lixisenatide 
treatment was not changed significantly (P=0.9) versus placebo (0.5±0.04 g/L) (Figure 6.3 
(C)). 
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Figure 6.3: F-HDL-C (A) plasma HDL-C (B) and F-HDL-apoA-I (C) concentrations 
after lixisenatide treatment versus placebo (n=4). Data expressed as mean ± 
SEM. Fasting concentrations at -240 minutes after lixisenatide and placebo 
treatments were analysed by paired two -tailed t-test. The mean of 
postprandial concentrations between 0 –  480 minutes after l ixisenatide and 
placebo treatments were analysed by paired two -tailed t -test. HDL: high 
density lipoprotein; CHOL: cholesterol; apoA -I:  apolipoprotein A-I;  F-HDL-
CHOL: cholesterol concentrations in HDL fraction; F -HDL-apoA-I:  
apolipoprotein A-I concentrations in HDL fraction.  
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6.5.6 The effect of lixisenatide treatment on TRL-apoB-100 and TRL-apoB-48 
concentrations 
The measurements of TRL-apoB-100 and TRL-apoB-48 concentrations after lixisenatide 
treatment versus placebo are shown in Figure 6.4 A and B respectively. The fasting mean 
TRL-apoB-100 concentration of 26.8±2.6 mg/L at -240 minutes after lixisenatide treatment 
was not significantly different (P=0.4) versus placebo (24.5±3.6 mg/L) (Figure 6.4 (A)). 
Postprandial TRL-apoB-100 concentration with a mean concentration of 28.8±4.3 mg/L were 
between 0 – 480 minutes after lixisenatide treatment was not significantly different (P=0.1) 
from placebo (31.6±5.3 mg/L) Figure 6.4 (A). 
The fasting TRL-apoB-48 concentration with a mean concentration of 2.3±0.7 mg/L at -240 
minutes after lixisenatide treatment was not significantly different (P=0.7) from placebo 
(2.0±0.4 mg/L) (Figure 6.4 (B)). Postprandial TRL-apoB-100 concentration with a mean 
concentration of 9.2±2.4 mg/L between 0 – 480 minutes after lixisenatide treatment was not 
significantly different (P=0.3) from placebo (9.8±2.7 mg/L) (Figure 6.4 (B)). 
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Figure 6.4: Fasting and postprandial concentrations of TRL -apoB-100 (A) and TRL-apoB-48 (B) (n=6). Data expressed as mean ± SEM. Fasting 
concentrations at -240 minutes after lixisenatide and placebo treatments were analysed by paired two -tailed t-test.  The mean of postprandial 
concentrations between 0 –  480 minutes after lixisenatide and placebo treatments were analysed by paired two -tailed t-test. TRL: triacylglycerol r ich -
lipoprotein; apoB-100: apolipoprotein B-10; apoB-48: apolipoprotein B-48. 
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6.5.7 The effect of lixisenatide treatment on leucine isotopic enrichment of TRL-
apoB-100, TRL-apoB-48 and HDL-apoA-I versus placebo 
The 13C leucine isotopic enrichment of TRL-apoB-100, TRL-apoB-48 and HDL-apoA-I after 
lixisenatide treatment versus placebo are shown in Figures 6.5 (A, B and C respectively). Post 
lixisenatide treatment versus placebo treatment measurements of 13C leucine enrichment 
was calculated and expressed as TTRs. The area under the curve (AUC) of the leucine TTR 
enrichment of TRLapoB-100 was not significantly different (AUC=10.9±0.2xmin) (P=0.8) after 
lixisenatide treatment versus placebo (AUC=10.0±0.2xmin) as shown in Figure 6.5 (A).  
The mean AUC of the leucine TTR enrichment of TRLapoB-48 not significantly different 
(AUC=4.4±0.1xmin) (P=0.8) after lixisenatide treatment versus placebo (AUC=4.0±0.1xmin) 
as shown in Figure 6.5 (B). 
Figure 6.5 (C) shows the mean AUC of the leucine TTR enrichment of HDL-apoA-I which was 
not significantly different (AUC=1.0±0.02xmin) (P=0.8) after lixisenatide treatment versus 
placebo (AUC=1.1±0.03xmin). 
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Figure 6.5: 
13
C Leucine TTR enrichment of TRL-apoB-100 (A), TRL-apoB-48 (B) and HDL-
apoA-I (C) across study time points. Data expressed as mean ± SEM. The mean of 
postprandial  TTR enrichment measurements between 0 –  480 minutes after 
lixisenatide and placebo treatments were analysed by AUC. 
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6.5.8 The effect of lixisenatide treatment on TRL-apoB-100, TRL-apoB-48 and HDL-
apoA-I kinetics 
TRL-apoB-100 fractional catabolic rate (FCR), pool size (PS) and production rate (PR) were 
calculated after lixisenatide treatment and placebo treatment (Figure 6.6 A, B and C 
respectively). TRL-apoB-100 FCR was increased significantly (P=0.01) after lixisenatide 
treatment (6.3±0.4) pools/day versus placebo (4.1±0.6) pools/day as shown in Figure 6.6 (A). 
TRL-apoB-100 PS was not significantly different (P=0.1) after lixisenatide treatment versus 
placebo as shown in Figure 6.6 (B). TRL-apoB-100 PR was higher, but not statistically 
significant (P=0.06) after lixisenatide treatment versus placebo as shown in Figure 6.6 (C). 
TRL-apoB-48 FCR, PS and PR were calculated after lixisenatide treatment and placebo and 
are shown in Figure 6.7 A, B and C respectively. TRL-apoB-48 FCR, PS and PR were not 
significantly different after lixisenatide treatment versus placebo. 
The HDL-apoA-I kinetics; FCR, PS and PR were calculated in 4 out of 6 participants after 
lixisenatide treatment and placebo and are shown in Figure 6.8 A, B and C respectively. HDL-
apoA-I FCR, PS and PR were not significantly different after lixisenatide treatment versus 
placebo. 
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Figure 6.6: TRL-apoB-100 kinetics after lixisenatide treatment versus placebo (n=6) .  
Data expressed as mean ± SEM. The mean of postprandial measurements 
between 0 –  480 minutes after lixisenatide and placebo treatments were 
analysed by paired two-tailed t -test. The P values <0.05 are marked as *P≤0.05 .  
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Figure 6.7: TRL-apoB-48 kinetics after lixisenatide treatment versus placebo (n=6) .  Data 
expressed as mean ± SEM. The mean of postprandial measurements between 0 
–  480 minutes after l ixisenatide and placebo treatm ents were analysed by 
paired two-tailed t-test.  
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Figure 6.8: HDL-apoA-I kinetics after lixisenatide treatment versus placebo (n=4 ).  Data 
expressed as mean ± SEM. The mean of postprandial measurements between 0 
–  480 minutes after l ixisenatide and placebo t reatments were analysed by 
paired two-tailed t-test.  
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6.6 Discussion 
This study was a randomised cross-over clinical trial, which investigated the effect of a 4-
week lixisenatide treatment intervention versus placebo treatment on TRL-apoB-100, TRL-
apoB-48 and HDL-apoA-I kinetics in patients with T2D. The study showed that TRL-apoB-100 
FCR was significantly increased after lixisenatide treatment versus placebo, and TRL-apoB-
100 PS and PR did not change significantly which resulted in a decrease in plasma TG 
concentration. TRL-apoB-48 and HDL-apoA-I FCR, PS and PR were not changed significantly 
after lixisenatide treatment versus placebo. Plasma and fractional concentrations of TG, 
cholesterol, plasma FFA and glucose were significantly reduced after lixisenatide treatment 
versus placebo. 
Previous studies conducted by Hermansen et al., 2013, Xiao et al., 2012, Bunck et al., 2010 
and Schwartz et al., 2010 investigated the effect of GLP-1 receptor agonists on 
postprandially elevated plasma lipid profiles, especially TG (Table 6.2). There are no previous 
clinical studies on the effects of GLP-1 receptor agonists on postprandial TRL-apoB-100 and 
TRL-apoB-48 and HDL-apoA-I kinetics in patients with T2D. 
The only published study which has investigated the effect of a GLP-1 receptor agonist on 
postprandial TRL-apoB-100 and TRL-apoB-48 kinetics was conducted by Xiao et al., 2012 in 
healthy subjects as shown in Table 6.2 which included key information from each study 
(including the current study) such as the number of participants recruited, period of 
treatment, healthy or with a metabolic disease, clinical protocol and GLP-1 receptor agonist 
dose used. Other studies carried out by Hermansen et al., 2013, Bunck et al., 2010 and 
Schwartz et al., 2010 investigated the effect of GLP-1 receptor agonists on postprandial 
plasma or serum lipid profile, glucose and insulin concentrations but not TRL-apoB-100, TRL-
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apoB-48 or HDL-apoA-I kinetics. Table 6.3 and 5.11 (see chapter 5) show key information 
from previous clinical studies that investigated the effect of different interventions on TRL-
apoB-100 and TRL-apoB-48 and HDL-apoA-I kinetics (FCR and PR calculated before and after 
each intervention) respectively in patients with altered lipid metabolism either healthy or 
with T2D.  
Table 6.2: Comparison of the current study with previous studies which investigated the 
effect of GLP-1 receptor agonists on postprandial lipid metabolism. 
Study 
Number of 
participants 
Health and 
disease status 
Period of 
treatment 
Measurements 
Study protocol and GLP-1 
receptor agonist used 
Current study 6 males T2D 
Four weeks of 
treatment 
with four 
weeks 
washout 
period 
Plasma and TRL 
fraction lipid 
profile and TRL-
apoB-100 and 
TRL-apoB-48 
kinetics  
1X daily (10µg for 14 days 
followed by an increase to 
20µg for 14 days) 
lixisenatide treatment 
versus placebo. 
(Hermansen et 
al., 2013) 
20 subjects 
(11 males and 
nine females) 
T2D 
Three weeks 
of treatment 
with 3-9 
weeks 
washout 
period 
Plasma lipid 
profile and 
plasma apoB-48 
concentrations 
1X daily gradually increased 
dose (0.6 to 1.8 mg) of 
liraglutide versus placebo 
(Xiao et al., 
2012) 
15 males Healthy obese 
Four-six 
weeks 
Plasma and TRL 
fraction lipid 
profile and TRL-
apoB-100 and 
TRL-apoB-48 
kinetics  
1X daily 10µg exenatide 
treatment versus placebo 
(Bunck et al., 
2010) 
30 males T2D 
Fifty one 
week 
Plasma lipid 
profile and 
plasma apoB-48 
concentrations 
2X daily 5µg exenatide 
progressing to 10µg and if 
needed to 20µg versus 
placebo 
(Schwartz et 
al., 2010b) 
35 subjects 
(31 males and 
four females) 
Impaired 
glucose 
tolerance or 
recent-onset 
T2D 
Three weeks 
Plasma lipid 
profile and 
plasma apoB-48 
concentrations 
1X daily 10µg exenatide 
treatment versus placebo 
TRL- triacylglycerol -rich lipoprotein; -X: how many times i.e. 5X: five times ; T2D: type 2 
diabetes; TRL: triacylglycerol -rich lipoprotein; apo: apolipoprotein.  
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Table 6.3: Previous studies which investigated the effect of different interventions on apoB -
100 and apoB-48 kinetics. 
Data are expressed as Mean ± SEM. TRL: triacylgly cerol-rich l ipoprotein; VLDL: very low -
density l ipoprotein; apoB-100: apolipoprotein B-100, apoB-48: apolipoprotein B-48; FCR:  
fractional catabolic rate; PR: production rate.  
ApoB-100 kinetics      . 
Study carried 
out by 
Methodology Subjects 
Nutritional 
state 
Intervention 
investigated 
Apo B-100 FCR 
(pools/day) for 
each 
intervention 
Apo B-100 PR 
(mg/kg/day) for 
each 
intervention 
(Xiao et al., 
2012) 
10 hours primed-
constant infusion of D3-
Leucine [(5,5,5-
2
H3)L-
Leucine] 
15 healthy obese 
males 
Constant-
feeding 
Effect of exenatide 
on TRL-apoB-100 and 
TRL-apoB-48 kinetics 
placebo TRL-
apoB-100= 
3.83±0.4 
 
Exenatide TRL-
apoB-100= 
3.03±0.2 
Placebo TRL-
apoB-100= 
9.88±1.6 
 
Exenatide TRL-
apoB-100= 
7.84±0.7 
(Duez et al., 
2008a) 
12 hours primed-
constant infusion of D3-
Leucine [(5,5,5-
2
H3)L-
Leucine] 
12 healthy obese 
males 
Constant-
feeding 
Effect of  short-term 
acute elevation of 
plasma FFA 
Controls VLDL-
apoB-100 = 
5.1±0.1 
 
After acute 
elevation of FFA  
VLDL-apoB-100 
= 5.0±0.1 
Controls VLDL-
apoB-100 = 
20.7±0.8 
 
After acute 
elevation of FFA 
VLDL-apoB-100 
=27.9±1.2 
(Hogue et al., 
2007b) 
12 hours primed-
constant infusion of D3-
Leucine [(5,5,5-
2
H3)L-
Leucine] 
24 males (11 
males with T2D 
versus 13 healthy 
males as control) 
Constant-
feeding 
TRL-apoB-100 and 
TRL-abpo48 kinetics 
in patient with T2D 
against healthy 
controls 
Controls VLDL-
apoB-100 = 
9.1±3.4 
 
T2D VLDL-apoB-
100 = 4.1±0.4 
Controls VLDL-
apoB-100 = 
32.1±7.7 
 
T2D VLDL-apoB-
100 = 41.1±4.8 
(Welty et al., 
2004) 
15 hours primed-
constant infusion of D3-
Leucine [(5,5,5-
2
H3)L-
Leucine] 
23 healthy 
subjects (17 
males and 6 
females) 
Constant-
feeding 
No interventions 
VLDL-apoB-100 
=6.1±0.7  
VLDL-apoB-100 
= 15.0±1.3 
ApoB-48 kinetics       . 
(Xiao et al., 
2012) 
10 hours primed-
constant infusion of D3-
Leucine [(5,5,5-
2
H3)L-
Leucine] 
15 healthy obese 
males 
Constant-
feeding 
Effect of exenatide 
placebo TRL-
apoB-48= 
1.54±0.2 
 
Exenatide TRL-
apoB-48 = 
1.36±0.2 
Placebo TRL-
apoB-48 = 
0.12±0.02 
 
Exenatide TRL-
apoB-48 = 
0.08±0.02 
(Duez et al., 
2008a) 
12 hours primed-
constant infusion of D3-
Leucine [(5,5,5-
2
H3)L-
Leucine] 
12 healthy obese 
males 
Constant-
feeding 
Effect of short-term 
acute elevation of 
plasma FFA 
Controls TRL-
apoB-48 = 
4.2±0.09 
 
After acute 
elevation of FFA 
TRL-apoB-48 = 
4.8±0.2 
Controls TRL-
apoB-48 = 
3.5±0.2 
 
After acute 
elevation of FFA 
TRL-apoB-48 = 
5.9±0.3 
(Hogue et al., 
2007b) 
12 hours primed-
constant infusion of D3-
Leucine [(5,5,5-
2
H3)L-
Leucine] 
24 males (11 
males with T2D 
versus 13 healthy 
males as control) 
Constant-
feeding 
TRL-apoB-100 and 
TRL-abpo48 kinetics 
in patient with T2D 
against healthy 
controls 
Controls TRL-
apoB-48 = 
7.8±0.6 
 
T2D TRL-apoB-
48 = 5.8±0.5 
Controls TRL-
apoB-48 = 
3.0±0.5 
 
T2D TRL-apoB-
48 = 11.0±0.6 
(Welty et al., 
2004) 
15 hours primed-
constant infusion of D3-
Leucine [(5,5,5-
2
H3)L-
Leucine] 
23 healthy 
subjects (17 
males and 6 
females) 
Constant-
feeding 
No interventions 
TRL-apoB-48 = 
4.3±0.4 
TRL-apoB-48 = 
0.94±0.2 
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6.6.1 Changes in fasting and postprandial lipid profile, TRL-apoB-100, TRL-apoB-48 
and HDL-apoA-I kinetics 
A 3-week liraglutide treatment period caused no significant change in fasting TG or FFA 
concentrations versus placebo in the study of T2D by Hermansen et al., 2013 which was 
similar to the results in the current study. In contrast, the study carried out by Bunck et al., 
2010 showed a significant reduction in fasting plasma TG after a 51-week exenatide 
treatment versus placebo. A significant reduction in postprandial plasma TG was observed 
after a 3-week liraglutide treatment period (Hermansen et al., 2013) and after a 3-week 
exenatide treatment period in patients with T2D (Schwartz et al., 2010) which was also 
similar to the results in the current study. However, the study conducted by Xiao et al., 2012 
in healthy obese subjects did not show a significant decrease in postprandial plasma TG or 
TRL-TG after a 4 to 6-week exenatide treatment period versus placebo contrary to the 
current study results. A significant overall prolonged reduction of postprandial FFA was 
detected after a 51-week exenatide treatment period (Bunck et al., 2010) and a 3-week 
exenatide treatment period (Schwartz et al., 2010) versus placebo which was similar to the 
current study. There was no significant reduction in plasma FFA after a 3-week liraglutide 
treatment period (Hermansen et al., 2013) and after a 4-week exenatide treatment period 
(Xiao et al., 2012) versus placebo. No significant changes in plasma and TRL total cholesterol 
were found after a 4 to 6-week exenatide treatment period (Xiao et al., 2012) and a 51-week 
exenatide treatment period (Bunck et al., 2010) versus placebo. However, in the study 
carried out by Schwartz et al., 2010 plasma remnant lipoprotein cholesterol (RLP-C) was 
significantly decreased after a 3-week exenatide treatment period versus placebo. 
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No significant changes in apoB-100 concentrations were observed after a 4 to 6-week 
exenatide treatment period (Xiao et al., 2012) and a 51-week exenatide treatment period 
(Bunck et al., 2010) versus placebo which is similarly seen in the current study. On the other 
hand, significant reductions in apoB-48 concentrations were detected after a 3-week 
liraglutide treatment period (Hermansen et al., 2013), after a 4 to 6-week exenatide 
treatment period (Xiao et al., 2012), after a 3-week exenatide treatment period (Schwartz et 
al., 2010) and after a 51-week exenatide treatment period (Bunck et al., 2010) versus 
placebo contrary to the finding in the current study. These previous studies might have had 
different effects due to the use of different GLP-1 analogues in each study with different 
durations of treatment. 
Xiao et al., 2012 measured the postprandial TRL-apoB-100 kinetics after a 4 to 6-week 
exenatide treatment in healthy obese subjects and showed that TRL-apoB-100 FCR and PR 
did not significantly change against placebo. On the contrary, the current study showed a 
significant increase in TRL-apoB-100 FCR after a 4-week lixisenatide treatment versus 
placebo. A possible mechanism for this is that lixisenatide significantly increased 
postprandial insulin concentrations in patients with T2D (Wilkins et al., 2014, Patel et al., 
2014, Xiao et al., 2012) (Figure 6.0). Increased insulin secretion increases uptake of TG by the 
adipose tissue via increased LPL activity in the adipose tissues (Fried et al., 1993, Taskinen, 
1987, Romon et al., 1983, Tan et al., 2006). An increased TRL-apoB-100 FCR contributes to 
decreasing the postprandial TG plasma pool. 
The study showed that TRL-apoB-100 PR is increased with borderline significance (P=0.06) 
after lixisenatide treatment versus placebo. This could be due to an increase in liver de novo 
lipogenesis (DNL) due to increased insulin concentrations (Dimitriadis et al., 2011, Patel et 
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al., 2014). This would increase the availability of TG for VLDL production despite the fact that 
insulin would be expected to reduce apoB-100 PR. 
Xiao et al., 2012 demonstrated that TRL-apoB-48 PR was significantly decreased, but not 
FCR, after 4 to 6-week exenatide treatment which was not shown in the current study. 
Serum HDL-C concentrations were significantly increased after a 51-week exenatide 
treatment period versus placebo (Bunck et al., 2010) but this was not seen in the current 
study in either plasma or fraction HDL-C concentrations. The study by Bunck et al., 2010 also 
showed no significant change in plasma apoA-I concentrations after treatment period with 
exenatide which is similar to the results seen in the current study. The reason for the 
different findings may be that the current study was not sufficiently powered to detect a 
significant increase in HDL-C (n=4). 
The current study is the only study which has investigated the effect of lixisenatide 
treatment on HDL-apoA-I kinetics against placebo in patients with T2D. This novel 
investigation showed no significant changes in HDL-apoA-I PS, FCR and PR after four-week 
lixisenatide treatment against placebo. 
6.6.2 Changes in plasma glucose, insulin and IR 
Fasting plasma glucose concentrations were significantly decreased after a 3-week 
liraglutide treatment period versus placebo (Hermansen et al., 2013) which is similar to the 
results in the current study. Postprandial glucose was significantly decreased after a 3-week 
liraglutide treatment period (Hermansen et al., 2013), after a 4 to 6-week exenatide 
treatment period (Xiao et al., 2012), after a 51-week exenatide treatment period (Bunck et 
al., 2010) and after a 3-week exenatide treatment period (Schwartz et al., 2010) versus 
placebo which is similar to the results of the current study. 
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Hermansen et al., 2013 showed that fasting insulin concentrations were significantly 
increased after a 3-week liraglutide treatment period versus placebo which was not found in 
the current study. Postprandial insulin concentrations were not significantly changed after a 
4 to 6-week exenatide treatment period (Xiao et al., 2012) and after a 51-week exenatide 
treatment period (Bunck et al., 2010) versus placebo which differs from the current study. 
Postprandial insulin concentrations were significantly increased after a 3-week liraglutide 
treatment versus placebo (Hermansen et al., 2013) which is similar to the current results, 
but significantly decreased after a 3-week exenatide treatment period versus placebo 
(Schwartz et al., 2010) which is opposite to the finding in the current study. 
The current study showed that IR, measured by HOMA2-IR, was not significantly different 
after a 4-week treatment period versus placebo. Reduced IR in patients with altered glucose 
metabolism was observed in previous studies after treatment with GLP-1 receptor agonists 
(Rizzo et al., 2009, Nystrom, 2008).  
6.6.3 GLP-1 receptor agonist administration, dosage and the meal given in this 
study 
Lixisenatide was administered daily in the present study with an increase after two weeks 
from the start of the treatment period for the duration of 4 weeks. A similar method of 
administration was seen in the studies conducted by Hermansen et al., 2013 and Bunck et 
al., 2010 for three weeks and 51-weeks respectively. Xiao et al., 2012 and Schwartz et al., 
2010 used a fixed dose of exenatide and administered for similar durations of 3-4 weeks. 
Administration of gradual dosing of GLP-1 receptor agonists is advised to be effective in 
reducing side effects which occur during the initial treatment period (Prasad-Reddy and 
Isaacs, 2015).  
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In this study, the feeding protocol used to produce a postprandial TG steady state was an 
hourly fat-rich liquid meal (Carbohydrates (CHO) 22%, total fat 66.1%, and protein 11.9% 
with a total of 2280 Kcal) (See Table 2.0 Chapter 2). The studies conducted by Hermansen et 
al., 2013, Bunck et al., 2010 and Schwartz et al., 2010 used fat-rich solid test meals during 
the clinical trial to measure the effect of a GLP-1-receptor agonist on apoB-48 
concentrations. Xiao et al., 2012 was the only study which used a similar hourly feeding 
protocol with CHO 38%, total fat 49%, and protein 13% to increase plasma TG 
concentrations to calculate TRL-apoB-100 and TRL-apoB-48 kinetics, but they did not achieve 
a steady state in their study as shown by changes in TRL-apoB-48 concentrations. They 
stated that they might use non-steady state modelling in the future to reanalyse their 
kinetics. In the latter study, both TRL-apoB-100 and TRL-apoB-48 kinetics were calculated 
using a one pool model based on the assumption that plasma TG was in a steady state. This 
indicates that their results could be questionable and needs reanalysis as they stated (Xiao et 
al., 2012). In contrast, the study design and the meal given in the current study were 
successful in achieving raised plasma TG and TRL-apoB-48 steady states. 
It is important to note, that in the clinical protocol for the current study the lixisenatide was 
administered on the study day 30 minutes prior to giving the liquid meal in order to achieve 
a raised postprandial TG steady state under the effect of lixisenatide after 4 hours of 
administration, at which point the stable isotope infusion for the kinetic study was started. 
Lixisenatide is a once daily treatment with a longer half-life and action duration (EMA, 2013) 
that exenatide (EMA, 2011). Duration of action of lixisenatide was expected to be for more 
than 10 hours enabling the measurements of TRL kinetics between 0 – 480 minutes (EMA, 
2013). On the contrary, the study carried out by Xiao et al., 2012 used a clinical protocol in 
which exenatide, with a shorter half-life of 2 hours (EMA, 2011), and the stable isotope was 
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injected at the same time, which is the reason for not achieving a steady state as they 
stated. 
6.6.4 Overall effects of lixisenatide on altered lipoprotein metabolism 
Many studies showed that GLP-1 receptor agonists cause a reduction in postprandial 
hypertriglyceridaemia by reducing TRL-apoB-48 concentrations (Hermansen et al., 2013, Xiao 
et al., 2012, Bunck et al., 2010, Schwartz et al., 2010). The mechanisms for this may be a 
reduction in gastric emptying which is a recognised effect of GLP-1 receptor agonists (Becker 
et al., 2015, Lorenz et al., 2013). Another possible mechanism is a reduction in activity of 
microsomal transfer protein (MTP) which is increased in patients or animal models with 
altered lipid metabolism and IR (Gutierrez-Repiso et al., 2015, Brahm and Hegele, 2015, 
Adelis and Lewis, 2008). Reducing gastric emptying plays a significant role in decreasing the 
lipid substrate needed for chylomicron (CM) formation in the enterocytes which causes a 
reduction in CM production rate (Becker et al., 2015, Lorenz et al., 2013). A decrease in MTP 
activity in the enterocytes will also result in a reduction in the assembly of CM particles 
which causes a decrease in CM production and chylomicron remnant (CMR) concentrations 
(Gutierrez-Repiso et al., 2015, Brahm and Hegele, 2015, Carpentier et al., 2002, Xiao et al., 
2012, Adelis and Lewis, 2008). A decrease in TRL-apoB-48 PR was not seen in the current 
study which may be due to the sample size of (n=6) being too small to detect the 
hypothesised differences. 
There is evidence that GLP-1 may decrease hepatic DNL via AMPK in DPP-4 deficient rats 
(Ben-Shlomo et al., 2011). Also, a GLP-1 receptor agonist has been shown to reduce MTP 
activity in hepatocytes which reduces TRL-apoB-100 production in hamsters (Carpentier et 
al., 2002). It was anticipated that TRL-apoB-100 PR would be reduced due to reduced hepatic 
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and adipose tissue DNL, decreased circulating FFA, increased hepatic fat oxidation and 
decreased CMR concentrations (Parlevliet et al., 2009b, Patel et al., 2014). However, the 
current study results showed that TRL-apoB-100 PR was increased with borderline 
significance after lixisenatide treatment which was not anticipated. A possible explanation is 
that acute suppression of hepatic VLDL production by insulin was ineffective due to elevated 
liver fat and hepatic IR in patients with the metabolic syndrome and altered lipid metabolism 
(Adiels et al., 2008, Adiels et al., 2007). Therefore, increased insulin secretion may not 
supress VLDL production in patients with elevated liver fat and/or hepatic IR. The liver fat 
percentage was not measured in the current study, however, elevated body fat % and 
abnormal ALT and AST concentrations suggest the presence of high liver fat percentage in 
the participants of the current study (Sanal, 2015, Calanna et al., 2014, Hsiao et al., 2007, 
Clain and Lefkowitch, 1987). Another possible explanation could be that an increase in TRL-
apoB-100 PR may also be due to an increase in hepatic DNL in response to increased insulin 
secretion (Dimitriadis et al., 2011, Patel et al., 2014) despite the fact that GLP-1 may 
decrease hepatic DNL in a DPP-4 deficient rat-model (Ben-Shlomo et al., 2011). Therefore, 
both explanations are debatable and the reason behind the increase in TRL-apoB-100 PR 
after GLP-1 receptor agonist treatment requires further investigation. 
6.6.5 Study limitations and future work 
The sample size for this study was estimated to be 18 based on the study power calculation 
of TRL-apoB-48 PR (see Chapter 2 section 2.3.3). Only six patients were recruited in this 
study which made the study underpowered to detect a 25% significant reduction of TRL-
apoB-48 PR after lixisenatide treatment with a power of 80% at the 5% concentration. 
However n=6 was estimated to detect a 40% significant reduction in TRL-apoB-48 PR and 
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TRL-apoB-100 kinetics after lixisenatide treatment with a power of 80% at the 5% 
concentration. 
The sample size for this study was estimated to be 14 based on another study power 
calculation for HDL-apoA-I FCR (see Chapter 2 section 2.3.3). Only four patients were 
recruited in this study which made the study underpowered to detect a 20% significant 
reduction of HDL-apoA-I FCR after exercise intervention with a power of 80% at the 5% 
concentration. However n=4 was estimated to detect a 35% significant reduction in HDL-
apoA-I FCR after exercise intervention with a power of 80% at the 5% concentration. 
The limited number of recruited patients was due to;  
1. Restricted selection criteria of type 2 diabetic patients with uncontrolled glucose 
concentrations taking only metformin for the maintaining their glucose and elevated TG 
concentrations. 
2. The lack of funds and financial support and time for the recruitment procedure. The 
recruitment process lasted for two years which was considered a long time in relation to 
a 4-year PhD programme. 
Therefore, recruiting further participants as indicated earlier in each study power calculation 
for TRL-apoB-48 PR and HDL-apoA-I FCR will enhance the power to find statistical differences 
in TRL-apoB-48 PR (further n=9 are needed) and HDL-apoA-I FCR (further n=11 are needed) 
kinetics. 
It was not possible to measure TRL-apoB-100 and TRL-apob-48 concentrations using a simple 
technique such as the measurement of HDL-apoA-I by MIRA COBAS auto analysers as they 
are chemically and structurally similar to each other. Therefore, two separate sensitive and 
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specific competitive ELISA methods were used for TRL-apoB-100 and TRL-apoB-48 which was 
financially expensive and time-consuming. 
Measuring the activity and concentrations of enzymes involved in VLDL and HDL metabolism 
such as CETP, HL and LPL could provide additional valuable information.  
The measurement of intrahepatic cellular lipid (IHCL) by magnetic resonance spectroscopy 
(MRS) could indicate whether the participants had a high percentage of liver fat, which 
might change after lixisenatide treatment (Armstrong et al., 2016a, Armstrong et al., 2016b, 
Li et al., 2015, Blaslov et al., 2014, Olaywi et al., 2013, Fruci et al., 2013, Sathyanarayana et 
al., 2011) and might explain the increase in TRL-apoB-100 PR after lixisenatide treatment.  
Estimation of gastric emptying using paracetamol after lixisenatide treatment could provide 
more information about the magnitude of the effect of lixisenatide on increasing the lipid 
substrate for CM formation in the enterocytes (Becker et al., 2015, Lorenz et al., 2013). 
Also, the measurement of VLDL-TG and CM-TG kinetics by immunochromatography (Sun et 
al., 2013) will provide valuable information about the amount of TG exported in VLDL 
particles instead of particle number reflected by apoB kinetics measurement. This will also 
be helpful in measuring the VLDL particle size after lixisenatide. The concentration of hepatic 
fat oxidation through the analysis of certain enzymes such as AMPK, malonyl-CoA and acetyl-
coA carboxylase (Lim et al., 2012) could be assessed in the future to investigate lixisenatide 
effect on hepatic fat oxidation concentration using a T2D animal model (Ben-Shlomo et al., 
2011, Svegliati-Baroni et al., 2011, Patel et al., 2014). 
TRL-apoB-100 and TRL-apoB-48 FCR and PR were similar to those reported by Xiao et al., 
2012 but were lower than other studies as seen in Table 6.3. This is due to the different 
methods used in measuring the two most important factors which contribute in the TRL-
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apoB-100 and TRL-apoB-48 kinetic calculations; 1) the method of measuring apoB-100 and 
apoB-48 concentrations, and 2) using a measurement of precursor pool such as 13C α-KIC 
measurements as an indicator of the Leucine precursor pool. The current study used a more 
robust method for measuring TRL-apoB-100 and TRL-apoB-48 concentrations using a highly 
sensitive and specific competitive ELISA. Xiao et al., 2012 used commercial ELISA kits with 
high sensitivity and specificity to determine TRL-apoB-100 and TRL-apoB-48 concentration 
which was similar to the method used in the current study especially the kit used for 
determining TRL-apoB-48 concentration which was from the same company (Shibayagi Co 
Ltd, Shibukawa, Gunma, Japan) (Xiao et al., 2012). Other studies such as the study conducted 
by Hogue et al., 2007 used a less specific and sensitive method in which they directly 
calculated the concentration using the density of the electrophoresis band for apoB-48 and 
apoB-100 using western immunoblotting. Hogue et al., 2007 and Xiao et al., 2012 
extrapolated that the TTRs of TRL-apoB-100 and TRL-apoB-48 to plateau without measuring 
α-KIC which is a different method to estimate the precursor pool from the one used in the 
current study. In the lixisenatide study, a continuous feeding protocol was developed to 
achieve a relatively steady state of plasma TG concentration for the calculation of TRL 
kinetics. Feeding a high fat, low carbohydrate meal hourly for the duration of 12 hours may 
affect the physiology of digestion and absorption, and therefore lipoprotein metabolism 
kinetics may differ from that following a single large meal. Therefore, this could interfere 
with TRL kinetic calculations. 
HDL-apoA-I kinetics were lower than the kinetics measured in previous studies. This has 
been justified previously (see Chapter 5 Table 5.11 and discussion under study limitations 
section). 
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6.7 Conclusion 
The laboratory and clinical protocols were successful in measuring the effect of four-weeks 
of lixisenatide treatment versus placebo on TRL-apoB-100, TRL-apoB-48 and HDL-apoA-I 
kinetics and lipid profile in patients with T2D. TRL-apoB-100 FCR increased significantly after 
lixisenatide while TRL-apoB-48 and HDL-apoA-I FCR and PR did not change significantly after 
lixisenatide treatment versus placebo. Lixisenatide treatment decreased postprandial plasma 
TG, cholesterol, FFA and glucose concentrations but did not affect plasma and fractional 
HDL-C. Lixisenatide caused a reduction in postprandial plasma TG due to increased removal 
of VLDL particles. This may be due to significantly increased insulin production. Increased 
insulin concentrations after lixisenatide treatment did not significantly reduce TRL-apoB-100 
PR which might be due to the presence of high liver fat percentage and increased hepatic IR, 
and might be due to an increase in hepatic DNL by the action of increased insulin after 
lixisenatide treatment. An increase in sample size is needed to investigate the effect of 
lixisenatide on TRL-apoB-48 and HDL-apoA-I kinetics. All the presented data provided 
substantial evidence that long-term lixisenatide treatment can improve glycemic control and 
correct altered lipid metabolism. Further investigations are needed to investigate the effects 
on lixisenatide on liver fat and hepatic DNL as there is a growing evidence which suggest the 
potential use of GLP-I receptor agonists in the treatment of patients with high liver fat 
percentage such as patients with NAFLD. 
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7. Chapter 7: General discussion 
7.1 Altered lipid metabolism in patients with T2D and NAFLD 
This project investigated the effect of exercise on HDL-apoA-I kinetics in NAFLD and the 
effect of lixisenatide on postprandial TRL-apoB-100, TRL-apoB-48 and HDL-apoA-I kinetics in 
patients with T2D. Both NAFLD and T2D are strongly associated with altered lipid 
metabolism, IR and visceral obesity (Noureddin and Rinella, 2015, Saponaro et al., 2015). 
About 30-80% of patients with T2D are also diagnosed with NAFLD (Richard and Lingvay, 
2011, Tolman and Dalpiaz, 2007). Therefore, there is a strong association between NAFLD 
and T2D and cross-interaction may worsen the pathogenicity and progression of each 
disease (Noureddin and Rinella, 2015, Saponaro et al., 2015, Fruci et al., 2013). The fasting 
baseline measurements of the participants in both studies were analysed by unpaired T-test 
to investigate if there were any major differences in the plasma lipid profile, glucose, insulin, 
IR and liver enzymes as shown in Table 7.0. The results indicate that there were no 
significant differences for all the measurements except fasting glucose concentration which 
was significantly higher (P=0.001) in patients with T2D, and fasting insulin concentration 
which was significantly higher (P=0.05) in patients with NAFLD. One of the exclusion criteria 
in the NAFLD study was patients with T2D. The clear difference between the two groups is 
that the patients with NAFLD had functional insulin secretion which maintains normal 
glucose metabolism (Sattar et al., 2014, Preiss and Sattar, 2008).  
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Table 7.0: Baseline measurements for the participants in the NAFLD (n=27) and Lixisenatide 
(n=6) studies. 
 NAFLD study Lixisenatide Study Un-Paired T-
test 
P value 
Baseline measurements 
(n=27) 
Baseline measurements 
(n=6) 
Age (years) 52.6±1.7 52.8±3.0 0.9 
Height (cm) 179.1±1.6 173.2±2.7 0.1 
Body weight (kg) 101.7±3.0 89.7±3.3 0.09 
BMI (kg/m2) 31.6±0.6 29.3±1.2 0.1 
Body fat (%) 28.6±0.9 26.8±1.6 0.4 
Systolic BP (mm Hg) 139.9±3.0 128.6±7.1 0.1 
Diastolic BP (mm Hg) 89.4±2.8 80.3±3.6 0.2 
Fasting glucose (mmol/L) 5.9±0.1 7.6±0.7 0.001 
Fasting TG (mmol/L) 1.8±0.2 1.5±0.2 0.5 
Fasting Total CHOL (mmol/L) 5.0±0.1 4.0±0.4 0.09 
ALT (IU/l) 46.6±4.1 46.7±11.8 0.9 
AST (IU/l) 33.4±2.2 34.7±10.4 0.8 
Serum fasting HDL-C (g/L) 1.0±0.1 1.1±0.1 0.9 
F-HDL-c (g/L) 0.6±0.1 (n=4)     0.5±0.1 0.3 
Insulin (pmol/L) 174.7±11.9 132.7±22.2 0.05 
HOMA2-IR (%) 3.3±0.2 2.8±0.4 0.3 
Data are expressed as Mean ± SEM. Data between the two groups were analysed by unpaired 
two-tailed t-test. P  values ≤0.05 are in bold. BMI: body mass index; BP: blood pressure TG: 
triacylglycerols; CHOL: cholesterol; ALT: alanine transferase; AST: aspartate transferase; HDL -
C: high-density l ipoprotein cholesterol; F -HDL-C: fractional high-density l ipoprotein 
cholesterol; HOMA2-IR: The Homeostasis Model Assessment for IR percentage.  
7.2 Exercise and lixisenatide for the treatment of altered lipoprotein metabolism 
via plasma insulin and IR 
Exercise significantly increased VLDL1-apoB-100 FCR via decreasing IR. Increased insulin 
sensitivity after exercise may have increased LPL activity in the muscle tissues which 
increases the hydrolysis of VLDL particle. This may eventually correct fasting 
hypertriglyceridaemia which was not however seen in this study, and a longer exercise 
intervention period might be needed to observe a difference (Figure 7.0). Exercise also 
significantly reduced percentage liver fat and plasma liver enzymes which indicated that 
exercise improved the overall liver function and condition in patients with NAFLD. 
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A four-week treatment period with Lixisenatide, a GLP-1 receptor agonist, versus placebo 
was shown to lower postprandial plasma hypertriglyceridaemia, hyperglycaemia and 
hypercholesterolaemia in patients with T2D which may have been due to the direct GLP-1 
receptor agonist action on β cells which caused a postprandial increase in plasma insulin 
concentrations (Figure 7.0). Reduced fasting and postprandial plasma hypertriglyceridaemia 
may have been due to the significant increase in postprandial insulin concentrations and 
TRL-apoB-100 FCR, reduced circulating FFA due to increased FFA uptake by adipose tissue 
and reduced lipolysis in adipose tissue. Lixisenatide, however, did not cause a significant 
change in TRL-apoB-48 kinetics.  
It appears that both exercise and lixisenatide exerted their effects on altered lipoprotein 
metabolism mainly via either increasing insulin concentration or increasing insulin 
sensitivity.  
7.3 Limitations of the project 
The laboratory work was time-consuming for both studies. It took at least five weeks to 
analyse samples from each study for a single subject. The analysis protocol was complicated 
with multiple methodologies, and errors could be generated at any single step which 
required repetition if needed. Visible results were seen at the last two steps; bands on the 
gel after the SDS-PAGE step and the ion peaks generated at the GC-MS step. Therefore, any 
errors made in all the previous steps including delipidation, hydrolysis, IEC, freeze drying and 
derivatization were not detectable. Thus the project needed to be cautiously designed to 
minimise errors as possible, and the work to be carried out by a skilled experimenter. 
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Figure 7.0: Exercise and lixisenatide as combined treatment for altered lipoprotein 
metabolism. IR: IR; VLDL: very low-density l ipoprotein; apo: apolipoprotein; FCR: fractional 
catabolic rate; PR: production rate; IHCL%: intrahepatocellular l ipid percentage; TG: 
triacylglycerol; FFA: free fatty acid; CE: cholesterol ester; TRL: triacylglycerol -rich l ipoprotein; 
HDL-C: high-density lipoprotein cholesterol; CETP: cholesterol ester transfer protein; ALP: 
atherogenic l ipoprotein phenotype; T2D: type 2 diabetes; NAFLD: non -alcoholic fatty liver 
disease.  
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7.4 Combined treatment of exercise and GLP-1 receptor agonist for the treatment 
of dyslipidaemia associated with NAFLD and T2D 
The final results of both studies suggests two possible approaches which can be used in 
correcting hypertriglyceridaemia; 1. Increasing postprandial insulin secretion by lixisenatide 
treatment to correct postprandial hypertriglyceridaemia in patients with T2D and altered 
lipoprotein metabolism. 2. Regular exercise to increase peripheral insulin sensitivity and 
correct fasting hypertriglyceridaemia in patients with NAFLD and altered lipoprotein 
metabolism. Therefore, a potential combination treatment approach of exercise and 
lixisenatide is shown in Figure 7.1 in which both treatment increases VLDL-apoB-100 FCR by 
both decreasing insulin concentration and resistance in the fasting state by the exercise 
effects or by increasing insulin concentrations by the lixisenatide treatment effect. As a 
result, it is been suggested that a combined treatment will be more efficient than using one 
treatment approach to reduce fasting and postprandial dyslipidaemia associated with NAFLD 
and T2D in fasting and postprandial states, and it could be considered as a new treatment 
approach as shown in Figure 7.1.  Also, the combined treatment might reduce liver fat 
percentage and improve liver function. 
Recent studies indicate that exercise does not increase plasma GLP-1 in patients with altered 
lipid metabolism (Bailey et al., 2015, Nyhoff et al., 2015, Eshghi et al., 2013, Ueda et al., 
2009, Martins et al., 2007). Therefore, it is suggested to conduct a clinical study investigating 
the effect of combined approaches of exercise and lixisenatide on postprandial 
hypertriglyceridaemia associated with altered lipid metabolism in diagnosed patients with 
T2D with an IHCL% above 5% to observe secondary effects on lipoprotein metabolism and 
liver fat accumulation and clearance. This may lead to a reduction in the TG plasma pool 
which will reduce the exchange rate between TRL and HDL via CETP (Sheridan, 2016, 
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Diffenderfer et al., 2012, Barter, 2000, Frayn, 2010). This would lead to a decrease in the 
formation of SDLDL and increase HDL-C reducing CVD risk (Barter, 2000, Frayn, 2010). 
 
Figure 7.1: Potential combination of exercise and lixisenatide treatments as a new treatment 
approach for dyslipidaemia associated with NAFLD and  T2D. NAFLD: Non-alcoholic fatty l iver 
disease; T2D: type 2 diabetes; VO 2 MA X: measurement of blood oxygen capacity during physical 
exercise; VLDL: very low-density l ipoprotein; HDL: high -density lipoprotein; TRL: triglycerides -
rich lipoprotein; S DLDL: smal l dense low-density l ipoprotein; HDL -C: high-density lipoprotein –  
cholesterol; apoB-100: apolipoprotein B-100; FCR: fractional catabolic rate; LPL: lipoprotein 
lipase; TG: triglycerides; CETP: cholesterol ester transfer protein; CVD: cardiovascular diseas e; 
CHD: coronary heart disease.  
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7.5 Conclusion 
Exercise and lixisenatide treatment increased VLDL-apoB-100 FCR. This may contribute to a 
correction of hypertriglyceridaemia. Both treatments increased VLDL-apoB-100 PR which 
may have been due to increased liver fat or increased hepatic DNL as both increases the 
availability of TG to export in VLDL which may contribute to increased plasma TG. Correcting 
hypertriglyceridaemia may result in increased HDL-C by reducing the rate of exchange of TG 
and CE between HDL and TRL. However, exercise did not cause a significant increase in HDL-
C due uncorrected hypertriglyceridaemia in the NAFLD study. The failure to detect a 
decrease in HDL-C in the lixisenatide study despite the fact that lixisenatide treatment 
decreased postprandial plasma TG may be due to the small sample size.  
The measurements of TRL-apoB-100, TRL-apoB-48 and HDL-apoA-I FCR and PR using stable 
isotope technique gives a better understanding of the possible metabolic mechanisms 
underlying hypertriglyceridaemia and low HDL-C concentration in patients with altered 
lipoprotein metabolism. Understanding these mechanisms provides information for new 
potential treatment approaches which can be used to correct hypertriglyceridaemia and low 
HDL-C concentration which will reduce the risk of CHD and CVD. 
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